Nephrology Dialysis Transplantation

Official Publication of the European Dialysis and Transplant Association—European Renal Association

Incorporating Proceedings of the European Dialysis and Transplant Association—European Renal Association

VOLUME 4: 1989

Editor-in-Chief:

Alex M. Davison
Leeds, UK

Editors:

H. Brynger
Göteborg, Sweden

V. Cambi
Parma, Italy

J. S. Cameron
London, UK

J. P. Grünfeld
Paris, France

L. Hernando
Madrid, Spain

K. Hierholzer
Berlin, FRG

H. Klinkmann
Rostock, GDR

H. Kreis
Paris, France

E. Ritz
Heidelberg, FRG

C. Van Ypersele
Bruxelles, Belgium

Advisory Editors:

J. F. Bach
Paris, France

R. S. Barsoum
Cairo, Egypt

J. Bergstrom
Stockholm, Sweden

J. Botella
Madrid, Spain

J. D. Briggs
Glasgow, UK

M. Broyer
Paris, France

A. Dal Canton
Catanzaro, Italy

G. D'Amico
Milano, Italy

R. A. Donckerwolcke
Utrecht, The Netherlands

J. F. Donohoe
Dublin, Ireland

T. Drüeke
Paris, France

P. Druet
Paris, France

J. Egido
Madrid, Spain

H. Eliahou
Tel Hashomer, Israel

D. Falkenhagen
Rostock, GDR

M. Goldman
Bruxelles, Belgium

R. Greger
Frankfurt, FRG

P. Hayry
Helsinki, Finland

P. J. Hoedemaeker
Leiden, The Netherlands

C. Jacobs
Paris, France

R. A. P. Koene
Nijmegen, The Netherlands

F. Kokot
Katowice, Poland

N. H. Lameire
Gent, Belgium

R. Maiorca
Brescia, Italy

N. P. Mallick
Manchester, UK

June Mason
Basel, Switzerland

J. Ph. Méry
Paris, France

C. Mion
Montpellier, France

K. Olgaard
Copenhagen, Denmark

G. Opelz
Heidelberg, FRG

A. Pasternack
Tampere, Finland

R. Pichlmayr
Hannover, FRG

M. Polenakovic
Skopje, Yugoslavia

C. Ponticelli
Milano, Italy

A. T. Raftery
Sheffield, UK

G. Remuzzi
Bergamo, Italy

L. Revert
Barcelona, Spain

G. F. Rizzoni
Padova, Italy

G. Sieberth
Aachen, FRG

I. Taraba
Budapest, Hungary

G. Thiel
Basel, Switzerland

D. W. Thoenes
Mainz, FRG

D. Thomson
Edinburgh, UK

A. Valek
Praha, Czechoslovakia

L. A. Van Es
Leiden, The Netherlands

A. J. Wing
London, UK

P. Zucchelli
Bologna, Italy

Springer International

Author Index to Volume 4

Aartsen E (abst) 751, 754
Abbott F, Jones S, Lockwood C M, Rees A J: Autoantibodies to Glomerular Antigens in Patients with Wegener's Granulomatosis 1
Abboud H (abst) 426
Abdel Ghaffer H (abst) 595
Abdelhamid S: *See* Röckel A et al.
Abendroth K: *See* Stein G et al.
Aber G M: *See* Bennett-Jones D N et al.
Abouna G M (abst) 589, 591, 592, 594, 597, 599
Abourachid H (abst) 432
Abramowicz D (abst) 497, 517
Ackrill P: *See* Pickering S J et al.
Adachi T (abst) 489
Adafer E (abst) 510
Adu D (abst) 313, 314
Adu D (letter) 758
Adu D: *See* Beaman M et al.
Adu D: *See* Crowson M C et al.
Afrasiabi M (abst) 476
Agishi T (abst) 485
Aguado S, Fdez B de Quirós J, Marín R, Gago E, Gómez E, Fdez-Vega F, Alvarez Grande J: Acute Mercury Vapour Intoxication: Report of Six Cases 133
Aguilo J: *See* Morales-Barria J et al.
Ahipaşoğlu Y (abst) 590
Ahmad T, Coulthard M G, Eastham E J: Reversible Renal Failure due to the Use of Captopril in a Renal Allograft Recipient Treated with Cyclosporin 311
Ahmed J (abst) 835
Aimo G (abst) 441
Airaghi C (abst) 417
Airaghi C: *See* Colussi G et al.
Ait-Slimane A (abst) 499
Ajzen H (abst) 461, 487
Akiba T (abst) 467, 475
Akira Yoshida, Hiroaki Aoki, Seinosuke Nakagawa, Mitsuo Ogura, Kiyoshi Ozawa, Takao Shoji, Takuo Sasaoka: Granulocyte Elastase and α_1-Protease Inhibitor in Dialysis Patients With or Without Carpal Tunnel Syndrome S3:134
Akisawa T (abst) 494
Akiyama T (abst) 467
Akizawa T, Koshikawa S, Nakazawa R, Yoshida T, Kaneko M, Nitadori Y: Elimination of β_2-Microglobulin by a New Polyacrylonitrile Membrane Dialyser: Mechanism and Physiokinetics 356
Al-Asfari R (abst) 593
Al-Haj K (abst) 597
Alaupovic P (abst) 448
Albano J D M: *See* Waters M R et al.
Albers C (abst) 458
Albertazzi A (abst) 448
Albrecht K H (abst) 502, 521
Alegre M (abst) 517
Alessio B: *See* Roccatello D et al.
Alessio M: *See* Roccatello D et al.
Alexandre G P J (abst) 506
Alexopoulos A (abst) 594
Alexopoulos E, Seron D, Hartley R B, Nolasco F, Cameron J S: The Role of Interstitial Infiltrates in IgA Nephropathy: A Study with Monoclonal Antibodies . . 187
Alfani D (abst) 518
Alfieri R (abst) 455
Algra P R (abst) 751
Ali Asghari M (abst) 591, 595
Alinovi R: *See* Buzio C et al.
Alivanis P (abst) 482, 514
Aljama P (abst) 451, 452, 480, 489, 491
Allende M T (abst) 468
Alliapoulos J C: *See* Leichter H E et al.
Almirall J: *See* Campistol J M et al.
Alsabadani B (abst) 473
Alsina J (letter) 675, 839
Altmann P (abst) 518
Altmann P (letter) 759
Altmann P: *See* Cunningham J et al.
Altmann P: *See* Sawyer N et al.
Altomonte M: *See* Sabbatini M et al.
Altunkanş (abst) 518, 590, 591, 593, 594, 595, 597, 598, 600, 601
Alvarez de Buergo M: *See* Praga M et al.
Alvaro F (abst) 500
Amin N S: *See* Sweny P, et al.
Amir-Ansari B (abst) 595, 599
Amiransari B (abst) 588
Amore A (abst) 423, 424, 430, 440, 470, 490
Amore A: *See* Coppo R et al.
Amore A: *See* Roccatello D et al.
Amorim M P S (abst) 461
Amoroso A (abst) 440, 441, 442
Amoroso A: *See* Coppo R et al.
Amprimo A (abst) 440
Amprimó M C: *See* Roccatello D et al.
Amraoui Z (abst) 497, 517
Amrein C (abst) 459
Anastasio P (abst) 416, 455
Andersen C B (abst) 502, 670
Andersen H K (abst) 672
Anderson J V (abst) 420
Ando R (abst) 467
André M (abst) 488
Andres A: *See* Praga M et al.

Andreu J (abst) 492, 502, 517
Andreucci V E (abst) 450, 516
See Fuiano G, et al.
Andreucci V E: *See* Sabbatini M et al.
Andrew S M: *See* Hamdy N A T et al.
Andrulli S: *See* Buzio C et al.
Antonaci S abst) 430
Antonov S (letter) 75, 602
Antonsen S (abst) 671, 673
Antonucci F (abst) 485
Aparicio M (abst) 513
Apostoli P (abst) 486
Apperl A (abst) 488, 508
Araj G (abst) 594, 597
Aranda P (abst) 435
Arap S (abst) 504, 507
Arfeen S (abst) 470, 495, 833
Argiles A (abst) 492
Argiles A: *See* Mourad G et al.
Aris L: *See* Morales-Barria J et al.
Arisz L (abst) 420, 450, 498, 501, 752, 754, 755
Arisz L: *See* Koopman M G et al.
Arndt R (abst) 520
Aroldi A (abst) 508, 514
Arrobas M (abst) 496
Arslan G (abst) 593, 597
Asghar S S (abst) 450
Asskari A (abst) 599
Ataman R (letter) 760
Atkin S L, Tomson C R V, Venning M C: Life-threatening Captopril-induced Hyperkalaemia in a Patient on Continuous Ambulatory Peritoneal Dialysis 1084
Atkins R C (abst) 492
Attman P-O (abst) 448
Auer J (abst) 833
Aurell M (abst) 447
Aurisch R (abst) 487
Ausserwinkler M (abst) 145, 149
Averbukh Z: *See* Modai D et al.
Awad J (abst) 428
Ayed K (abst) 593
Ayed M (abst) 599
Azoulay E (abst) 494
Bach J F (abst) 514
Bach P H (abst) 448
Bachetoni A (abst) 518, 520
Bahari C (abst) 439
Bahner U (abst) 463
Baker F (abst) 515, 835
Baker F: *See* Jenkins D et al.
Baker K: *See* Bennett-Jones D N et al.
Baker L R I: *See* Edmunds M E, et al.
Baker L R I (abst) 495, 833
Bakkaloğlu M (abst) 594
Bakkeren A J M (abst) 754
Bakr A (abst) 595
Balcke P (abst) 147, 148, 150, 151, 153, 154, 456, 478, 483, 488, 508, 511, 518, 596
Balcke P: *See* Biesenbach G et al.
Baldet P: *See* Canaud B et al.
Balkanci F (abst) 594
Balla A (abst) 482
Ballardie F W (abst) 831
Ballarin J A (abst) 438, 439
Ballesta A M (abst) 449
Balletta M: *See* Fuiano G et al.
Balzar E (abst) 145, 446
Bambauer R (abst) 446
Banfi G (abst) 508
Bangsgaard Pedersen F (abst) 671
Bangsgaard Pedersen F (letter) 676
Bárány P (abst) 471, 478
Barbiano di Belgiojoso G (abst) 426
Barceló P (abst) 438, 439
Bariety J (abst) 472
Barnaba A (abst) 485
Barnas U (abst) 473
Barnes A D: *See* Crowson M C et al.
Barocci S (abst) 517
Baronti A: *See* Grazi G et al.
Barradas M A: *See* Sweny P et al.
Barrientos A (abst) 506
Barrientos A (letter) 840
Barrio V (abst) 451, 480, 489, 491
Barros E J G (abst) 448
Barsoum R (abst) 600
Bartolomeo F (abst) 439
Basile C (abst) 470
Basolo B (abst) 430, 512
Bassett A (abst) 458
Bassett A H (abst) 316
Bassi S (abst) 497
Bastin G: *See* Cappello M et al.
Bataille P (abst) 432
Bateman J M: *See* Harrison N A et al.
Bateson K (abst) 832
Bätge B (abst) 520
Baudin G: *See* Floege J et al.
Baumann G (abst) 501
Baumelou A (abst) 464
Baumgartl P (abst) 154
Baur X: *See* Röckel A et al.
Baurmeister U, Vienken J, Daum V: High-flux Dialysis Membranes: Endotoxin Transfer by Backfiltration can be a Problem S3:89
Bausewein K (abst) 464
Baysal Ç (abst) 590
Baz M (abst) 452
Beaman M (abst) 313, 314
Beaman M, Michael J, MacLennan I C M, Adu D: T-Cell-Independent and T-Cell-Dependent Antibody Responses in Patients with Chronic Renal Failure 216
Beardsworth S F, Vernon V, Harrison D, Fructosamines in Uraemia and Renal Replacement Therapy 748
Beastall G (abst) 318
Beaufils M (abst) 419
Becquemont L (abst) 443
Bedair A (abst) 600
Bedani P L (abst) 513
Beelen R H J (abst) 755
Belbrik S: *See* Moriniere Ph et al.
Belechri A M (abst) 469
Belghiti J (abst) 438
Bellas C (abst) 423, 428
Bellini L (abst) 455
Bellizzi V (abst) 450
Bello I: *See* Praga M et al.
Belpaire F (abst) 754
Beltrame G (abst) 486
Ben Abdallah T (abst) 593, 599

Ben Ayed H (abst) . . . 593
Ben Ayed H A (abst) . . . 599
Ben Ayed H E (abst) . . . 599
Ben-Arie J (abst) . . . 458, 463
Benarbia S (abst) . . . 591
Benazzi E (abst) . . . 417
Benazzi E: *See* Colussi G et al.
Bender-Säbelkampf H (abst) . . . 145
Bendjelloul A (abst) . . . 499
Bennett S E: *See* Jenkins D et al.
Bennett-Jones D N, Aber G M, Baker K: Successful Pregnancy in a Patient Treated with Continuous Ambulatory Peritoneal Dialysis . . . 583
Benoit G (abst) . . . 510
Benoliel D: *See* Lock P M et al.
Benton M: *See* Smith W G J et al.
Benzakour M: *See* Vincent D et al.
Beraud J J: *See* Canaud B et al.
Berg U (abst) . . . 432
Bergbreiter R: *See* Mann J F E et al.
Berger F: *See* Garnier J L et al.
Bergerone S (abst) . . . 465
Bergmann M (abst) . . . 473
Bergot C (abst) . . . 432
Bergström J (abst) . . . 471, 478
Bergström J: *See* Lindholm B et al.
Bergstrom R: *See* Hanas E et al.
Berisa F: *See* Crowson M C et al.
Berland Y (abst) . . . 452
Berlin Y (abst) . . . 464
Berloco P (abst) . . . 518
Bernheim J (abst) . . . 417
Bernheim J (abst) . . . 421, 439, 453, 457
Bernieh B (abst) . . . 492
Bernstein K (abst) . . . 462
Berquier F (abst) . . . 485
Bertani T (abst) . . . 426
Berthet P (abst) . . . 454
Berthoux F: *See* Guerin C et al.
Bertoli S (abst) . . . 426
Bessalem S (abst) . . . 591
Bessho M (abst) . . . 475
Better O S (abst) . . . 458, 463
Betuel H: *See* Garnier J L et al.
Bewick M (abst) . . . 319, 838
Bewick M: *See* Henning P H et al.
Bianchi A M (abst) . . . 424
Bianchi A M: *See* Grazi G et al.
Bianco O (abst) . . . 437
Biesenbach G (abst) . . . 145, 148, 511
Biesenbach G, Zazgornik J, Kaiser W, Stöger H, Derfler K, Balcke P, Hauser Ch: Cyclosporin Requirement During Pregnancy in Renal Transplant Recipients . . . 667
Bijman J T (abst) . . . 445
Bilgin N (abst) . . . 518, 590, 591, 593, 598, 600, 601
Bilo H J G (abst) . . . 459, 511
Binda P (abst) . . . 440, 442
Bindi P (abst) . . . 499
Binswanger U (abst) . . . 509
Bird A G (abst) . . . 832
Birtwistle R J (abst) . . . 314
Bittar A E, Ratcliffe P J, Richardson A J, Brown R C, Woodhead J S, Morris P J: Hyperparathyroidism, Hypertension and Loop Diuretic Medication in Renal Transplant Recipients . . . 740
Bittner K (abst) . . . 509
Blaehr H (abst) . . . 670
Blanc N: *See* Garnier J L et al.
Blohmé I (abst) . . . 510
Bloom S R (abst) . . . 463
Blum W (abst) . . . 451
Blumenstein M, Ziegler-Heitbrock H W L, Schiller B, Schmidt B, Ward R A, Gurland H J: Activation of Mononuclear Cells by Aqueous Extracts from Hollow-fibre Haemodialysers . . . 569
Blumenstein M: *See* Bosch Th et al.
Bobrie G (abst) . . . 438
See Pochet J-M et al
Bobrie G: *See* Kleinknecht D et al.
Bochenek A (abst) . . . 505
Bock A: *See* Raine A E G et al.
Boelaert J (abst) . . . 480, 754
Boelaert J R (letter) . . . 676
Boelaert J R, De Smedt R A, De Baere Y A, Godard C A, Matthys E G, Schurgers M L, Daneels R F, Gordts B Z, Van Landuyt H W: The Influence of Calcium Mupirocin Nasal Ointment on the Incidence of *S. Aureus* . . . 278
Boer P, Koomans H A, Boer W H, Dorhout Mees E J: Urinary Angiotensin Excretion During Sodium Restriction and Diuretics . . . 713
Boer W H: *See* Boer P et al.
Boer W H: *See* Rabelink A J et al.
Boero R (abst) . . . 512
Boeschoten E W (abst) . . . 498, 501, 752, 755
Bogaert A M (abst) . . . 483, 484
Bogaert M (abst) . . . 754
Boggio-Bertinet D (letter) . . . 238
Bogićević M (abst) . . . 444
Bogin E: *See* Modai D et al.
Bohdanecká M (abst) . . . 457
Böhler J (abst) . . . 416, 454
Böhler J, Hauenstein K-H, Hasler K, Schollmeyer P: Renal Vein Thrombosis in a Dehydrated Patient on an Oral Contraceptive Agent . . . 993
Böhler J: *See* Keller E et al.
Bohman S-O (abst) . . . 447
Boim M A (abst) . . . 448, 454, 516
Boitard C (abst) . . . 514
Boletis J: *See* Hamdy N A T et al.
Bolli P: *See* Raine A E G et al.
Bommer G (abst) . . . 471
Bommer J (abst) . . . 471, 489
Bommer W (abst) . . . 453
Bone J M (abst) . . . 444, 445
Bone J M (letter) . . . 917
Bone J M: *See* Williams P S and Bone J M
Bonello F (abst) . . . 486
Boner G: *See* Cohen S L et al.
Bonomelli D (abst) . . . 440
Bonzel K E (abst) . . . 495
Boogaerts M A (abst) . . . 479
Borelli I (abst) . . . 440, 441
Borgialli R: *See* Roccatello D et al.
Borris L C (abst) . . . 673
Bos H J (abst) . . . 755
Bosch Dr (letter) . . . 839
Bosch F H (letter) . . . 239
Bosch R J (abst) . . . 503
Bosch Th, Blumenstein M, Gurland H J: Biocompatibility—Review and Ex Vivo Evaluation . . . S3:41

Bosman F T:*See* Knols G et al.
Botey A:*See* Campistol J M et al.
Boucher A (abst) . . . 510
Boudaillez B (abst) . . . 432, 467
Boudailliez B: *See* Moriniere Ph et al.
Bouillon R (abst) . . . 432
Boultbee J E (abst) . . . 447, 508
Boulton-Jones J M (abst) . . . 831
Boulton-Jones J M: *See* Sutcliffe N P et al.
Bourdon R (abst) . . . 470
Bowley J A: *See* Pickering S J et al.
Brabant E G (abst) . . . 478
Brady A J B and Wing A J: Hyperpigmentation due to Cyclosporin Therapy . . . 309
Brandi L (abst) . . . 480, 672
Brando B (abst) . . . 481
Branger B (abst) . . . 473
Branger B: *See* Floege J et al.
Braquet P: *See* Mampaso F M et al.
Braquet P (abst) . . . 448, 516
Braun W (abst) . . . 495
Brȩborowicz A (abst) . . . 498
Breddin K (abst) . . . 473
Bregman R (abst) . . . 454, 487, 516
Breitenfellner P (abst) . . . 144, 153, 154
Brenchley P E: *See* Short C D et al.
Brenchley P E C (abst) . . . 831
Brewer Y (abst) . . . 319, 838
Brezis M (abst) . . . 417
Bricio T (abst) . . . 423, 428
Bricio T: *See* Mampaso F M et al.
Bridges J M (abst) . . . 420, 476
Bridges J M: *See* Brown J H et al.
Briggs J D (abst) . . . 318
Bright C: *See* Coles G A et al.
Brindley F (abst) . . . 512
Brocklebank J T: *See* Heney D et al.
Brockmöller J (abst) . . . 477
Bronswijk H v (abst) . . . 752
Brooke I P: *See* Dische F E et al.
Broomhead V (abst) . . . 832
Brown A L (abst) . . . 495, 833
Brown C B: *See* Hamdy N A T et al.
Brown C B: *See* Smith W G J et al.
Brown E A (abst) . . . 318, 495
Brown E A: *See* Sethi D et al.
Brown J H, Lappin T R J, Elder G E, Taylor T N, Bridges J M, McGeown M G: The Initiation of Erythropoiesis Following Renal Transplantation . . . 1076
Brown R C: *See* Bittar A E et al.
Browne D (abst) . . . 317
Browne O: *See* O'Meara Y et al.
Brownjohn A M: *See* Young G A et al.
Broyer M: *See* Brunner F P et al.; Ehrich J H H et al.; Tufveson G et al.
Broyet C: *See* Guerin C et al.
Bruck S (abst) . . . 151
Bruggeman C A (abst) . . . 521
Bruijn J A (abst) . . . 423, 424, 425
Brunati C (abst) . . . 472, 481
Bruneval P (abst) . . . 472
Brunkhorst R (abst) . . . 433
Brunkhorst U (abst) . . . 433
Brunner F P, Fassbinder W, Broyer M, Brynger H, Dykes S R, Ehrich J H H, Geerlings W, Rizzoni G, Selwood N H, Tufveson G, Wing A J: Combined Report on Regular Dialysis and Transplantation in Europe, XVIII, 1987 . . . S2:5
Brunner F P: *See* Ehrich J H H et al.; Raine A E G et al.; Rizzoni G et al.; Tufveson G et al.; Zuber M et al.
Brunori G: *See* Maiorca R et al.
Brynger H (abst) . . . 510, 521
Brynger H: *See* Brunner F P et al.; Ehrich J H H et al.; Rizzoni G et al.; Tufveson G et al.
Buchholz B (abst) . . . 521
Buczko W (abst) . . . 452
Buhler F R: *See* Raine A E G et al.
Bulla M (abst) . . . 446
Bulut O (abst) . . . 518, 591, 592, 594, 597, 601
Bunzendahl H (abst) . . . 511
Burden R P (abst) . . . 435
Burdiel L G (abst) . . . 451, 489
Burger E (abst) . . . 440
Burnett J C Jr (abst) . . . 463
Burnie J: *See* Pickering S J et al.
Burton P R: *See* Jenkins D et al.
Burton P R: *See* Williams B et al.
Busch R (abst) . . . 520
Busing M (abst) . . . 597
Butter K C: *See* Cunningham J et al.
Buzio C (abst) . . . 429
Buzio C, Mutti A, Capani F, Andrulli S, Perazzoli F, Alinovi R, Negro A, Rustichelli R: Circadian Rhythm of Proteinuria: Effects of an Evening Meat Meal . . . 266
Bygren P, Cederholm B, Heinegard D, Wieslander J: Non-Goodpasture Anti-GBM Antibodies in Patients with Glomerulonephritis . . . 254
Cabello M (abst) . . . 435
Cada E, Karnel F, Mayer G, Längle F, Schurawitzki H, Graf H: Percutaneous Transluminal Angioplasty of Failing Arteriovenous Dialysis Fistulae . . . 57
Cada E M (abst) . . . 146, 147
Çağlar Ş (abst) . . . 594, 601
Cahen R, Francois B, Trolliet P, Gilly J, Parchoux B: Aetiology of Membranous Glomerulonephritis: A Prospective Study of 82 Adult Patients . . . 172
Cairns H S (abst) . . . 835
Caldara R (abst) . . . 507
Calero F (abst) . . . 439
Callard P: *See* Kleinknecht D et al.
Callebert J (abst) . . . 480
Cambar J (abst) . . . 513
Cambi V: *See* David S et al.
Cambridge G (abst) . . . 832
Camerini R: *See* Maiorca R et al.
Cameron J S (abst) . . . 426
Cameron J S: *See* Alexopoulos E et al.
Cameron J S: *See* Cheng H-F et al.
Camilleri J P (abst) . . . 472
Campanini M (abst) . . . 431
Campbell E: *See* O'Meara Y et al.
Campbell T (abst) . . . 444
Campioli D (letter) . . . 1083
Campise M: *See* Casati S et al.
Campistol J M (abst) . . . 492, 502, 517
Campistol J M, Almirall J, Montoliu J, Revert Ll: Electrographic Alterations Induced by Hyperkalaemia Simulating Acute Myocardial Infarction . . . 233
Campistol J M, Galofre J, Botey A, Torras A, Revert Ll: Reversible Membranous Nephritis Associated with Diclofenac . . . 393

Campistol J M: *See* Lens X M et al.
Camussi G (abst) . . . 491
Canaud B (abst) . . . 482
Canaud B, Beraud J J, Mion C, Baldet P, Mimran A: Successful Treatment of Legionella-associated Haemolytic Uraemic Syndrome with Acute Renal Failure and Malignant Hypertension by Prostacyclin (Epoprostenol) . . . 995
Canaud B, Nguyen Q V, Garred L J, Nicholle R, Mion C: Germicidal Effectiveness of Dialox, A New Stable Peroxyacetic Acid Solution, in the Re-use of High-Flux Dialysers . . . 999
Canavese C (abst) . . . 442, 466, 467
Cancarini G C: *See* Maiorca R et al.
Canepa A (abst) . . . 497
Cannata B (abst) . . . 468
Cannata J B (abst) . . . 468
Cantaluppi A (abst) . . . 475, 490, 496
Cantarovich D (abst) . . . 503
Capaldo B (abst) . . . 450
Capani F: *See* Buzio C et al.
Capasso G (abst) . . . 416, 455
Capdeville P (abst) . . . 445
Cappelli P (abst) . . . 448
Cappellini M D (abst) . . . 472
Cappello M, De Pauw L, Bastin G, Prospert F, Delcour C, Thaysse C, Dhaene M, Venherweghem J L, Kinnaert P: Central Venous Access for Haemodialysis Using the Hickman Catheter . . . 987
Caravaca F (abst) . . . 496
Carayon A (abst) . . . 464
Carey C (abst) . . . 477
Carlisle E (letter) . . . 237
Carlsen O (abst) . . . 673
Carlsson M (abst) . . . 417
Carmody M: *See* O'Meara Y et al.
Carozzi S (abst) . . . 475, 490, 496, 517
Carpentier A (abst) . . . 459
Carthy J (abst) . . . 452
Caruso A (abst) . . . 513
Cary N R B: *See* Sethi D, et al.
Casadevall N (abst) . . . 472
Casadevall N (letter) . . . 675
Casado S (abst) . . . 503
Casarosa L (abst) . . . 424
Casati S, Campise M, Crepaldi M, Lobo J, Graziani G, Ponticelli C: Haemodialysis Efficiency After Long-Term Treatment with Recombinant Human Erythropoietin . . . 718
Casciani C U (letter) . . . 76
Casciani C U: *See* Taccone-Gallucci M et al.
Cases A (abst) . . . 449
Cases A: *See* Lens X M et al.
Cashman S J (abst) . . . 314, 315, 837
Cashman S J: *See* Dische F E et al.
Cashman S J: *See* Sutcliffe N P et al.
Caslake M (abst) . . . 831
Cassader M (letter) . . . 238
Castelao A M (letter) . . . 675
Castellani A (abst) . . . 497
Castelnovo C (abst) . . . 496, 514
Castillo D (abst) . . . 451, 452, 480, 489, 491
Castillo R (abst) . . . 449
Cattell V (abst) . . . 315, 836
Cattell W R (abst) . . . 420, 466, 495, 836
Catto G R D (abst) . . . 838
Caudwell V (abst) . . . 492
Cavaillon J-M (abst) . . . 480
Cavalli G (abst) . . . 440
Cavalli G: *See* Roccatello D et al.
Caviglia M P (abst) . . . 475, 496
Caviglia P M (abst) . . . 517
Céballos I (abst) . . . 450
Cecchin E (abst) . . . 433, 489
Cederholm B: *See* Bygren P et al.
Cenci A M (letter) . . . 1083
Cesana B: *See* Passerini Patrizia et al.
Chan C Y: *See* Chan M K et al.
Chan M K, Chan P C K, Cheng I P K, Chan C Y, Ng W S F: Pseudomonas Peritonitis in CAPD patients: Characteristics and Outcome of Treatment . . . 814
Chan M K, Chan P C K, Wong K, K, Cheng I K P, Li M K, Chang W K: Hepatitis B Infection and Renal Transplantation . . . 297
Chan P C K: *See* Chan M K et al.
Chanard J (abst) . . . 438, 492
Chanard J, Toupance O, Lavaud S, Jaisser F, Gillery P: Serum β_2 Microglobulin and Extracellular Fluid Volume During Haemodialysis . . . 549
Chang W K: *See* Chan M K et al.
Channon S M (abst) . . . 454
Channon S M: *See* Tomson C R V et al.
Chantler C (abst) . . . 313
Chantler C: *See* Clarke A G B et al.
Chantler C: *See* Henning P H et al.
Chapuis-Cellier C: *See* Garnier J L et al.
Charbonnel B (abst) . . . 503
Charmes J P: *See* Vincent D et al.
Charpentier B (abst) . . . 510
Chauveau P (abst) . . . 450, 480
Chen-Gal B (abst) . . . 513
Cheng H-F, Nolasco F, Cameron J S, Hildreth G, Neild G, Hartley B: HLA-DR Display by Renal Tubular Epithelium and Phenotype of Infiltrate in Interstitial Nephritis . . . 205
Cheng I K P: *See* Chan M K et al.
Cheng I P K: *See* Chan M K et al.
Cheriex E C, Leunissen K M L, Janssen J H A, Mooy J M V, van Hooff J P: Echography of the Inferior Vena Cava is a Simple and Reliable Tool for Estimation of 'Dry Weight' in Haemodialysis Patients . . . 563
Cheriex E C: *See* Leunissen K M L et al.
Chida Y (abst) . . . 467
Chleq C (abst) . . . 454
Christensen L A, Schmidt E B, Mortensen P B, Hojhus J H: Pneumatosis Intestinalis in a Patient on Chronic Haemodialysis Treatment . . . 745
Chrzanowski W (abst) . . . 451
Chugh K S (letter) . . . 157
Chugh K S: *See* Pereira B J G et al.
Chung T G: *See* Ogawa H et al.
Cianciaruso B (abst) . . . 450
Ciccarelli M (abst) . . . 468
Cierniewski C S (abst) . . . 451
Cinti P (abst) . . . 518, 520
Cirami C (abst) . . . 424
Cirami C: *See* Grazi G et al.
Cirillo D (abst) . . . 455
Ciscato M (abst) . . . 485
Citti G: *See* Taccone-Gallucci M et al.
Civati G (abst) . . . 472, 481, 488
Cizman B (abst) . . . 593

Clark A G B (abst) . . . 313
Clark A G B, Oner A, Ward G, Turner C, Rigden S P A, Haycock G B, Chantler C: Safety and Efficacy of Calcium Carbonate in Children with Chronic Renal Failure . . . 539
Clark W F (abst) . . . 477
Clarke B F (abst) . . . 317, 436
Coad N A G (abst) . . . 313, 433
Coakley J (abst) . . . 444
Cobo M E: *See* Mampaso F M et al.
Cocchi R (abst) . . . 433
Cochlin D L (abst) . . . 319
Cohen S L (abst) . . . 317
Cohen S L, Boner G, Shmueli D, Yusim A, Rosenfeld J, Shapira Z: Cyclosporin: Poorly Tolerated in Familial Mediterranean Fever . . . 201
Cohen S L: *See* Woolf A S et al.
Cohen Solal M: *See* Moriniere Ph et al.
Cohen Solal M E (abst) . . . 467
Cohn M: *See* Modai D et al.
Colantonio G (abst) . . . 487
Coles G A (abst) . . . 318, 319, 476
Coles G A, Meadows J H, Bright C, Tomlinson K: The Estimation of Dietary Protein Intake in Chronic Renal Failure . . . 877
Coles G A: *See* Smith W G J et al.
Colhoun E N: *See* Madden B et al.
Colizzi M (abst) . . . 430
Collart F (abst) . . . 497
Collart F E: *See* Tielemans C L et al.
Colussi G (abst) . . . 417
Colussi G (letter) . . . 678
Colussi G, Rombola G, Surian M, De Ferrari M E, Airaghi C, Benazzi E, Malberti F, Minetti L: Effects of Acute Administration of Acetazolamide and Frusemide on Lithium Clearance in Humans . . . 707
Colussi G: *See* Surian M et al.
Comans E F I (abst) . . . 418
Comberti E: *See* Vigano G et al.
Comi N: *See* Fuiano G et al.
Cominotto R: *See* Grazi G et al.
Conte G: *See* Sabbatini M et al.
Conte J J (abst) . . . 434
Cook D (abst) . . . 470
Cook H T (abst) . . . 315
Cook T (abst) . . . 836
Coolen L (abst) . . . 479
Coppo B (abst) . . . 424
Coppo R (abst) . . . 423, 430, 440, 470, 490
Coppo R: *See* Roccatello D et al.
Coppo R, Amore A, Roccatello D, Amoroso A, Maffei S, Quattrocchio G, Molino A, Gianoglio B, Piccoli G: Complement Receptor (CR1) and IgG or IgA on Erythrocytes . . . 932
Coppola S (abst) . . . 416, 455
Çopur M S (abst) . . . 601
Corbetta C (abst) . . . 497
Cordes M (abst) . . . 436
Cordonnier D (abst) . . . 421
Cordonnier D (letter) . . . 839
Cordy P E (abst) . . . 477
Coronel F (letter) . . . 840
Corradi B: *See* Surian M et al.
Cortesini R (abst) . . . 518, 520
Corver W E (abst) . . . 424
Coscarella G (abst) . . . 416, 455
Cosseddu D (abst) . . . 437
Cosyns J P (abst) . . . 434, 506
Cotes P M (abst) . . . 833
Couetil J P (abst) . . . 459
Coulthard M G: *See* Ahmad T et al.
Coupes B M: *See* Short C D et al.
Courteau M (abst) . . . 429, 837
Couttenye M (abst) . . . 479
Cowan P (abst) . . . 317, 436
Cowie J F: *See* Jenkins D A S et al.
Craig K (abst) . . . 317
Crepaldi M: *See* Casati S et al.
Crevat A (abst) . . . 452
Cristinelli L (abst) . . . 441
Crowson M C, Berisa F, McGonigle R J S, Adu D, Michael J, Barnes A D: Selective Conversion from Azathioprine to Cyclosporin for Steroid-resistant Rejection in Renal Transplants: An Alternative Therapy . . . 129
Cubero J J (abst) . . . 496
Cumming A D (abst) . . . 481
Cunningham J (abst) . . . 428, 477, 518
Cunningham J (letter) . . . 759
Cunningham J: *See* Edmunds M E et al.
Cunningham J: *See* Sawyer N et al.
Cunningham J, Altmann P, Gleed J H, Butter K C, Marsh F P, O'Riordan J L H: Effect of Direction and rate of Change of Calcium on Parathyroid Hormone Secretion in Uraemia . . . 339
Curatola A (abst) . . . 468
Curatola G (abst) . . . 492
Curtis J R: *See* Sampson B et al.
Cutrupi S (abst) . . . 492
Cuzzola F (abst) . . . 463, 468
Dadah S (abst) . . . 594
Daelemans R (abst) . . . 479
Dagen M (abst) . . . 831
Daha M R (abst) . . . 521
Dal Canton A (abst) . . . 516
Dal Canton A: *See* Sabbatini M et al.
Dall'Aglio P P (abst) . . . 429
D'Amico G (abst) . . . 431
Danby P (abst) . . . 834
Danby P (letter) . . . 918–19
Daneels R (abst) . . . 754
Daneels R F (letter) . . . 676
Daneels R F: *See* Boelaert J R et al.
Daniel V (abst) . . . 506
Daniel W G (abst) . . . 478
Darvill A (abst) . . . 831
Da Silva J L (abst) . . . 472
Daugaard H (abst) . . . 480, 672
Daum V: *See* Baurmeister U et al.
Davenport A (abst) . . . 443, 503, 512
Davenport A, Will E J, Davison A M: The Effect of Lactate-Buffered Solutions on the Acid-Base Status of Patients with Renal Failure . . . 800
David B (abst) . . . 480
David S, Tagliavini D, Cambi V: Pre-postdilution Haemofiltration . . . 37
David-Neto E (abst) . . . 504
Davies J A: *See* Hopper A H et al.
Davies M (abst) . . . 419, 427
Davies M E (abst) . . . 319, 476
Davies S: *See* Sampson B et al.
Davison A M (abst) . . . 435, 443, 503, 512

Davison A M: *See* Davenport A et al.
Davison A M: *See* Worth D P et al.
Dawes J (abst) 481
Dawnay A (abst) 420, 466, 836
De Backer W A: *See* Heyrman R M et al.
De Baere Y A: *See* Boelaert J R et al.
De Baz H (abst) 485
De Bock V, Verbeelen D, Meas V, Sennesael J: Pharmacokinetics of Vancomycin in Patients Undergoing Haemodialysis and Haemofiltration 635
De Broe M E (abst) 479
De Broe M E: *See* Heyrman R M et al.
De Broe M E: *See* Van de Vyver F L et al.
de Paepe M (abst) 753
de Vinuesa S G (abst) 484
Decaux G (abst) 421
Deelder A (abst) 431
De Ferrari M E (abst) 417
De Ferrari M E (letter) 678
De Ferrari M E: *See* Colussi G et al.
de Fijter C W H (abst) 418, 752, 755
Defregger M (abst) 149, 151, 152
Degli Esposti E (abst) 433
Delcour C: *See* Cappello M et al.
Delgado A (abst) 514
Delons S (abst) 480
Del Principe D: *See* Taccone-Gallucci M et al.
delRió G (abst) 438
Delvallez L (letter) 76
Demaine A G (abst) 313
De Marchi S (abst) 433, 489
De Maria G (abst) 486
De Meyer M (abst) 434, 481
De Nicola L (abst) 516
De Nicola L: *See* Sabbatini M et al.
de Nicolas R (abst) 427
Denis M C (abst) 421
Denneberg T (abst) 417, 434
De Oleo P (abst) 506
De Pauw L (abst) 517
De Pauw L: *See* Cappello M et al.
Depierreux M (abst) 517
De Plaen J F (abst) 444, 493
Deppisch R (abst) 489
Deray G (abst) 464
Derfler K (abst) . . . 150, 151, 153, 154, 456, 483, 488, 511, 518
Derfler K: *See* Biesenbach G et al.
Derveniotis V (abst) 482, 514
DeSanto N G (abst) 416, 455
Deschodt G (abst) 473
Deschodt G: *See* Floege J et al.
Deschodt-Lanckman M (abst) 517
Deschryver F: *See* Najean Y et al.
Desgres J (abst) 500
DeSimone G (abst) 455
De Smedt R A: *See* Boelaert J R et al.
De Sousa C: *See* Rogerson M E at al.
DeTommaso G (abst) 416
Devaux S (abst) 487
De Vecchi A (abst) 496, 514
Dewar J (abst) 470
Dewar J H: *See* Rodger R S C et al.
Dhaene M: *See* Cappello M et al.
D'Haese P C: *See* Van de Vyver F L et al.
Dharmasena A D (abst) 318
Dharmasena A D: *See* Smith W G J et al.
Diaz-Tejeiro R, Diez J, Maduell F, Esparza N, Errasti P, Purroy A: Successful Treatment with Ciprofloxacin of Multiresistant Salmonella Arthritis in a Renal Transplant Recipient 390
Dibble J B: *See* Young G A et al.
Di Carlo V (abst) 507
Dienstl E (abst) 148
Dietl P (abst) 149, 152
Díez J (abst) 443
Díez J: *See* Díaz-Tejeiro R et al.
Diles K (abst) 594, 598
Dion R (abst) 481
Disch F (abst) 838
Dische F E, Brooke I P, Cashman S J, Severn A, Taube D, Parsons V, Kershaw M, Reed A, Pusey C D: Reactivity of Monoclonal Antibody P1 with Glomerular Basement Membrane in Thin-Membrane Nephropathy 611
Dittmer R (abst) 520
Dittrich P (abst) 149, 151, 152, 154
Doche C (abst) 460
Dodds R A (abst) 419
Doerge L (abst) 512
Dogliani M (abst) 442, 466
Doherty C C (abst) 438
Doherty C C (letter) 237
Donker A J (abst) 455
Donker A J M (abst) 418, 422, 457, 459, 511, 752
Donohoe J: *See* O'Meara Y et al.
Donohoe M (abst) 435
Doorenbos C J (abst) 751
Dorhour Mees E J: *See* Rabelink A J et al.
Dorhout Mees E J: *See* Boer P et al.
Dosquet P: *See* Rondeau E et al.
Dossetor J B (abst) 428
Doubma S N (abst) 462
Douglas J F (abst) 476
Doumas M N (abst) 462
Drachman R, Isacsohn M, Rudensky B, Drukker A: Vaccination against Hepatitis B in Children and Adolescent Patients on Dialysis 372
Draibe S A (abst) 448, 454, 461, 487, 516
Dratwa M (abst) 497
Dratwa M: *See* Tielemans C L et al.
Drechsler U (abst) 455
Dreschler W D (abst) 752
Dreyfus G (abst) 459
Dreyling K W (abst) 418, 472
Drif M (abst) 499
Drinovec J (abst) 593, 599
Droz D (abst) 510
Drüeke T (abst) 470
Drueke T: *See* Najean Y et al.
Druet P (abst) 427, 517
Drukker A: *See* Drachman R et al.
Drukker W: The Founding of the EDTA: Facts and Lessons 401
Dubbelman R (abst) 751, 754
Dubernard J M: *See* Garnier J L et al.
Dubois M (abst) 454
Dubost C (abst) 470
Dueymes J M (abst) 434
Dulawa J (abst) 505
Dumann H (abst) 424, 520
Duncker W D: *See* Waldherr R et al.
Dupuy C A (abst) 482
Duque I (abst) 515

Dykes S R: *See* Brunner F P et al.; Ehrich J H H et al.; Rizzoni G et al.; Tufveson G et al.
Eadington D (letter) . . . 77
Earle K (abst) . . . 317
Eastham E J: *See* Ahmad T et al.
Eckardt K-U: *See* Kindler J et al.
Edefonti A (abst) . . . 497
Edmunds M E: *See* Williams B et al.
Edmunds M E, Walls J, Tucker B, Baker L R I, Tomson C R V, Ward M, Cunningham J, Moore R, Winearls C G: Seizures in Haemodialysis Patients Treated with Recombinant Human Erythropoietin . . . 1065
Edwards B S (abst) . . . 463
Efremidis S C (abst) . . . 463
Egfjord M (abst) . . . 673
Egido J (abst) . . . 423, 427, 429, 512
See Mampaso F M et al.
Ehmer B (abst) . . . 474
Ehmer B: *See* Kindler J et al.
Ehrich J H H (abst) . . . 425
Ehrich J H H, Rizzoni G, Broyer M, Brunner F P, Brynger H, Dykes S R, Geerlings W, Fassbinder W, Tufveson G, Selwood N H, Wing A J: Combined Report on Regular Dialysis and Transplantation of Children in Europe, 1987 . . . S2:33
Ehrich J H H: *See* Brunner F P et al.; Rizzoni G et al.; Tufveson G et al.
Eigler F W (abst) . . . 502, 521
Eilles Ch (abst) . . . 464
Eisenbach G (abst) . . . 433
Eisenbach G M: *See* Floege J et al.
Eiskjær H (abst) . . . 461, 464
Eklöf O (abst) . . . 436
Elder G (abst) . . . 419
Elder G E: *See* Brown J H et al.
El Esper N (abst) . . . 418
Eliasson K (abst) . . . 462
Elli M: *See* Taccone-Gallucci M et al.
Elliott H L (abst) . . . 835
El Matri A (abst) . . . 593, 599
El Nahas A M (abst) . . . 316, 456, 458
El Nahas A M: Glomerulosclerosis: Insights Into Pathogenesis and Treatment . . . 843
El Nahas A M: *See* Smith W G J et al.
El Ouakdi M (abst) . . . 593
El Quakdi M (abst) . . . 599
Elsen R (abst) . . . 452
Emancipator S N (abst) . . . 426
Emanuelsson B-M (abst) . . . 417
Emori T (abst) . . . 467
Endler M (abst) . . . 150
Enestrōm S (abst) . . . 434
Engelhardt E (abst) . . . 487
Engemann D (abst) . . . 595
Englund M (abst) . . . 432
Era K (abst) . . . 485
Erek E (letter) . . . 760
Eren Z (abst) . . . 590
Erenoğlu E (abst) . . . 590
Erkan İ (abst) . . . 594
Erman A (abst) . . . 513
Erne P: *See* Raine A E G et al.
Ernst W (abst) . . . 504
Errasti P: *See* Díaz-Tejeiro R et al.
Ertl G (abst) . . . 464
Esbrit P: *See* Manzano F et al.
Escassi A (abst) . . . 480, 489
Escolar G (abst) . . . 449
Esparrago J (abst) . . . 496
Esparza N (abst) . . . 443
Esparza N: *See* Díaz-Tejeiro R et al.
Esposito A: *See* Fuiano G et al.
Esposito C (abst) . . . 516
Esposito C: *See* Sabbatini M et al.
Etienne A (abst) . . . 482
Evangelista M (abst) . . . 448
Evangelisti R (abst) . . . 513
Evans D J (abst) . . . 314, 435, 832
Fagel W J (abst) . . . 751
Failla S (abst) . . . 496
Fairbanks L D (abst) . . . 835
Fairley K E (abst) . . . 831
Farge D (abst) . . . 459
Farmo A (abst) . . . 487
Farradini M (abst) . . . 486
Farrell P (abst) . . . 499
Fasciolo F (abst) . . . 497
Fassbinder W: *See* Brunner F P et al.; Ehrich J H H et al.; Noronha I L et al.; Rizzoni G et al.; Tufveson G et al.
Fauchald P (abst) . . . 509
Faure J L: *See* Garnier J L et al.
Faure M (abst) . . . 421
Fauvel J P (abst) . . . 460
Faxel I (abst) . . . 588
Fay W P (abst) . . . 477
Fazekas F (abst) . . . 474
Fazel I (abst) . . . 589
Fdez B de Quiros J: *See* Aguadó S et al.
Fdez I (abst) . . . 468
Fdez J L (abst) . . . 468
Fdez-Vega F: *See* Aguadó S et al.
Fecht H: *See* Keller E et al.
Feehally J (abst) . . . 515, 833, 834, 835
Feehally J (letter) . . . 918–19
Feehally J: *See* Williams B et al.
Feest T G (abst) . . . 435
Felix R (abst) . . . 436
Feller P (abst) . . . 486
Feller P: *See* Maiorca R et al.
Fellstrom B: *See* Hanas E et al.
Ferhaoui S (abst) . . . 591
Fernández C (abst) . . . 438, 439
Fernández E (letter) . . . 840
Fernandez Martin J L (abst) . . . 468
Fernandez Mdez M J (abst) . . . 468
Fernando O N: *See* Lui S F et al.
Fernando O N: *See* Sweny P et al.
Ferradini M (abst) . . . 487
Ferrari G (abst) . . . 507
Ferrario F (abst) . . . 425
Fervenza F (abst) . . . 472
Fianchino O (abst) . . . 442
Fich C (abst) . . . 434
Fiegel P: *See* Röckel A et al.
Fieren M W J A (abst) . . . 751
Fiers W (abst) . . . 497
Fievet P (abst) . . . 418
Filella X (abst) . . . 449
Fine R N: *See* Leichter H E et al.
Fiocchi O (abst) . . . 513
Fiorelli G (abst) . . . 472
Fischbach M (abst) . . . 482

Fitting C (abst) . . . 480
Fjeldborg O (abst) . . . 670
Flatmark A (abst) . . . 509
Flavier J L (abst) . . . 482
Fleming S (abst) . . . 315, 835
Fleming S, Jones D B, Moore K: B-cell Markers in the Human Kidney . . . 85
Fleming S J: *See* Pickering S J et al.
Fleuren G J (abst) . . . 423, 424
Floege J (abst) . . . 422, 425, 493
Floege J, Granolleras C, Deschodt G, Heck M, Baudin G, Branger B, Tournier O, Reinhard B, Eisenbach G M, Smeby L C, Koch K M, Shaldon S: High-Flux Synthetic Versus Cellulosic Membranes for β_2-Microglobulin Removal . . . 653
Floege J, Granolleras C, Shaldon S, Koch K M: Dialysis-related Amyloidosis: Pathogenetic Aspects and Open Questions. . . . S3:3
Floren T (abst) . . . 469
Foda M (abst) . . . 519
Foged N (abst) . . . 672
Fogh-Andersen N (abst) . . . 504, 672
Forman E (abst) . . . 472
Formica M (abst) . . . 470, 490, 512
Forneris G (abst) . . . 512
Forsythe J L R: *See* Kirby J A et al.
Fort J (abst) . . . 493
Foulon T (abst) . . . 421
Fournier A (abst) . . . 418, 432, 467
Fournier A: *See* Moriniere Ph et al.
Fox J G: *See* Sutcliffe N P et al.
Fracasso A R: *See* Pertosa G et al.
Frampton G (abst) . . . 426
Franco A (abst) . . . 486
Francois B: *See* Cahen R et al.
Frankenschmidt A (abst) . . . 418
Franklin H (abst) . . . 751, 754
Franks C R (abst) . . . 445
Freestone S: *See* Jeffrey R F et al.
Frei D (abst) . . . 509
Frei U (abst) . . . 478, 511
Frenken L A M, Verberckmoes R, Michielsen P, Koene R A P: Efficacy and Tolerance of Treatment with Recombinant-Human Erythropoietin in Chronic Renal Failure (Pre-Dialysis) Patients . . . 782
Fries D (abst) . . . 510
Fritschka E (abst) . . . 477
Fröhling P T (abst) . . . 451, 453
Frutos M A (abst) . . . 435
Frycz J (abst) . . . 505
Fuiano G (abst) . . . 516
Fuiano G, Stanziale P, Balletta M, Sepe V, Marinelli G, Comi N, Esposito A, Andreucci V E: Effectiveness of Steroid Therapy in Different Stages of Membranous Nephropathy . . . 1022
Fumiaki Marumo, Yusuke Tsukamoto, Shigeru Iwanami: Trace Elements in Chronic Renal Failure Patients . . S3:97
Fumiaki Marumo: *See* Yusuke Tsukamoto et al.
Fumitake Gejyo, Noriyuki Homma, Masaaki Arakawa, β_2-Microglobulin-derived Amyloid and Calcium Deposition in Dialysis Patients . . . S3:11
Funaro A: *See* Roccatello D et al.
Fürsch A (abst) . . . 458
Fusaroli M (abst) . . . 433
Fyhrquist F (abst) . . . 465
Gabl F (abst) . . . 153
Gagliardi L (abst) . . . 442
Gago E: *See* Aguadó S et al.
Gahl G (abst) . . . 436, 498
Galato R (abst) . . . 488
Gale E A M (abst) . . . 420
Gallego A (abst) . . . 444
Gallice P (abst) . . . 452
Galofre J: *See* Campistol J M et al.
Gammelgaard B (abst) . . . 671
Gans R O B (abst) . . . 459
Ganten D (abst) . . . 460, 463
Garabedian M (abst) . . . 467
Garavaglia G (abst) . . . 462
Garbis S (abst) . . . 594, 598
Garcia M C (abst) . . . 504
Garcia M F (abst) . . . 444
Garcia R (abst) . . . 832
Garcia-Canero R: *See* Manzano F et al.
Garcia-Ocana A: *See* Manzano F et al.
Gardin J P (abst) . . . 510
Garnier J L, Berger F, Betuel H, Vuillaume M, Chapuis-Cellier C, Blanc N, Faure J L, Dubernard J M, Lenoir G, Touraine J L: Epstein-Barr Virus Associated Lymphoproliferative Diseases *(B Cell Lymphoma)* After Transplantation . . . 818
Garofalo A R (abst) . . . 430
Garred L J (abst) . . . 482
Garred L J: *See* Canaud B et al.
Garrido M (abst) . . . 449
Garvie N (abst) . . . 477
Gaskin G (abst) . . . 435, 832
Gassner H (abst) . . . 154
Gaube S (abst) . . . 459
Gaucher A (abst) . . . 494
Gaudin O: *See* Guerin C et al.
Geerlings W: *See* Brunner F P et al.; Ehrich J H H et al.; Rizzoni G et al.; Tufveson G et al.
Geiger H (abst) . . . 463, 464, 472
Geisert J (abst) . . . 482
Geissler K (abst) . . . 147
Genderini A (abst) . . . 426
Gesualdo L (abst) . . . 426
Ghatei M A (abst) . . . 463
Ghio L (abst) . . . 497
Ghods A (abst) . . . 588, 589
Ghoneim M (abst) . . . 431, 519, 595
Ghoneim M A: *See* Moustafa F E et al.
Ghysen J (abst) . . . 493
Giachino G (abst) . . . 470
Giangrande A: *See* Vigano G et al.
Giani M (abst) . . . 497
Gianoglio B (abst) . . . 423, 424, 490
Gianoglio B: *See* Coppo R et al.
Giardini O (letter) . . . 76
Giardini O: *See* Taccone-Gallucci M et al.
Gibson J: *See* Young G A et al.
Gibson-Knight C (abst) . . . 448
Gielow P (abst) . . . 493
Giesel R (abst) . . . 460
Giessauf W (abst) . . . 144
Gilbertson A A (abst) . . . 445
Giles G R (abst) . . . 503
Gilgin N (abst) . . . 598
Gillery P: *See* Chanard J et al.
Gilli G (abst) . . . 487
Gilly J: *See* Cahen R et al.

Gil-Vernet S (letter) . . . 675
Giordani M: *See* Taccone-Gallucci M et al.
Giordano D R (abst) . . . 416, 455
Giraudo G (abst) . . . 430
Gisinger C (abst) . . . 151, 459
Giura C (abst) . . . 487
Gladziwa U: *See* Ittel T H et al.
Glaros D (abst) . . . 470
Gleed J H: *See* Cunningham J et al.
Glez-Posada J M (abst) . . . 504
Gloer D (abst) . . . 416
Gloor F (abst) . . . 145
Glud T (abst) . . . 465
Gobran H (abst) . . . 600
Godard C A: *See* Boelaert J R et al.
Godin M (abst) . . . 419
Goksoy E (letter) . . . 760
Gol Danesh S (abst) . . . 595
Goldfarb B (abst) . . . 483
Goldfarb B: *See* Pochet J -M et al.
Goldman M (abst) . . . 497, 517
Golzio P G (abst) . . . 465
Gómez C (abst) . . . 427, 512
Gómez E: *See* Aguadó S et al.
Gómez-Chiarri M (abst) . . . 427, 512
Gómez-Tejada E (letter) . . . 840
Gonzales R (abst) . . . 513
González E: *See* Mampaso F M et al.
González E (abst) . . . 427, 512
González M T (letter) . . . 675
Gonzalez-Cabrero J (abst) . . . 429
Goodship T H J (abst) . . . 437, 495, 833
Gordts B Z: *See* Boelaert J R et al.
Goren E: *See* Modai D et al.
Gotti E: *See* Vigano G et al.
Götz R (abst) . . . 455, 464
Gouldesbrough D: *See* Jenkins D A S et al.
Gower P E (abst) . . . 318, 494, 495
Gower P E: *See* Sethi D et al.
Grabensee B (abst) . . . 500, 514
Grady D (abst) . . . 495, 833
Graf H (abst) . . . 146, 147, 153, 155, 473
Graf H: *See* Cada E et al.
Grafinger P (abst) . . . 145
Gräning M (abst) . . . 495
Granolleras C (abst) . . . 473
Granolleras C: *See* Floege J et al.
Grant A (abst) . . . 835
Grant A C (abst) . . . 318
Grazi G (abst) . . . 424
Grazi G, Cirami C, Panichi V, Bianchi A M, Parrini M, Baronti A, Cominotto R, Montagnani E, Palla R: Renal Effects of Enalapril in Hypertensive Patients with Glomerulonephritis . . . 396
Graziani G (abst) . . . 514
Graziani G: *See* Casati S et al.
Grčevska L (abst) . . . 461
Green A: *See* O'Meara Y et al.
Greger B (abst) . . . 597
Gregg N J (abst) . . . 448
Gregoire I (abst) . . . 418
Gregorini G (abst) . . . 431
Grekas D (abst) . . . 482, 514
Griegat K P (abst) . . . 595
Griffiths R D (abst) . . . 444
Grönhagen-Riska C (abst) . . . 465
Grosoli M (letter) . . . 1083
Gross M (abst) . . . 462
Gross-Heitfeld E (abst) . . . 474
Grosse-Wilde H (abst) . . . 502, 521
Grossi G: *See* Vandelli L et al.
Groszmann R J (abst) . . . 458
Grünfeld J P (abst) . . . 419, 438, 506, 514
Grünfeld J P: *See* Pochet J-M et al.
Grünfeld J P: *See* van den Heuvel L P W J et al.
Grutzmacher P (abst) . . . 473, 474
Grzeszczak W (abst) . . . 475, 505
Grzeszczak W: *See* Kokot F et al.
Gu J-H (abst) . . . 446
Gualde N: *See* Vincent D et al.
Guarena C (abst) . . . 470, 512
Guastoni C (abst) . . . 481, 488
Guerin C, Pozzetto B, Broyet C, Gaudin D, Berthoux F: Ganciclovir Therapy of Symptomatic Cytomegalovirus Infection . . . 906
Gueris J (abst) . . . 467
Guerra M G (abst) . . . 430
Guerra M G: *See* Roccatello D et al.
Guerrero R (abst) . . . 480, 489
Guery J-C (abst) . . . 427
Guiguet M (abst) . . . 500
Guillemain R (abst) . . . 459
Guivarch P H (letter) . . . 839
Gulay H (abst) . . . 518, 590, 591, 592, 593, 594, 595, 597, 598, 600, 601
Gupta A: *See* Pereira B J G et al.
Gurioli L (abst) . . . 442, 466
Gurland H J: *See* Blumenstein M et al.; Bosch Th et al.; Ward R A et al.
Gusmano R (abst) . . . 497
Gwyther S J (abst) . . . 447
Haberal H (abst) . . . 590
Haberal M (abst) . . . 518, 591, 592, 593, 594, 595, 597, 598, 600, 601
Habscheid W (abst) . . . 464
Habul V (abst) . . . 443
Hackenthal E: *See* Mann J F E et al.
Hadidiy S (abst) . . . 593
Hadj-Aïssa A (abst) . . . 445, 456, 460
Haentjens D (abst) . . . 753
Hafez H (abst) . . . 600
Haid A (abst) . . . 154
Haimovitch L (abst) . . . 439
Hajek-Rosenmayr A (abst) . . . 589
Halbauer M: *See* Tomić B H et al.
Halilbašić A (abst) . . . 443
Hall I P (abst) . . . 435
Hall T L: *See* Leichter H E et al.
Halloran P F (abst) . . . 428
Hamaloğlu E (abst) . . . 518, 591, 594, 597, 598, 601
Hamari N (abst) . . . 591
Hamdy N A T, Andrew S M, Shortland J R, Boletis J, Raftery A T, Kanis J A, Brown C B: Fatal Cardiac Zygomycosis in a Renal Transplant Patient Treated with Desferrioxamine . . . 911
Hamdy N A T, Brown C B, Kanis J A: Intravenous Calcitriol Lowers Serum Calcium Concentrations in Uraemic Patients with Severe Hyperparathyroidism and Hypercalcaemia . . . 545
Hamdy N A T, McCloskey E V, Naylor V A, Brown C B, Kanis J A: Phosphate Binding Efficiency of a Polyuronic Acid in Normal Subjects . . . 829

Hanas E, Totterman T H, Fellstrom B, Bergstrom R, Tufveson G: Circulating T-Lymphocyte Sub-Subsets and NK-Like Cells in Renal Transplant Patients: Patterns Associated with Rejection 735
Hancock K (letter) 759
Hanke P (abst) 504
Hannedouche T (abst) 419, 514
Hänsch G M (abst) 431
Hansen H H (abst) 461
Hansen J M (abst) 504, 672
Hansen P R (abst) 502, 670
Hanson M E (abst) 447, 508
Harada T (abst) 426
Harding M: *See* Vienken J, Harding M
Harfmann P (abst) 520
Harris K P G (abst) 834
Harris K P G (letter) 679
Harrison D (letter) 77
Harrison D: *See* Beardsworth S F et al.
Harrison N A, Masterton R G, Bateman J M, Rainford D J: C-Reactive Protein in Acute Renal Failure 864
Hartley B: *See* Cheng H-F et al.
Hartley G H (abst) 437
Hartley R B: *See* Alexopoulos E et al.
Hartter E (abst) 148
Harumitsu Kumajai: *See* Kaoru Onoyama et al.
Hasibeder W (abst) 154
Haskova V (abst) 596
Hasler K: *See* Bohler J et al.
Hass R (abst) 422
Hassan A (abst) 600
Hasslacher Ch: *See* Mann J F E et al.
Hasslacher Ch, Ritz E, Wahl P, Michael C: Similar Risks of Nephropathy in Patients with Type I or Type II Diabetes Mellitus 859
Hattersley J (abst) 833
Hauenstein K-H: *See* Bohler J et al.
Hauser A C (abst) 150, 153, 154, 456, 483, 488, 508, 518
Hauser C (abst) 150, 151
Hauser C: *See* Biesenbach G et al.
Hauser I (abst) 504
Havemann K (abst) 509
Hawkins P N (abst) 494
Haycock G B: *See* Clarke A G B et al.
Heaf J G (abst) 671
Heck M: *See* Floege J et al.
Hed J (abst) 490
Heering P (abst) 514
Heezius H C J M (abst) 752
Heidbreder E (abst) 455, 464
Heidland A (abst) 455, 463, 464
Heidland A, Schaefer R M, Teschner M, Hörl W H: Proteases in Uraemia S3:127
Heimbürger D: *See* Lindholm B et al.
Heine R J (abst) 459
Heinegard D: *See* Bygren P et al.
Heinrich U (abst) 451
Heintz A P M (abst) 751, 754
Heintz B (abst) 474
Helliwell T R (abst) 444
Heney D, Brocklebank J T, Wilson N: Continuous Arteriovenous Haemofiltration in the Newlyborn with Acute Renal Failure and Congenital Heart Disease 870
Henin P (abst) 444
Henning K (abst) 145
Henning P H, Bewick M, Reidy J F, Rigden S P A, Neild G H, Chantler C: Increased Incidence of Renal Transplant Arterial Stenosis in Children 575
Henon G (abst) 432
Herman A: *See* Vanholder R et al.
Hernandez D (abst) 504
Hernando L (abst) 427, 429, 503, 512, 515
Hernando L: *See* Mampaso F M et al.
Hernando N (abst) 503
Hernando P (abst) 427
Herrero-Beaumont G (abst) 429
Hertel J: *See* Röckel A et al.
Hess Thaysen J (abst) 671
Heymanns J (abst) 509
Heyrman R M, De Backer W A, Van Waeleghem J P, De Broe M E: The Effect of Acetate on Ventilation in Haemodialysis Patients 1060
Hidalgo L (abst) 506
Hidemune Naito, Tetsuo Miyazaki: Haemodialysis with Protein Permeable Membranes S3:78
Hiesse C (abst) 510
Hildreth G: *See* Cheng H-F et al.
Hilgers K F (abst) 460
Hill C M (abst) 438
Hill C M (letter) 237
Hillis A N (abst) 419
Hilton P J (abst) 316, 516, 838
Hinterberger W (abst) 147
Hirashima K (abst) 475
Hiroaki Aoki: *See* Akira Yoshida et al.
Hiroko Nomiyama: *See* Kazuo Nomiyama, Hiroko Nomiyama
Hiroshi Fukumura: *See* Susumu Yoshikawa et al.
Hiroyuki Kobayakawa: *See* Kenji Maeda et al.
Hirsch D J: Death from Dialysis Termination 41
Hitman G A (abst) 428
Hobby P (abst) 429, 837
Hobson S M: *See* Young G A et al.
Hocine Ch: *See* Moriniere Ph et al.
Hodsman A B (abst) 477
Hodson A (abst) 508
Hoedemaeker Ph J (abst) 423
Hoefsmit E C M (abst) 752
Hoek D J (abst) 420
Hoek F J (abst) 498, 501, 755
Hoffbrand B I (abst) 317
Höffler D (abst) 520
Hofstädter F (abst) 484
Hofstädter F: *See* Ittel T H et al.
Hoitsma A J (letter) 239
Hoitsma A J: *See* Wetzels J F M et al.
Hojhus J H: *See* Christensen L A et al.
Holden M: *See* Smith W G J et al.
Holland M J (abst) 314
Hollomby D J (abst) 477
Hölscher M (abst) 590
Holzer H (abst) 144, 474
Homatas J (abst) 594, 598
Hombrouckx R (abst) 483, 484
Hopferwieser T (abst) 154
Hopper A H, Tindall H, Davies J A: Administration of Aspirin-Dipyridamole Reduces Proteinuria in Diabetic Nephropathy 140
Hopt U T (abst) 597
Horina J (abst) 144, 146, 474
Hörl W H (abst) 472

Hörl W H: *See* Heidland A et al.; Wanner C et al.
Hörner M (abst) 456
Hortal L (letter) 840
Horton J (abst) 419
Horton J K (abst) 427
Hosokawa S, Yoshida O: Vanadium in Patients Undergoing Chronic Haemodialysis. 282
Hourmant M (abst) 503
Howard J: *See* Rogerson M E at al.
Howie A J (abst) 314
Hruby Z (abst) 428
Hughes R T (abst) 833
Huissoon A P: *See* Madden B et al.
Hulme B (letter) 759
Hultman E (abst). 471
Hundeshagen H (abst) 493
Huser B: *See* Zuber M et al.
Hutton R D (abst). 319, 476
Huysmans F Th M: *See* Wetzels J F M et al.
Iacone A (abst) 416
Iaina A (abst). 462
Ianhez L E (abst) 504, 507
Ibels L (abst) 499
Ilan Z (abst) 462
Ilić S (abst) 444
Imamović G (abst) 443
Isacsohn M: *See* Drachman R et al.
Iscovici E (abst) 462
Iskander I (abst) 600
Ittel T H (abst) 484
Ittel T H, Hofstädter F, Gladziwa U, Sieberth H G: Reduced Deposition of Aluminium in Trabecular Bone of Uraemic Rats Treated with Dihydroxylated Vitamin D Metabolites. 957
Ivanovich P: *See* Stein G et al.
Ivaskova E (abst). 589
Jacobs C (abst) 443, 454, 464
Jacobsen B A (abst) 671, 673
Jacobsen L (abst). 671
Jacobson S H (abst) 436, 490
Jacquillat C (abst) 454
Jacquot C (letter). 675
Jacquot Ch: *See* Najean Y et al.
Jahn C (abst) 478
Jaisser F: *See* Chanard J et al.
James E: *See* Morales-Barria J et al.
Jandeleit K (abst) 474
Jandeleit K: *See* Kindler J et al.
Janetschko R (abst) 144, 153, 154
Jans I (abst) 432
Janssen J H A: *See* Cheriex E C et al.
Jaudon M C (abst) 454
Javnikar A M (abst) 477
Jayne D (abst) 426
Jayne D R W (abst) 314
Jeffrey R F, MacDonald T M, Freestone S, Lee M R: The Effect of Carbidopa and Lithium on the Systemic and Renal Response to Acute Intravenous Saline Loading in Normal Man 271
Jenkins D (letter). 679
Jenkins D, Burton P R, Bennett S E, Baker F, Walls J: The Metabolic Consequences of the Correction of Acidosis in Uraemia 92
Jenkins D A S (abst). 317, 436
Jenkins D A S, Gouldesbrough D, Smith G D, Cowie J F, Winney R J: Can Low-dosage Aluminium Hydroxide Control the Plasma Phosphate without Bone Toxicity? 51
Jensen B N (abst). 673
Jensen F T (abst). 461
Jeremy J Y: *See* Sweny P et al.
Jespersen B (abst) 461, 464
Jeung H M (abst) 501, 752, 755
Jiménez Diaz F (abst) 512
Jimenez-Clavero M A: *See* Manzano F et al.
Jirka J (abst). 589, 596
Joffe P (abst) 671
John P (abst). 591, 592
Johnson R W G: *See* Short C D et al.
Johnston C F (abst) 420
Jolain B (letter). 839
Jones D B (abst) 315
Jones D B: *See* Fleming S et al.
Jones M C (abst) 838
Jones S: *See* Abbott F et al.
Jones S J (abst) 314
Jones S L (abst) 419
Jonges E (abst) 521
Jordan S C (abst). 452
Jörres A (abst) 498
Jothy S (abst). 428
Judmaier G (abst) 152
Juhasz M (abst) 152
Julien J (abst). 459
Junco E (abst) 484, 486
Junge W: *See* Neumayer H-H et al.
Jünger E (abst) 440
Jungers P (abst) 450
Junor B J R (abst) 318
Juul N O (abst). 671
Kaeser U: *See* Sundal E, Kaeser U, Kågedal B (abst). . . . 417
Kainberger F (abst) 150
Kaiser W (abst) 145, 148, 511
Kaiser W: *See* Biesenbach G et al.
Kalafat H (letter). 760
Kalawi M (abst) 597
Kalef-Ezra J (abst). 470
Kalekou H (abst). 514
Kambova L (letter) 602
Kamgooyan M (abst) 588
Kamgouian M (abst). 595
Kamoun P (abst). 450
Kamper A L (abst) 450, 672
Kandus A (abst) 593
Kaneko M: *See* Akizawa T et al.
Kanfer A: *See* Nehme D et al.
Kanfer A: *See* Rondeau E et al.
Kanis J A: *See* Hamdy N A T et al.
Kaoru Onoyama, Harumitsu Kumajai, Kazuto Takeda, Kazumasa Shimamatsu, Mastoshi Fujishima: Effects of Human Recombinant Erythropoietin on Anaemia, Systemic Haemodynamics and Renal Function in Predialysis Renal Failure Patients 966
Kaplan-Pavlovcic S (abst). 599
Kapoulas S (abst) 482
Karaaslan Y (abst). 594
Karamehic J (abst). 520
Karamouzis M (abst) 514
Karayiannis A J (abst). 462
Karcher D: *See* Mann J F E et al.
Karèche M (abst). 499
Kargl R (abst) 148
Karnel F (abst) 152, 153

Karnel F: *See* Cada E et al.
Kaslik J (abst) . . . 596
Kaslikova J (abst) . . . 596
Kathrein H (abst) . . . 151, 152
Kauffmann R H (abst) . . . 753
Kaufmann J (abst) . . . 479
Kazua Ota: *See* Mitsuyasu Toyoda et al.
Kazuko Hayashi: *See* Susumu Yoshikawa et al.
Kazumasa Shimamatsu: *See* Kaoru Onoyama et al.
Kazuo Nomiyama, Hiroko Nomiyama: Some Considerations in the Determination of Metals in Biological Materials . . . S3:114
Kazuo Ota, Uri Kitano, Nobuyuki Miyasaka: Clinical and Pathophysiological Aspects of Dialysis-associated Amyloidosis . . . S3:7
Kazuto Takeda: *See* Kaoru Onoyama et al.
Keavey P M (abst) . . . 437
Kechrid C (abst) . . . 593, 599
Kei Furiya: *See* Mitsuyasu Toyoda et al.
Keller E (abst) . . . 416, 454
Keller E, Fecht H, Böhler J, Schollmeyer P: Single-Dose Kinetics of Imipenem/Cilastatin During Continuous Arteriovenous Haemofiltration in Intensive Care Patients . . . 640
Kemmer F (abst) . . . 500
Kendall S: *See* Young G A et al.
Kenji Maeda, Takahiro Shinzato, Hiroyuki Kobayakawa: Effect of Convective Transport on Removal of Small Molecular Proteins—Application of Push/Pull Haemodiafiltration . . . S3:83
Kennedy H (abst) . . . 438
Keogh J A B: *See* Madden B et al.
Keown P A (abst) . . . 477
Kern P (abst) . . . 452
Kerr D N S: EDTA to ERA . . . 411
Kerr D N S: *See* Rodger R S C et al.
Kershaw M: *See* Dische F E et al.
Keske U (abst) . . . 436
Kessel M (abst) . . . 498
Kessler M (abst) . . . 494
Kesteloot D (abst) . . . 422
Kesteloot D: *See* Vanholder R et al.
Keusch G (abst) . . . 509
Khodia Bach M (abst) . . . 591
Khoss A E (abst) . . . 145, 146
Khoury G (abst) . . . 481
Kiersztejn M (abst) . . . 466
Kincaid-Smith P S (abst) . . . 831
Kindler J (abst) . . . 474, 484
Kindler J, Eckardt K-U, Ehmer B, Jandeleit K, Kurtz A, Schreiber A, Scigalla P, Sieberth H-G: Single-dose Pharmacokinetics of Recombinant Human Erythropoietin in Patients with Various Degrees of Renal Failure . . . 345
Kinnaert P (abst) . . . 517
Kinnaert P: *See* Cappello M et al.
Kiparski A v (abst) . . . 509
Kirby J A, Forsythe J L R, Simm A, Proud G, Taylor R M R: Renal Allograft Rejection: Protection of Renal Tubular Epithelial Cells from Lymphokine Activated Killer Cell Mediated Lysis by Pretreatment with Cytokines . . . 824
Kirjakov Z (letter) . . . 75, 602
Kirkwood A (abst) . . . 495, 833
Kishimoto T (abst) . . . 489
Kitano Y (abst) . . . 485
Kitaoka T (abst) . . . 494
Kitas G (abst) . . . 313
Kiyoshi Ozawa: *See* Akira Yoshida et al.
Kiyotaka Sakai: Technical Determination of Optimal Dimensions of Hollow Fibre Membranes for Clinical Dialysis . . . S3:73
Kizaki T (abst) . . . 314
Kjellstrand C M (abst) . . . 462
Klare B (abst) . . . 446
Klaus G (abst) . . . 469
Klauser R (abst) . . . 459
Klehr H U (abst) . . . 462
Kleinknecht D (abst) . . . 419
Kleinknecht D, Bobrie G, Meyer O, Noël L H, Callard P, Ramdane M: Recurrent Thrombosis and Renal Vascular Disease in Patients With a Lupus Anticoagulant . . . 854
Klin M (abst) . . . 466, 475
Klinke B: *See* Röckel A et al.
Klinkmann H (abst) . . . 452
Klinkmann H: Summary of Dialysis Update 1988 . . . S3:151
Klinkmann H: The First Twenty-five Years . . . 400
Kloss M (abst) . . . 831
Kluthe R (abst) . . . 501
Knapowski J (abst) . . . 498
Knapp E (abst) . . . 154
Knols G, Leunissen K M L, Spaapen L J M, Bosman F T, Wiel T W M v d, Kootstra G, van Hooff J P: Recurrence of Nephrocalcinosis After Renal Transplantation in an Adult Patient with Primary Hyperoxaluria Type I . . . 137
Kobryn A (abst) . . . 589
Kocandrle V (abst) . . . 589, 596
Koch K M (abst) . . . 425, 433, 448, 478, 493
Koch K M: *See* Floege J et al.
Koch M (letter) . . . 399
Koene R A P (letter) . . . 239
Koene R A P: *See* Frenken L A M et al.
Koene R A P: *See* Wetzels J F M et al.
Köhler H (abst) . . . 424, 520
Koivula T: *See* Pietilä K et al.
Kokot F (abst) . . . 466, 475, 505
Kokot F, Grzeszczak W, Wiecek A: Water Immersion Induced Alterations of Atrial Natriuretic Peptide in Patients with Non-Inflammatory Acute Renal Failure . 691
König P (abst) . . . 149, 151, 152
Kontessis P S (abst) . . . 419
Koomans H A: *See* Boer P et al.
Koomans H A: *See* Rabelink A J et al.
Koomen G C M (abst) . . . 420, 450, 498, 501, 755
Koomen G C M: *See* Koopman M G et al.
Koopman M G (abst) . . . 420
Koopman M G, Krediet R T, Koomen G C M, Strackee J, Arisz L: Circadian Rhythm of Proteinuria: Consequences of the Use of Urinary Protein:Creatinine Ratios . . . 9
Koostra G (abst) . . . 590
Kootstra G: *See* Knols G et al.
Kootte A M M (abst) . . . 505
Kopple J D (abst) . . . 450
Kopsa H (abst) . . . 153, 505, 596
Korninger Ch (abst) . . . 148
Korstanje M J (abst) . . . 511
Korzets A (letter) . . . 918–19
Korzets Z (abst) . . . 439, 453
Koselj M (abst) . . . 599
Koshikawa S (abst) . . . 494
Koshikawa S: *See* Akizawa T et al.

Koshino Y (abst) . . . 315, 837
Kostakis A (abst) . . . 594, 598
Koteva A (letter) . . . 75
Köttgen E (abst) . . . 498
Kovarik J (abst) 149, 150, 152, 459, 506, 519, 520, 588, 589, 596
Kox W (abst) . . . 447
Kramar R (abst) . . . 144
Kramer W (abst) . . . 479
Kraus L (abst) . . . 453
Krause P H (abst) . . . 510
Krediet R J (abst) . . . 755
Krediet R T (abst) . . . 420, 450, 498, 501, 754, 755
Krediet R T: *See* Koopman M G et al.
Kreis H (abst) . . . 510, 519
Krivoshiev S (letter) . . . 75, 602
Krouri A (abst) . . . 499
Kuczera M (abst) . . . 460, 466
Küfner A: *See* Neumayer H-H et al.
Kumar L (letter) . . . 157
Kumar M S A (abst) . . . 589, 591, 592, 594, 597, 599
Kundi M (abst) . . . 596
Küntziger H (abst) . . . 482
Kurihara S (abst) . . . 475
Kuriyama R (abst) . . . 467
Kurtz A: *See* Kindler J et al.
Kyriakidis S T (abst) . . . 594, 598
Kyrle P A (abst) . . . 148
Laaban J P (abst) . . . 443
Labeeuw M (abst) . . . 437, 456, 460, 468
Lacerda M H: *See* Ponce P et al.
Lacombe C (abst) . . . 472
Lacour B (abst) . . . 470, 514
Ladefoged J (abst) . . . 670
Ladefoged S (abst) . . . 502, 670
Ladefoged S D (abst) . . . 504, 672
Laekeman G: *See* Vanholder R et al.
Lahdensua A: *See* Puolijoki H et al.
Laidlaw S: *See* Leichter H E et al.
Laker M F (abst) . . . 454
Laker M F: *See* Tomson C R V et al.
Lakhdar B (abst) . . . 513
Lamas S (abst) . . . 515
Lamb E (abst) . . . 420
Lamberights G (abst) . . . 753
Lambie A T (abst) . . . 481
Lámeire N (abst) . . . 422, 497, 753
Lámeire N: *See* Vanholder R et al.
Lamm M F (abst) . . . 426
Lamperi S (abst) . . . 475, 490, 496
Landais P: *See* Pochet J -M et al.
Landais P (abst) . . . 519
Landon J (abst) . . . 466, 836
Landriani N (abst) . . . 426
Lange H (abst) . . . 509
Langer K (abst) . . . 453
Langle F: *See* Cadá E et al.
Lanigan C: *See* Rogerson M E at al.
Lantz O (abst) . . . 510
Lapin A (abst) . . . 150, 153, 505
Lappin T R J (abst) . . . 420, 476
Lappin T R J: *See* Brown J H et al.
Laradi A (abst) . . . 499
Lareal M C (abst) . . . 437, 468
Largiader F (abst) . . . 509
La Rocca E (abst) . . . 507
Launay J-M (abst) . . . 480
Laupacis A (abst) . . . 477
Lauritsen H K (abst) . . . 504, 672
Lauritzen H K (abst) . . . 502, 670
Laval Jeantet A M (abst) . . . 432
Lavaud S (abst) . . . 492
Lavaud S: *See* Chanard J et al.
Lavelle J M (letter) . . . 679
Laville M (abst) . . . 456, 460
Le Bras J-H (abst) . . . 456
Leaker B (abst) . . . 832
Le Carpentier J E (abst) . . . 316, 456, 458
Lechner K (abst) . . . 148
Lecrique T (abst) . . . 438
Lee M R: *See* Jeffrey R F et al.
Legendre Ch (abst) . . . 519
Legrand J C (abst) . . . 464
Leichter H E, Salusky I B, Lilien T v, Laidlaw S, Alliapoulos J C, Hall T L, Fine R N: Peritoneal Clearances with Different Dialysis Regimens in Children Undergoing Continuous Cycling Peritoneal Dialysis . . . 893
Leimenstoll G (abst) . . . 595
Leitner E (abst) . . . 144, 153, 154
Lemke E (abst) . . . 451
Lenclud C M: *See* Tielemans C L et al.
Lenoir G: *See* Garnier J L et al.
Lens X M, Montoliu J, Cases A, Campistol J M, Revert L: Treatment of Hyperkalaemia in Renal Failure: Salbutamol v. Insulin . . . 228
Leo O (abst) . . . 517
Lerche D (abst) . . . 476
Lerma J L (abst) . . . 512
Leroux-Robert C: *See* Vincent D et al.
Leroy F (abst) . . . 483, 484
Lesavre P (abst) . . . 438
Leunissen K M L (abst) . . . 515
Leunissen K M L: *See* Cheriex E C et al.
Leunissen K M L: *See* Knols G et al.
Leunissen K M L, Menheere P P C A, Cheriex E C, van den Berg B W, Noordzij T C, van Hooff J P: Plasma Alpha-human Atrial Natriuretic Peptide and Volume Status in Chronic Haemodialysis Patients . . . 382
Levy M: *See* Rondeau E et al.
Lewis N P (abst) . . . 319
Lhotta K (abst) . . . 149, 152
Li M K: *See* Chan M K et al.
Liaño F (abst) . . . 423, 428, 444
Liberatore S (letter) . . . 839
Lichodziejewska M (abst) . . . 437
Licina A (abst) . . . 599
Lienhart C (abst) . . . 144
Lilian T v: *See* Leichter H E et al.
Lillevang S T (letter) . . . 676
Linari F (abst) . . . 437
Lindell Å (abst) . . . 434
Lindenau K (abst) . . . 451, 453
Lindgren S (abst) . . . 417
Lindholm B̈ (abst) . . . 499
Lindholm B, Heimbürger O, Waniewski J, Werynski A, Bergström J: Peritoneal Ultrafiltration and Fluid Reabsorption During Peritoneal Dialysis . . . 805
Lindsay R M (abst) . . . 477
Lins L-E (abst) . . . 436, 490
Lins R L (abst) . . . 479
Lison A E (abst) . . . 521
Lobo J: *See* Casati S et al.

Locatelli F (abst) . . . 457
Loch K M: *See* Floege J et al.
Lock P M, Benoliel D, Parsons V: Success of Communication About Renal Transplantation Between Patient and Doctor . . . 119
Lockwood C M (abst) . . . 314
Lockwood C M: *See* Abbott F et al.
Lockwood C M: *See* van den Heuvel L P W J et al.
Lockwood M (abst) . . . 426
Logue F (abst) . . . 318
Loibl U (abst) . . . 473, 478
Lombardi A (abst) . . . 455
London G (abst) . . . 483
Lopez de Novales E (abst) . . . 435
Lopez Gomez J M (abst) . . . 486
López O (abst) . . . 438, 439
López-Novoa J M (abst) . . . 515
López-Novoa M (abst) . . . 503
López-Pedret J (abst) . . . 449
Lorenzo V (abst) . . . 504
Losada M (abst) . . . 504
Lowry R (abst) . . . 428
L-Rivas A (abst) . . . 500
Lubrano R (letter) . . . 76
Lubrano R: *See* Taccone-Gallucci M et al.
Lubrich-Birkner I (abst) . . . 501
Lucas E (abst) . . . 428
Luger A (abst) . . . 146
Lui S F: *See* Sweny P et al.
Lui S F, Sweny P, Scoble J E, Varghese Z, Moorhead J F, Fernando O N: Low-dose vs High-dose Intravenous Methylprednisolone Therapy for Acute Renal Allograft Rejection in Patients Receiving Cyclosporin Therapy . 387
Lund L (abst) . . . 671
Lundahl J (abst) . . . 490
Luño J (abst) . . . 484, 486
Lurdes F M: *See* Ponce P et al.
Lusvarghi E (letter) . . . 1083
Lysaght M (abst) . . . 499
McCauley J, Sorkin M I: Exacerbation of Aluminium Encephalopathy After Treatment with Desferrioxamine . . . 110
McClelland P (abst) . . . 444, 445
McClelland P (letter) . . . 917
McCloskey E V: *See* Hamdy N A T et al.
Macdonald N J (abst) . . . 835
MacDonald T M: *See* Jeffrey R F et al.
Macdougall I C (abst) . . . 318, 319, 476
Maceira B (abst) . . . 504
McGeown M G (abst) . . . 420
McGeown M G: *See* Brown J H et al.
McGibben P D (abst) . . . 438
McGonigle R J S: *See* Crowson M C et al.
Macia M (abst) . . . 506
Mackay I G (abst) . . . 420
Mackenzie J C (abst) . . . 420
Mackenzie R (abst) . . . 437
McLean C (abst) . . . 466, 836
MacLennan I C M: *See* Beaman M et al.
McNally P G (abst) . . . 515, 835
Macurova H (abst) . . . 589
McVie J G (abst) . . . 751, 754
Madden B, Huissoon A P, Colhoun E N, Keogh J A B: Superior Vena Caval Obstruction: A Rare Complication of Quinton Double-lumen Haemodialysis Catheters . . . 586
Madrenas J (abst) . . . 428
Madsen B (abst) . . . 461
Madsen H T (abst) . . . 673
Madsen M (abst) . . . 670, 671
Maduell F: *See* Díaz-Tejeiro R et al.
Maeda K: *See* Niwa T et al.
Maekawa M (abst) . . . 489
Maffei S (abst) . . . 424
Maffei S: *See* Coppo R et al.
Magen H (abst) . . . 453
Maggiore Q (abst) . . . 439, 492
Maggiore Q: *See* Zoccali C et al.
Maher E R (abst) . . . 317
Mahiout A (abst) . . . 498
Main J (abst) . . . 834
Main J (letter) . . . 602
Maina A (abst) . . . 442
Maini R N (abst) . . . 318, 495
Maiorca R (abst) . . . 440, 441, 442, 486
Maiorca R, Cancarini G C, Camerini C, Brunori G, Manili L, Movilli E, Feller P, Mombelloni S: Is CAPD Competitive with Haemodialysis for Long-term Treatment of Uraemic Patients? . . . 244
Mairbäurl H (abst) . . . 154
Maistre G (abst) . . . 464
Makiko Tsutsui, Masashi Suzuki, Yoshihei Hirasawa: Renewed Cardiovascular Dynamics Induced by Recombinant Erythropoietin Administration . . . S3:146
Malacarne F (abst) . . . 513
Malara E (abst) . . . 492
Malavasi F (abst) . . . 430
Malberti F (abst) . . . 485
Malberti F (letter) . . . 678, 759
Malberti F: *See* Colussi G et al.
Malberti F: *See* Surian M et al.
Malisiovas N (abst) . . . 482
Mallamaci F (abst) . . . 463, 468
Mallick M P: *See* Short C D et al.
Malovrh M (abst) . . . 593
Malyszko J (abst) . . . 452
Mampaso F (abst) . . . 423, 428, 512
Mampaso F M, Egido J, Martínez-Montero J C, Bricio T, González E, Cobo M E, Pirotzky E, Braquet P, Hernando L: Interstitial Mononuclear Cell Infiltrates in Experimental Nephrosis: Effect of PAF Antagonist . . . 1037
Mancini E: *See* Zucchelli P et al.
Manganoni A (abst) . . . 440, 441, 442
Mangiarotti G (abst) . . . 467
Manili L: *See* Maiorca R et al.
Manker W (abst) . . . 478
Mann J (abst) . . . 460
Mann J F E (abst) . . . 460
Mann J F E, Mürtz H, Sis J, Usadel K H, Hasslacher Ch, Ritz E: Specific Binding of Angiotensin II and Atrial Natriuretic Factor in Non-nephropathic Type I Diabetes Mellitus . . . 530
Mann J F E, Reisch C, Bergbreiter R, Karcher D, Hackenthal E, Vecsei P, Nussberger J, Ritz E: Effects of WY47987 (Atrial Natriuretic Factor 102–126) in Patients with Renal Insufficiency . . . 776
Mannhalter Ch (abst) . . . 150
Manno C: *See* Pertosa G et al.
Mansell M A (abst) . . . 317
Mansy H (abst) . . . 437
Mansy H: *See* Thomas T H et al.

Manzano F, Esbrit P, Garcia-Ocana A, Garcia-Canero R, Jimenez-Clavero M A: Partial Purification and Characterisation of a Renal Growth Factor from Plasma of Uninephrectomised Rats 334
Marai P (abst) 457
Marangella M (abst) 437
Marcelli D (abst) 457
Marchini M (abst) 485
Marelli A (abst) 487
Margreiter R (abst) 145
Marie A (abst) 467
Marín R: *See* Aguadó S et al.
Maninelli G: *See* Fuiano G et al.
Marsh F (abst) 518
Marsh F (letter) 759
Marsh F P (abst) 428, 477
Marsh F P: *See* Cunningham J et al.
Marsh F: *See* Sawyer N et al.
Marshall P D (abst) 314
Marshall T (abst) 433
Martani C (abst) 507
Martin S: *See* Short C D et al.
Martin X (abst) 437, 468
Martin-Malo A (abst) 451, 452, 480, 489, 491
Martin-Reyes G (abst) 435
Martina G (abst) 430, 512
Martinelli D (abst) 487
Martinez F (abst) 464
Martinez J C (abst) 512
Martinez M A: *See* Praga M et al.
Martinez M T (abst) 484
Martínez-Montero J C (abst) 429
Martínez-Montero J C: *See* Mampaso F M et al.
Martini C (abst) 437
Martorano C (abst) 439
Martorano C: *See* Zoccali C et al.
Marumo F (abst) 467, 475
Marx M (abst) 424, 520
Masaaki Arakawa: *See* Fumitake Gejyo et al.
Masanobu Maekawa: *See* Taketoshi Kishimoto et al.
Masao Shibata: Current Topics in Nutrition for Dialysis Patients S3:138
Masaru Miya: *See* Susumu Yoshikawa et al.
Masashi Suzuki, Sachio Takahashi, Yoshihei Hirasawa: Therapeutic Approach to Dialysis-related Osteoarthropathy S3:32
Masashi Suzuki: *See* Makiko Tsutui et al.
Massara C (abst) 466, 486
Masterton R G: *See* Harrison N A et al.
Mastoshi Fujishima: *See* Kaoru Onoyama et al.
Mastrolitti G: *See* Pertosa G et al.
Matoušovic K (abst) 457
Matsuoka M (abst) 485
Matsuyama M (abst) 314
Matthess A (abst) 458
Matthijs E (abst) 754
Matthys D (abst) 753
Matthys E (abst) 753
Matthys E G (letter) 676
Matthys E G: *See* Boelaert J R et al.
Maxwell A P (abst) 420, 438, 476
Mayer G (abst) 146, 147, 153, 155, 473
Mayer G: *See* Cada E et al.
Mayeux D (abst) 494
Mazengo M (abst) 490
Mazzarella V *see* Taccone-Gallucci M et al.
Mazzola G (abst) 440
Mazzucco G (abst) 424, 440
Meadows J H: *See* Coles G A et al.
Meager A (abst) 837
Meas V: *See* De Bock V et al.
Mecca G (abst) 487
Mee A D (abst) 508
Megumo Hino: *See* Toshihiko Ono et al.
Mehls O (abst) 432, 451, 469, 495
Mehmel H C (abst) 453
Meier W (abst) 476
Meisl F (abst) 473
Meissl F (abst) 478
Melhado V E R (abst) 454
Melin J P (abst) 438
Mellert J (abst) 597
Meloni C: *See* Taccone-Gallucci M et al.
Memmos D (abst) 469
Menault P (abst) 445
Mendiluce A (abst) 512
Mengus L (abst) 482
Menheere P P C A: *See* Leunissen K M L et al.
Menicelli A *see* Taccone-Gallucci M et al.
Menoyo V (abst) 517
Mercantini F (abst) 485
Mercatello A (abst) 445
Merke J (abst) 431, 469
Merkel F (abst) 520
Meron G (abst) 519
Meschini L: *See* Taccone-Gallucci M et al.
Mešić E (abst) 443
Messerli F H (abst) 462
Messinger D (abst) 474
Metsärinne K (abst) 465
Meuer S (abst) 520
Meuer S C (abst) 424
Meuwissen S G M (abst) 422
Meyer O: *See* Kleinknecht D et al.
Meyer zum Büschenfelde K H (abst) 424, 520
Meyrier A (abst) 443
Meyrier A: Treatment of Glomerular Disease with Cyclosporin A 923
Michael C: *See* Hasslacher Ch et al.
Michael J (abst) 313, 314
Michael J: *See* Beaman M et al.
Michael J: *See* Crowson M C et al.
Michalak E (abst) 451
Michel C (abst) 499, 500
Michielsen P: *See* Frenken L A M et al.
Michihito Okubo: *See* Yusuke Tsukamoto et al.
Mignon F (abst) 499, 500
Migone L (abst) 429
Miguel M A (abst) 468
Mikhailidis D P: *See* Sweny P et al.
Milde P (abst) 469
Milford D V (abst) 433
Millar N D (abst) 420
Millet V G: *See* Praga M et al.
Mimran A: *See* Canaud B et al.
Mimran A: *See* Mourad G et al.
Mineshima M (abst) 485
Minetti L (abst) 417, 472, 481, 488
Minetti L (letter) 678
Minetti L: *See* Colussi G et al.
Minetti L: *See* Surian M et al.
Mion C (abst) 482, 492

Mion C: *See* Canaud B et al.
Mion C: *See* Mourad G et al.
Mistry N (abst) 515, 835
Mitsuma T: *See* Niwa T et al.
Mitsuo Ogura: *See* Akira Yoshida et al.
Mitsuyasu Toyoda, Kei Furiya, Sumie Manno, Shigeo Kita, Tsutomu Sanaka, Kazua Ota, Yoshiyuki Osamura: Recent Advances in AL Amyloidosis S3:19
Miyagawa T (abst) 467
Mocarquer A: *See* Morales-Barria J et al.
Modai D, Averbukh Z, Weissgarten J, Bogin E, Rosenmann E, Cohn M, Goren E, Shaked U: Uninephrectomy and Repetitive Pregnancies in Mice: A Combined Stimulus for Renal Hypertrophy 701
Molina A (abst) 423
Molina R (abst) 449
Molino A (abst) 423, 430
Molino A: *See* Coppo R et al.
Mombelloni S (abst) 486
Mombelloni S: *See* Maiorca R et al.
Monnens L A H (abst) 754
Montagnani E (abst) 424
Montagnani E: *See* Grazi G et al.
Montagnino G (abst) 508
Monteagudo J (abst) 449
Montessori M L M (abst) 753
Monti J P (abst) 452
Montoli A (abst) 485
Montoli A (letter) 759
Montoliu J: *See* Campistol J M et al.
Montoliu J: *See* Lens X M et al.
Moonen M M J (abst) 751
Moore K: *See* Fleming S et al.
Moore R (abst) 518
Moore R: *See* Edmunds M E et al.
Moore R H (abst) 428, 477
Moorhead F (abst) 316, 317, 837
Moorhead J F: *See* Lui S F et al.
Moorhead J F: *See* Sweny P et al.
Mooy J M V: *See* Cheriex E C et al.
Morales J Ma: *See* Praga M et al.
Morales-Barria J, Zehnder C, Mocarquer A, James E, Aris L, Trivino R, Aguilo J: A Prospective One-year Study Evaluating the Clinical Outcome of Recipients of Living Donor Kidneys Treated with Cyclosporin and Azathioprine 293
Moreau J F: *See* Nehme D et al.
Moriniere Ph (abst) 467
Moriniere Ph, Boudailliez B, Hocine Ch, Belbrik S, Renaud H, Westeel P F, Cohen Solal M, Fournier A: Prevention of Osteitis Fibrosa, Aluminium Bone Disease, and Soft-Tissue Calcification in Dialysis Patients 1045
Morland C M (abst) 314
Morosetti M: *See* Taccone-Gallucci M et al.
Morris P J: *See* Bittar A E et al.
Mörsky P: *See* Pietilä K et al.
Mortensen P B (abst) 673
Mortensen P B: *See* Christensen L A et al.
Moser E (abst) 144, 153, 154
Moskovtchenko J F (abst) 445
Mosso R (abst) 470
Mostafa F (abst) 431
Mostafa S M (abst) 445
Motz W (abst) 148
Mougenot B: *See* Rondeau E et al.
Moulart J (abst) 497
Moulonguet-Doleris L (abst) 517
Moult P J A (abst) 317
Mourad G (abst) 492
Mourad G, Ribstein J, Argiles A, Mimran A, Mion C: Contrasting Effects of Acute Angiotensin Converting Enzyme Inhibitors and Calcium Antagonists in Transplant Renal Artery Stenosis 66
Mousson Ch (abst) 500
Moustafa F E, Sobh M A, Ghoneim M A: Peripheral Blood Morphology: Could it be of Value in Prediction and Diagnosis of Renal Allograft Rejection? 302
Movilli E (abst) 486
Movilli E: *See* Maiorca R et al.
Moynot A: *See* Najean Y et al.
Mühlbacher F (abst) 152, 508
Muirhead N (abst) 477
Müller C (abst) 498
Muller F B: *See* Raine A E G et al.
Müller-Wiefel D E (abst) 446
Mumcuoglu E (abst) 477
Munekazu Kyo: *See* Taketoshi Kishimoto et al.
Munla F (abst) 593
Muñoz J (abst) 500
Muñoz-Gomez J (abst) 492
Murat A (abst) 503
Murray A (abst) 836
Murray A E (abst) 445
Mürtz H: *See* Mann J F E et al.
Mustonen J: *See* Pietilä K et al.
Mustonen J: *See* Puolijoki H et al.
Mutti A: *See* Buzio C et al.
Myśliwiec M (abst) 452
Nair D R (abst) 837
Naish P (abst) 836
Najean Y, Moynot A, Deschryver F, Zins B, Naret C, Jacquot Ch, Drueke T: Kinetics of Erythropoiesis in Dialysis Patients Receiving Recombinant Erythropoietin Treatment 350
Nakajima M: *See* Ogawa H et al.
Nakashima Y (abst) 494
Nakazawa R: *See* Akizawa T et al.
Narang A: *See* Pereira B J G et al.
Naranjo P (abst) 506
Naranjo P (letter) 840
Naret C (letter) 675
Naret C: *See* Najean Y et al.
Nasini M G (abst) 475, 490, 496, 517
Naylor V A: *See* Hamdy N A T et al.
Négrier S (abst) 445
Negro A: *See* Buzio C et al.
Nehme D, Rondeau E, Paillard F, Moreau J F, Nussaume O, Kanfer A, Sraer J-D: Aseptic Necrosis of Bone Following Renal Transplantation: Relation with Hyperparathyroidism 123
Neild G: *See* Cheng H-F et al.
Neild G H (abst) 835
Neild G H: *See* Henning P H et al.
Neimöller U M (abst) 596, 597
Nejad Ghashti H (abst) 588
Nelson S R (abst) 494
Nelson W E (abst) 438
Nemmar M (abst) 591
Neri M (abst) 424
Neri T M (abst) 429
Netter P (abst) 494

Neumayer H-H (abst) . . . 477
Neumayer H-H, Junge W, Küfner A, Wenning A: Prevention of Radiocontrast-media-induced Nephrotoxicity by the Calcium Channel Blocker Nitrendipine: A Prospective Randomised Clinical Trial . . . 1028
Newstead C (abst) . . . 518
Newstead C G (abst) . . . 477
Newstead C G: Jejunal Dialysis in Man Using Mannitol as the Perfusate . . . 658
Newton K E (abst) . . . 503
Neyer U (abst) . . . 145, 154
Ng W S F: *See* Chan M K et al.
Nguyen Q V: *See* Canaud B et al.
Niag T (abst) . . . 446
Nicholle R: *See* Canaud B et al.
Niebel W (abst) . . . 502, 521
Niederkorn K (abst) . . . 474
Niedermayer W (abst) . . . 595
Nielsen F W (abst) . . . 752
Nielsen H K (abst) . . . 673
Nielsen S L (abst) . . . 450, 672
Nikbin B (abst) . . . 588, 589
Nitadori Y: *See* Akizawa T et al.
Niwa M (abst) . . . 489
Niwa T, Sobue G, Maeda K, Mitsuma T: Myoinositol Inhibits Proliferation of Cultured Schwann Cells: Evidence for Neurotoxicity of Myoinositol . . . 662
Nobuyuki Miyasaka: *See* Kazuo Ota et al.
Noël L: *See* van den Heuvel L P W J et al.
Noël L H (abst) . . . 438, 506, 510, 519
Noël L H: *See* Kleinknecht D et al.
Nolasco F: *See* Alexopoulos E et al.
Nolasco F: *See* Cheng H-F et al.
Nolph K (abst) . . . 499
Nonnast-Daniel B (abst) . . . 478, 493
Noonan K (letter) . . . 759
Noonan K: *See* Sawyer N et al.
Noordzij T C (abst) . . . 515
Noordzij T C: *See* Leunissen K M L et al.
Nordlander M (abst) . . . 447
Noriyuki Homma: *See* Fumitake Gejyo et al.
Noriyuki Iwamoto: *See* Toshihiko Ono et al.
Noronha I L (abst) . . . 506
Noronha I L, Ritz E, Waldherr R, Stein G, Fassbinder W: Renal Cell Carcinoma in Dialysis Patients with Acquired Renal Cysts . . . 763
North R A (abst) . . . 831
Nortier J (abst) . . . 497
Novara A (abst) . . . 424
Novara R (abst) . . . 430
Nowack A (abst) . . . 458
Nowotny C (abst) . . . 150
Nunez B (abst) . . . 462
Nussaume O: *See* Nehme D et al.
Nussberger J: *See* Mann J F E et al.
Obregoñ L (abst) . . . 515
Obrez I (abst) . . . 599
Oda O: *See* Ogawa H et al.
O'Donoghue D J (abst) . . . 831
Oe P L (abst) . . . 418, 752, 755
Offermann G (abst) . . . 510
Ogasawara K (abst) . . . 494
Ogawa H, Saito A, Ono M, Oda O, Nakajima M, Chung T G: Novel β_2-Microglobulin and its Amyloidogenic Predisposition in Patients on Haemodialysis . . . S3:14
Ohrenberger G (abst) . . . 152
Olaizola I (abst) . . . 468
Olbert F (abst) . . . 152
Øldhafer K (abst) . . . 511
Olgaard K (abst) . . . 480, 672, 673
Oliver A (abst) . . . 438, 439
Oliver D O (abst) . . . 472, 494, 833
Olmos A (abst) . . . 493
Olsen F (abst) . . . 671
Olsen N V (abst) . . . 504, 672
O'Meara T, Green A, Carmody M, Donohoe J, Campbell E, Browne O, Walshe J: Recurrent Glomerulonephritis in Renal Transplants: Fourteen Years' Experience . . . 730
Onen K (letter) . . . 760
Oner A: *See* Clarke A G B et al.
Ono M: *See* Ogawa H et al.
O'Nunan T: *See* Williams B et al.
Opelz G (abst) . . . 506, 596
Oppenheim B A: *See* Pickering S J et al.
Oppenheimer F (abst) . . . 492, 502, 517
Oppermann F (abst) . . . 487
O'Riordan J L H: *See* Cunningham J et al.
Orlandini G: *See* Surian M et al.
Orofino L (abst) . . . 444
Ortuño J (abst) . . . 428, 444
Osman O (abst) . . . 470
Ota K (abst) . . . 485
Oudshoorn M (abst) . . . 424
Ozono Y (abst) . . . 429, 837
Pacitti A (abst) . . . 465, 467, 486, 491
Packard C (abst) . . . 831
Packham D P (abst) . . . 831
Pacsa A (abst) . . . 589
Paez A (abst) . . . 506
Pagliarini A (abst) . . . 513
Pagniez D C (letter) . . . 76
Paillard F: *See* Nehme D et al.
Paineau J (abst) . . . 503
Palkovits M (abst) . . . 463
Palla R (abst) . . . 424
Palla R: *See* Grazi G et al.
Palmer A (abst) . . . 319, 838
Palmer P (abst) . . . 445
Palmieri P F (abst) . . . 448
Pals G (abst) . . . 422
Panarello G (abst) . . . 485
Panichi V (abst) . . . 424
Panichi V: *See* Grazi G et al.
Panjwani D (abst) . . . 594, 597
Panjwani D D (abst) . . . 599
Panzer S (abst) . . . 150
Papachristophorou K (abst) . . . 594
Papadimitriou M (abst) . . . 469
Papadimitrou M G (abst) . . . 462
Papaioannou A (abst) . . . 598
Papayianni A (abst) . . . 482, 514
Papiha S (abst) . . . 428
Parchoux B: *See* Cahen R et al.
Pardo-Mindán F J (abst) . . . 443
Parfrey N A (abst) . . . 428
Parkin A (abst) . . . 512
Parlongo S (abst) . . . 468
Parravicini C (abst) . . . 426
Parrini M (abst) . . . 424
Parrini M: *See* Grazi G et al.

Parson V: *See* Rogerson M E et al.
Parsons V (abst) . . . 838
Parsons V: *See* Dische F E et al.
Parsons V: *See* Lock P M et al.
Parvy P (abst) . . . 450
Parzer S (abst) . . . 150
Pascual J (abst) . . . 423, 428, 444
Pasini J: *See* Tomić B H et al.
Pasquali S: *See* Passerini P et al.
Passerini P, Pasquali S, Cesana B, Zucchelli P, Ponticelli C: Long-term Outcome of Patients with Membranous Nephropathy After Complete Remission of Proteinuria . . . 525
Passlick-Deetjen J (abst) . . . 500
Pasternack A: *See* Pietilä K et al.
Pasternack A: *See* Puolijoki H et al.
Pasyk S (abst) . . . 505
Patek E (abst) . . . 508
Patte R (abst) . . . 482
Paul L S (abst) . . . 505
Paulitschke M (abst) . . . 476
Pavlovic D: *See* Tomić B H et al.
Pawlowska Z (abst) . . . 451
Pecchio A (abst) . . . 465
Pecherstorfer M (abst) . . . 149
Pedersen E B (abst) . . . 461, 464, 465
Penkoff H (abst) . . . 144
Pepys M B (abst) . . . 494
Perazzoli F: *See* Buzio C et al.
Pere P (abst) . . . 494
Perego A (abst) . . . 481, 488
Pereira B J G (letter) . . . 157
Pereira B J G, Narang A, Pereira S, Gupta A, Sakhuja V, Chugh K S: Acute Renal Failure in Infants in the Tropics . . . 535
Pereira S: *See* Pereira B J G et al.
Perez G R (abst) . . . 486
Perez R (abst) . . . 484
Perfumo F (abst) . . . 497
Perkin G D (abst) . . . 318, 495
Perrino M L (abst) . . . 472, 481, 488
Persuad J W (abst) . . . 837
Pertosa G, Mastrolitti G, Späth P J, Fracasso A R, Manno C, Schena F P: Effect of Fibronectin on C3b and Fc Receptor-mediated Phagocytosis by Peripheral Blood Monocytes in Uraemic Patients . . . 15
Peten E (abst) . . . 506
Peterlongo F (letter) . . . 675
Petit J (abst) . . . 432
Petrarulo M (abst) . . . 437
Petropoulou E (abst) . . . 469
Pettersson E (abst) . . . 478
Pettersson E: *See* Puolijoki H et al.
Philip T (abst) . . . 445
Philips E M (abst) . . . 592
Phillips E M (abst) . . . 599
Phillips M E (abst) . . . 447, 508
Picard F (letter) . . . 675
Picca M (abst) . . . 497
Piccoli G (abst) . . . 423, 424, 430, 440, 470, 490, 512
Piccoli G: *See* Coppo R et al.
Piccoli G: *See* Roccatello D et al.
Piccoli G B (abst) . . . 486
Pichlmayr R (abst) . . . 511
Pickering S J, Fleming S J, Bowley J A, Sissons P, Oppenheim B A, Burnie J, Ralston A J, Ackrill P: Urokinase: A Treatment for Relapsing Peritonitis due to Coagulase-negative Staphylococci . . . 62
Piera L (abst) . . . 493
Piers-Becht T P (abst) . . . 455
Pietilä K, Mustonen J, Mörsky P, Seppälä E, Pasternack A, Koivula T: Effect of One Haemodialysis Treatment on the Plasma Concentrations of Intact Parathyroid Hormone and Ionised Calcium . . . 116
Pietraszek M (abst) . . . 452
Pikielny S (abst) . . . 453
Pinto G: *See* Ponce P et al.
Pinto J R (abst) . . . 419
Pinzani M (abst) . . . 426
Pippard M J (abst) . . . 833
Pirotzky E (abst) . . . 448, 516
Pirotzky E: *See* Mampaso F M et al.
Pirson V (abst) . . . 481, 506, 507
Pisani G (abst) . . . 520
Pizarro J L (abst) . . . 496
Plaza J J (abst) . . . 503
Plum J (abst) . . . 500
Pochet J M (abst) . . . 507
Pochet J-M, Bobrie G, Landais P, Goldfarb B, Grünfeld J P: Renal Prognosis in Alport's and Related syndromes: Influence of the Mode of Inheritance . . . 1016
Pødenphant J (abst) . . . 671
Podjarny E (abst) . . . 417, 421, 457
Pogglitsch H (abst) . . . 144, 474
Pohanka E (abst) . . . 149, 519, 588, 589
Poignet J-L (abst) . . . 480
Polenaković M (abst) . . . 461
Poli L (abst) . . . 520
Polio J (abst) . . . 458
Pollock C (abst) . . . 499
Polloni R (abst) . . . 470
Pomer S (abst) . . . 506
Pomerantz A (abst) . . . 453
Pomeranz A (abst) . . . 439, 457
Pomeranz M (abst) . . . 439
Ponce P, Ramos A, Lurdes Ferreira M, Pinto G, Lacerda M H: Renal Involvement in Leprosy . . . 81
Ponticelli C (abst) . . . 496, 508, 514
Ponticelli C (letter) . . . 839
Ponticelli C: *See* Casati S et al.
Ponticelli C: *See* Passerini P et al.
Porcu M C . . . 442, 466
Poston L (abst) . . . 516, 838
Postorino M (abst) . . . 439, 463, 492
Postorino M: *See* Zoccali C et al.
Potaux L (abst) . . . 513
Poux C (abst) . . . 482
Povlsen J V (abst) . . . 671
Power D A (abst) . . . 838
Pozet N (abst) . . . 437, 445, 456, 460, 468
Pozza G (abst) . . . 507
Pozzetto B: *See* Guerin C et al.
Pozzi C (abst) . . . 431
Pracht G (abst) . . . 474
Praga M, Martinez M A, Andres A, Alvarez de Buergo M, Bello I, Millet V G, Morales J Ma: Acute Renal Failure and Tubular Dysfunction Associated with Minimal Change Nephrotic Syndrome . . . 914
Prager R (abst) . . . 459
Prat V (abst) . . . 457
Prati E (abst) . . . 440, 441, 442
Prehn J (abst) . . . 452

Pretagostini R (abst) . . . 518
Price R G: *See* van den Heuvel L P W J et al.
Proesmans W (abst) . . . 479
Pronai W (abst) . . . 152
Propper D J (abst) . . . 838
Prospert F (abst) . . . 421
Prospert F: *See* Cappello M et al.
Proud G: *See* Kirby J A et al.
Prowant B (abst) . . . 499
Pugh C W (abst) . . . 494
Puolijoki H, Mustonen J, Pettersson E, Pasternack A, Lahdensuo A: Proteinuria and Haematuria are Frequently Present in Patients with Lung Cancer . . . 947
Purkiss J (abst) . . . 836
Purroy A: *See* Diaz-Tejeiro R et al.
Pusey C D (abst) . . . 314, 435, 832
Pusey C D: *See* Dische F E et al.
Pyrpasopoulos M (abst) . . . 482, 514
Quaia P (abst) . . . 485
Quarello F (abst) . . . 470, 486, 512
Quarenghi M (abst) . . . 487
Quattrocchio G (abst) . . . 423, 424, 430, 440, 470, 490
Quattrocchio G: *See* Coppo R et al.
Quattrocchio G: *See* Roccatello D et al.
Querfeld U (abst) . . . 452
Quesada J (abst) . . . 452
Quesada J M (abst) . . . 451
Quinn A (abst) . . . 832
Quirós J (abst) . . . 429
Rabelink A J, Koomans H A, Boer W H, Dorhout Mees E J, van Rijn H J M: Indomethacin Increases Renal Lithium Reabsorption in Man . . . 27
Radice A (abst) . . . 431
Radkowski M (abst) . . . 498
Raftery A T: *See* Hamdy N A T et al.
Ragni R (abst) . . . 437, 486
Rahbar K (abst) . . . 589
Raine A E G, Bock A, Muller F B, Erne P, Bolli P, Brunner F, Buhler F R: Comparative Effects of Haemodialysis and Haemofiltration on Plasma Atrial Natriuretic Peptide . . . 222
Rainford D J: *See* Harrison N A et al.
Rainfray M (abst) . . . 443
Ralston A J: *See* Pickering S J et al.
Rambausek M (abst) . . . 429, 440, 506
Rambausek M: *See* Waldherr R et al.
Ramdane M: *See* Kleinknecht D et al.
Ramos A: *See* Ponce P et al.
Ramos B (abst) . . . 435
Ramos O (abst) . . . 461
Ramos O L (abst) . . . 487
Ramsy R (abst) . . . 431
Ranke M (abst) . . . 451
Rapp U (abst) . . . 425
Rasmussen A (abst) . . . 670, 671
Rasmussen N (abst) . . . 431
Rasoul-Rockenschaub S (abst) . . . 596
Ratcliffe P J: *See* Bittar A E et al.
Rathaus M (abst) . . . 417, 421, 457
Rauer S (letter) . . . 677
Rauterberg E (abst) . . . 440
Rauterberg E W (abst) . . . 469, 489
Ravelli M (abst) . . . 486
Ravina M (abst) . . . 504
Redon P (abst) . . . 513
Reed A: *See* Dische F E et al.
Rees A J (abst) . . . 315, 435, 832, 837
Rees A J: *See* Abbott et al.
Regele H (abst) . . . 153
Regis G (abst) . . . 491
Reidy J F: *See* Henning P H et al.
Reijden H J vd (abst) . . . 752
Reinhard B: *See* Floege J et al.
Reisch C: *See* Mann J F E et al.
Religa Z (abst) . . . 505
Remuzzi G: *See* Vigano G et al.
Renaud H: *See* Moriniere Ph et al.
Rengel M A (abst) . . . 484
Renna Molajoni E (abst) . . . 518, 520
Repp H (abst) . . . 511
Resch K (abst) . . . 422, 425
Reuben A (abst) . . . 458
Revert L (abst) . . . 449
Revert L: *See* Campistol J M et al.
Revert L: *See* Lens X M et al.
Revillard J P (abst) . . . 492
Reynolds J (abst) . . . 314
Ribeiro D S (abst) . . . 507
Ribstein J: *See* Mourad G et al.
Ricart M J (abst) . . . 492, 502, 517
Richards N (abst) . . . 428
Richards N T (abst) . . . 316, 516, 838
Richardson A J: *See* Bittar A E et al.
Richter D (abst) . . . 498
Riegel W: *See* Wanner C et al.
Rifle G (abst) . . . 500
Rigaud M: *See* Vincent D et al.
Rigden S P A: *See* Clarke A G B et al.
Rigden S P A: *See* Henning P H et al.
Ritz E (abst) . . . 429, 431, 440, 453, 458, 460, 469, 471, 489
Ritz E (letter) . . . 399
Ritz E: *See* Hasslacher Ch et al.
Ritz E: *See* Mann J F E et al.
Ritz E: *See* Noronha I L et al.
Ritz E: *See* Waldherr R et al.
Ritz R: *See* Zuber M et al.
Rivera M (abst) . . . 444
Rizzoni G, Ehrich J H H, Brunner F P, Brynger H, Dykes S R, Geerlings W, Fassbinder W, Tufveson G, Selwood N H, Wing A J: Combined Report on Regular Dialysis and Transplantation of Children in Europe, 1988 . . . S4:31
Rizzoni G: *See* Brunner F P et al.; Ehrich J H H et al.; Tufveson G et al.
Roberts D E (abst) . . . 318
Robertson W R (abst) . . . 834
Robinson C (abst) . . . 470
Robinson K N (abst) . . . 317
Robinson P J: *See* Worth D P et al.
Robledo C (abst) . . . 443
Robles R (abst) . . . 484
Roccatello D (abst) . . . 423, 424, 430, 440, 470, 490
Roccatello D: *See* Coppo R et al.
Roccatello D, Coppo R, Piccoli G, Cavalli G, Guerra M G, Funaro A, Amore A, Roggero S, Borgialli R, Amprimo M C, Scalzo B, Alessio M, Quattrocchio G, Sena L M: Phenotypic and Functional Analysis . . . 618
Röckel A, Klinke B, Hertel J, Baur X, Thiel Cl, Abdelhamid S, Fiegel P, Walb D: Allergy to Dialysis Materials . . . 646
Rodger R S C (abst) . . . 318, 834, 835
Rodger R S C, Sheldon W L, Watson M J, Dewar J H,

Wilkinson R, Ward M K, Kerr D N S: Zinc Deficiency and Hyperprolactinaemia are not Reversible Causes of Sexual Dysfunction in Uraemia 888
Rodríguez-Puyol D (abst) 515
Rodríguez-Puyol M (abst) 515
Rogerson M E (abst) 835
Rogerson M E, Rylance P B, Wilson R, De Sousa C, Lanigan C, Rose P E, Howard J, Parson V: Carnitine and Weakness in Haemodialysis Patients 366
Roggero S: *See* Roccatello D et al.
Rojas R (abst) 491
Rolando P (letter) 678
Rollino C (abst) 423, 430, 512
Romano G (abst) 516
Romao J E (abst) 504, 507
Rombolà G (abst) 417
Rombola G: *See* Colussi G et al.
Rombolà R (letter) 678
Romero R (letter) 675
Rondeau E (letter) 918
Rondeau E: *See* Nehme D et al.
Rondeau E, Levy M, Dosquet P, Ruedin P, Mougenot B, Kanfer A, Sraer J D: Plasma Exchange and Immunosuppression for Rapidly Progressive Glomerulonephritis: Prognosis and Complications . . . 196
Roob J (abst) 144, 474
Roodhooft A M (abst) 753
Roos J C (abst) 418
Roots I (abst) 477
Rose P E: *See* Rogerson M E et al.
Röseler E (abst) 487
Rosendahl W (abst) 432
Rosenfeld J: *See* Cohen S L et al.
Rosenfeld J B (abst) 513
Rosenmann E: *See* Modai D et al.
Rosman J B (abst) 455, 457, 458
Rosseneu M J (abst) 753
Rossi R (abst) 487
Rossmann P (abst) 457
Rousaud F (abst) 439
Roza M (abst) 468
R-Tarduchy G (abst) 500
Rudensky B: *See* Drachman R et al.
Ruder H (abst) 432
Rueda P (abst) 500
Ruedin P: *See* Rondeau E et al.
Ruffmann K (abst) 453
Ruiz C (abst) 519
Russell G I (letter) 679
Rustichelli R: *See* Buzio C et al.
Ryan J (abst) 837
Rylance P B: *See* Rogerson M E at al.
Sabawi N (abst) 599
Sabbaga E (abst) 504, 507
Sabbatini M (abst) 516
Sabbatini M, Esposito C, De Nicola L, Uccello F, Altomonte M, Conte G, Dal Canton A, Andreucci V E: Reversibility of Acute Cyclosporin Nephrotoxicity by Dopamine. Micropuncture Study in the Rat 327
Saccà L (abst) 450
Sachio Takahashi: *See* Masashi Suzuki et al.
Saito A: *See* Ogawa H et al.
Sakai K (abst) 494
Sakhuja V (letter) 157
Sakhuja V: *See* Pereira B J G et al.
Salah H (abst) 591
Saldanha L B (abst) 507
Salido E (abst) 504
Salit M (abst) 475, 490, 496
Sallusto F (abst) 518
Salmon M (abst) 313
Salnitro F (abst) 463, 468
Salnitro F: *See* Zoccali C et al.
Salomone M (abst) 467, 486, 491
Salusky I B: *See* Leichter H E et al.
Samhan M (abst) 591, 592, 594
Sampson B, Curtis J R, Davies S: Survey of Blood Lead and Plasma Aluminium Concentrations in Patients of a Renal Unit 375
Sanchez-Casada E (abst) 496
Sandrini S (abst) 441
Santamaria M (abst) 452
Santelli G (abst) 510
Santiago J (abst) 451
Santos D F P (abst) 516
Santos O F P (abst) 448
Saragananda B: *See* Vanholder R et al.
Saragoça M A S (abst) 487
Saraqoca M A S (abst) 461
Sariyar M (letter) 760
Sato M (abst) 494
Satoh S (abst) 494
Saunders M J (abst) 319
Savage C O S: *See* Sutcliffe N P et al.
Savage C O S: *See* van den Heuvel L P W J et al.
Savi M (abst) 429
Savoldi S (abst) 440, 441, 442
Sawyer N (letter) 759
Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J: High-dose Calcium Carbonate with Stepwise Reduction in Dialysate Calcium Concentration: Effective Phosphate Control and Aluminium Avoidance in Haemodialysis Patients 105
Scaini P (abst) 440, 441, 442
Scalamogna A (abst) 496
Scalzo B: *See* Roccatello D et al.
Scaroni P (abst) 486
Schaefer K: Uraemic Hyperphosphataemia—What is the Therapy of choice? 1005
Schaefer R M: *See* Heidland A et al.; Wanner C et al.
Schaeffer J (abst) 478
Schafer C (abst) 484
Schärer K (abst) 432, 452, 495
Schauer A (abst) 451
Schedel I (abst) 433
Schelotto C (abst) 475, 496, 517
Schena F P (abst) 426, 430
Schena F P: *See* Pertosa G et al.
Schenkel J (abst) 440
Scherberich J E (abst) 458
Schernthaner G (abst) 151, 459
Scheuermann E (abst) 504
Schieroni M P (letter) 238
Schiffl H (abst) 461
Schiller B: *See* Blumenstein M et al.
Schmicker R (abst) 453
Schmid M (abst) 458
Schmidt B: *See* Blumenstein M et al.; Ward R A et al.
Schmidt E B (abst) 671
Schmidt E B: *See* Christensen L A et al.
Schmidt G (abst) 476
Schmidt H (abst) 458, 487

Schmidt P (abst) . . . 145, 149
Schmieder R (abst) . . . 462
Schmitt V (abst) . . . 489
Schnack Ch (abst) . . . 151
Schneider N (abst) . . . 453
Schneider R (abst) . . . 462
Schobersberger W (abst) . . . 154
Schoeppe W (abst) . . . 458, 473, 487, 504
Schollmeyer P (abst) . . . 418, 472, 501
Schollmeyer P (letter) . . . 677
Schollmeyer P: *See* Bohler J et al.
Schollmeyer P: *See* Keller E et al.
Schollmeyer P J (abst) . . . 416, 454
Schönermark M (abst) . . . 431
Schor N (abst) . . . 448, 454, 516
Schor N S (abst) . . . 487
Schreiber A: *See* Kindler J et al.
Schroder C H (abst) . . . 754
Schulz E (abst) . . . 498
Schurawitzki H (abst) . . . 152, 153
Schurawitzki H: *See* Cada E et al.
Schurgers J R: *See* Boelaert J R et al.
Schurgers M (abst) . . . 753, 754
Schurgers M L (letter) . . . 676
Schwab T R (abst) . . . 463
Schwaighofer B (abst) . . . 150
Schwarz A (abst) . . . 510
Schwarz H P (abst) . . . 155
Schwarz M (abst) . . . 149
Scigalla P (abst) . . . 474, 477
Scigalla P: *See* Kindler J et al.
Sciuto G (abst) . . . 486
Scoble J E (abst) . . . 316, 317
Scoble J E: *See* Lui S F et al.
Scolari F (abst) . . . 440, 441, 442
Sebert J L (abst) . . . 467
Secchi A (abst) . . . 507
Segal A W (abst) . . . 832
Segoloni G (abst) . . . 467, 491
Segoloni G P (abst) . . . 465, 486, 512
Segoloni G P (letter) . . . 238
Seiji Yamagami: *See* Taketoshi Kishimoto et al.
Seinosuke Nakagawa: An Introductory Approach to Recently Investigated Metabolic and Endocrinological Problems in Uraemia . . . S3:123
Seinosuke Nakagawa: *See* Akira Yoshida et al.
Selb B (abst) . . . 487
Selgas R (abst) . . . 500
Selwood N H: *See* Brunner F P et al.; Ehrich J H H et al.; Rizzoni G et al.; Tufveson G et al.
Sena L M (abst) . . . 424, 440
Sena L M: *See* Roccatello D et al.
Senior J C M (abst) . . . 316
Sennesael J: *See* De Bock V et al.
Sepe V (abst) . . . 516
Sepe V: *See* Fuiano G et al.
Seppälä E: *See* Pietilä K et al.
Serdengecti K (letter) . . . 760
Serlenga E (abst) . . . 430
Seron D: *See* Alexopoulos E et al.
Serrano I (abst) . . . 452
Sert Ş (abst) . . . 518, 590, 591, 592, 593, 594, 595, 597, 598, 600, 601
Sertl K (abst) . . . 488, 508
Sethi D (abst) . . . 318, 494, 495
Sethi D, Cary N R B, Brown E A, Woodrow D F, Gower P E: Dialysis-Associated Amyloid: Systemic or Local? . . . 1052
Severn A: *See* Dische F E et al.
Seveso M (abst) . . . 472, 488
Shaked U: *See* Modai D et al.
Shaldon S (abst) . . . 473, 489, 493
Shaldon S: EDTA and Industry: 25 Years of Symbiotic Synergism . . . 408
Shaldon S: *See* Floege J et al.
Shapira J (abst) . . . 421
Shapira Z: *See* Cohen S L et al.
Sharman V L: *See* Waters M R et al.
Shehab A (abst) . . . 595
Shehab El-Din A (abst) . . . 519
Sheldon W L: *See* Rodger R S C et al.
Shepherd J (abst) . . . 831
Shigeo Kita: *See* Mitsuyasu Toyoda et al.
Shigeru Iwanami: *See* Fumiaki Marumo et al.
Shimizu F (abst) . . . 314
Shin-ya Inai: *See* Susumu Yoshikawa et al.
Shirota K (abst) . . . 428
Shmueli D: *See* Cohen S L et al.
Short C D, Coupes B M, Brenchley P E, Martin S, Williams S, Johnson R W G, Mallick M P, Williams G: Membranous Nephropathy: Monoclonal IgG and Nephrotic-range Proteinuria in a Renal Transplant Recipient . . . 1080
Shortland J R: *See* Hamdy N A T et al.
Shozo Koshikawa: *See* Tadao Akizawa and Shozo Koshikawa
Siamopoulos K (abst) . . . 470
Sieberth H G (abst) . . . 474, 484
Sieberth H G: *See* Ittel T H et al.
Sieberth H G: *See* Kindler J et al.
Silberbauer K abst) . . . 152
Silva C S G (abst) . . . 592
Silva F J E: *See* Van de Vyver F L et al.
Silver A (abst) . . . 420
Simeoni U (abst) . . . 482
Simforoosh N (abst) . . . 591, 595, 599
Simfroosh N (abst) . . . 588
Simm A: *See* Kirby J A et al.
Simon P (abst) . . . 442
Singh U (letter) . . . 157
Singhi P D (letter) . . . 157
Sinico R A (abst) . . . 431
Sirajeddine K (abst) . . . 421
Sis J: *See* Mann J F E et al.
Sisca S (abst) . . . 492
Sissons P: *See* Pickering S J et al.
Skogh T (abst) . . . 434
Skröder R (abst) . . . 462
Slaughter D (abst) . . . 477
Sloot J A P v d (abst) . . . 751, 754
Smeby L C: *See* Floege J et al.
Smith G D: *See* Jenkins D A S et al.
Smith J (abst) . . . 315, 836
Smith W G J, Dharmasena A D, El Nahas A M, Thomas D M, Coles G A: Short-Term Effect of Captopril on Renal Haemodynamics in Chronic Renal Failure . . . 696
Smith W G J, Holden M, Benton M, Brown C B: Glycosylated and Carbamylated Haemoglobin in Uraemia . . . 96
Smollich B P (abst) . . . 422
Smye S W: *See* Worth D P et al.
Snoek F (abst) . . . 752

Snowden S (abst) . . . 838
Sobh M (abst) . . . 431, 519, 595
Sobh M A: *See* Moustafa F E et al.
Sobue G: *See* Niwa T et al.
Söderstrom T (abst) . . . 510, 521
Sohtell M (abst) . . . 447
Solana R (abst) . . . 452
Sold M (abst) . . . 464
Solé M (abst) . . . 492
Sonnleitner A (abst) . . . 149
Sørensen P (abst) . . . 465
Sørensen S S (abst) . . . 461, 465
Sorkin M I: *See* McCauley J and Sorkin M I
Sotirchos J abst) . . . 598
Soubrane C (abst) . . . 454
Soulillou J P (abst) . . . 503
Soupart A (abst) . . . 421
Souvignet C (abst) . . . 421
Sozirchos G (abst) . . . 594
Spaapen L J M: *See* Knols G et al.
Spagnuolo G (abst) . . . 455
Späth P J: *See* Pertosa G et al.
Spechthof E (abst) . . . 512
Spencer E (abst) . . . 672
Sperschneider H: *See* Stein G et al.
Spielberger M (abst) . . . 151
Spindler E (abst) . . . 493
Sprenger R (abst) . . . 145, 154
Squifflet J P (abst) . . . 506
Sraer J D: *See* Nehme D et al.
Sraer J D: *See* Rondeau E et al.
Stabellini G (abst) . . . 513
Stanek G (abst) . . . 155
Stanziale P: *See* Fuiano G et al.
Staudacher C (abst) . . . 507
Steadman R (abst) . . . 437
Stefanovic V (abst) . . . 444
Steffenelli Th (abst) . . . 147
Steger G (abst) . . . 153
Steger H (abst) . . . 145
Stegmeier K (abst) . . . 512
Stein G, Sperschneider H, Ivanovich P, Abendroth K: Dialysis Encephalopathy and Bone Disease Due to Aluminium Toxicity . . . S3:100
Stein G: *See* Noronha I L et al.
Steiner G (abst) . . . 520
Steinhauer H B (abst) . . . 418, 472, 501
Steininger R (abst) . . . 508
Steinmann E: *See* Zuber M et al.
Stelzer N (abst) . . . 151
Stenger K O (abst) . . . 520
Stephens N (abst) . . . 319
Stephenson J R (abst) . . . 495, 833
Steropoulos G (abst) . . . 470
Sterzel R B (abst) . . . 458
Stevens J M (abst) . . . 833
Stevens M E (letter) . . . 917
Stevens P E (abst) . . . 447, 508
Stewart C J (letter) . . . 758
Stewart K N (abst) . . . 838
Steyrer E (abst) . . . 144
Stockenhuber F (abst) . . . 147, 148, 150, 151, 153, 154, 456, 478, 483, 488, 508, 518
Stöger H: *See* Biesenbach G et al.
Stoof T J (abst) . . . 511
Storm T (abst) . . . 480, 672
Stouthard J M L (abst) . . . 498, 754
Strackee J: *See* Koopman M G et al.
Strandgaard S (abst) . . . 450, 672
Stratta P (abst) . . . 442, 466, 467
Strauch M (abst) . . . 512
Strazzullo P (abst) . . . 416
Street P R: *See* Woolf A S et al.
Strong C A (abst) . . . 833
Struijk D G (abst) . . . 450, 498, 501, 752, 755
Stuby U (abst) . . . 145
Stummvoll H K (abst) . . . 144, 146, 153, 154
Stümpflein A (abst) . . . 483, 488
Stümpflen A (abst) . . . 505
Stumvoll H K (abst) . . . 147
Sturani A (abst) . . . 433
Sugimura T (abst) . . . 489
Sugiura S (abst) . . . 485
Sumie Manno: *See* Mitsuyasu Toyoda et al.
Sundal E, Kaeser U: Correction of Anaemia of Chronic Renal Failure with Recombinant Human Erythropoietin: Safety and Efficacy of One Year's Treatment in a European Multicentre Study of 150 Haemodialysis-Dependent Patients . . . 979
Sundal E (letter) . . . 675
Sunder-Plassmann G (abst) . . . 147, 148, 150, 151, 153, 154
Suria S (abst) . . . 504
Surian M (abst) . . . 485
Surian M (letter) . . . 678, 759
Surian M: *See* Colussi G et al.
Surian M, Malberti F, Corradi B, Orlandini G, Varini E, Colussi G, Minetti L: Adequacy of Haemodiafiltration . . . 32
Susumu Yoshikawa, Kazuko Hayashi, Hiroshi Fukumura, Masaru Miya, Youji Akagaki, Shin-ya Inai: Complement Activation and Thrombogenesis on Polymer Surfaces: Comparative Studies with Ethylene-Vinyl Alcohol Copolymers . . . S3:67
Sutcliffe N P, Cashman S J, Savage C O S, Fox J G, Boulton-Jones J M: Variability of the Antigenicity of the Glomerular Basement Membrane in Nail-patella Syndrome . . . 262
Suzuki T (abst) . . . 485
Swainson C P (abst) . . . 436
Swainson C P, Walker R J: Renal Haemodynamic and Hormonal Responses to a Mixed High-Protein Meal in Normal Men . . . 683
Swedenborg J (abst) . . . 462
Sweny P (abst) . . . 316, 317
Sweny P: *See* Lui S F et al.
Sweny Pheeler D C, Lui S F, Amin N S, Varghese Z, Fernando O N, Moorehead J F, Barradas M A, Jeremy J Y, Mikhailidis D P: Dietary Fish Oil Supplements Preserve Renal Function in Renal Transplant Recipients With Chronic Vascular Rejection . . . 1070
Sylvén M (abst) . . . 462
Syre G (abst) . . . 145
Szewczyk Z (abst) . . . 428
Szpirt W (abst) . . . 431
Tabaqchali S (abst) . . . 495, 833
Taccone-Gallucci M (letter) . . . 76
Taccone-Gallucci M, Lubrano R, Del Principe D, Menichelli A, Giordani M, Citti G, Morosetti M, Meloni C, Mazzarella V, Meschini L, Tozzo C, Elli M, Giardini O, Casciani C U: Platelet Lipid Peroxidation in Haemodialysis Patients: Effects of Vitamin E Supplementation . . . 975

Tadao Akizawa, Shozo Koshikawa: Clinical Effects of Membrane-induced Complement Activation on Haemodialysis Patients at High Risk S3:50
Taghavi M (abst) 588, 589
Tagliavini D: *See* David S et al.
Takahashi K (abst) 485
Takahiro Shinzato: *See* Kenji Maeda et al.
Takao Shoji: *See* Akira Yoshida et al.
Takehisa Matsuda: Biological Responses at Non-physiological Interfaces and Molecular Design of Biocompatible Surfaces S3:60
Taketoshi Kishimoto, Munekazu Kyo, Seiji Yamagami, Masanobu Maekawa: Effect of Membrane Area and Blood Flow Rate on Plasma C3a and C5a Concentration During Haemodialysis with Regenerated Cellulosic Membrane Dialysers S3:46
Takuo Sasaoka: *See* Akira Yoshida et al.
Talartschik J (abst) 478
Talbot J A (abst) 834
Talseth T (abst) 509
Tambourin P (abst) 472
Tamburro M L (abst) 520
Tange R A (abst) 752
Tapson J (abst) 508
Tapson J S (abst) 437
Tarantino A (abst) 508
Taşdemir I (abst) 594, 601
Tattersall J (abst) 836
Tattersall J E (abst) 466
Taube D (abst) 319, 838
Taube D: *See* Dische F E et al.
Tavella M (abst) 448
Taylor A E: *See* Young G A et al.
Taylor C M (abst) 433
Taylor O M (abst) 313
Taylor R M R: *See* Kirby J A et al.
Taylor T N: *See* Brown J H et al.
Teatini U (abst) 481, 488
Tel N (abst) 590
Templ H (abst) 146
ten Bokkel Huinink W W (abst) 751, 754
ten Kate R W (abst) 422
Tentori F (abst) 457
Teraoka S (abst) 485
Teruel J L (abst) 444
Teschner M: *See* Heidland A et al.
Tesio F (abst) 485, 489
Tetsuo Miyazaki: *See* Hidemune Naito, Tetsuo Miyazaki,
Tetta C (abst) 491
Tetta C (letter) 238
Thalén P (abst) 447
Thaysse C: *See* Cappello M et al.
Thea A (abst) 466
Thebaud H E (abst) 442
Theil J (abst) 461
Thick M (abst) 319
Thiel Cl: *See* Röckel A et al.
Thiel G: *See* Zuber M et al.
Thomas B (letter) 399
Thomas D B (abst) 435
Thomas D M: *See* Smith W G J et al.
Thomas H: *See* Van de Vyver F L et al.
Thomas T (abst) 834
Thomas T (letter) 602
Thomas T H, Mansy H, Wilkinson R: Erythrocyte Sodium and Sodium Flux in Relation to Hypertension in Chronic Renal Failure 21
Thompson J P: *See* Williams B et al.
Thomsen B (abst) 431
Thomson D (abst) 836
Thum J (abst) 146, 147, 155
Tidgren B (abst) 462
Tielemans C (abst) 488
Tielemans C L, Lenclud C M, Wens R, Collart F E, Dratwa M: Critical Role of Iron Overload in the Increased Susceptibility of Haemodialysis Patients to Bacterial Infections. Beneficial Effects of Desferrioxamine 883
Tikkanen I (abst) 465
Tincani A (abst) 431
Tindall H: *See* Hopper A H et al.
Tjandra Y I (abst) 755
Tobies A (abst) 418
Todros T (abst) 442
Tognarelli G (abst) 465
Tognet E (abst) 445
Tomić B H, Pavlović D, Halbauer M, Pasini J: Parathyroid Sonography in Secondary Hyperparathyroidism: Correlation with Clinical Findings 45
Tomita K (abst) 467
Tomlinson K: *See* Coles G A et al.
Tomosugi N (abst) 315
Tompkins L: *See* Young G A et al.
Tomson C R V (abst) 454
Tomson C R V: *See* Atkin S L et al.
Tomson C R V: *See* Edmunds M E et al.
Tomson C R V, Channon S M, Ward M K, Laker M F: Plasma Oxalate Concentration, Oxalate Clearance and Cardiac Function in Patients Receiving Haemodialysis. 792
Tönshoff B (abst) 446, 451, 469
Toorn L v d (abst) 459
Toothill C (abst) 503
Topley N (abst) 422, 425, 437
Tornero F (abst) 506
Torras A: *See* Campistol J M et al.
Torres A (abst) 491, 504
Torri G (abst) 507
Toshihiko Ono, Noriyuki Iwamoto, Megumo Hino: Clinical and Histological Patterns in Aluminium-related Bone Disease S3:107
Tötterman K-J (abst) 465
Totterman T H: *See* Hanas E et al.
Toupance O (abst) 492
Toupance O: *See* Chanard J et al.
Touraine J L: *See* Garnier J L et al.
Tournade H (abst) 427
Tournier O: *See* Floege J et al.
Toussaint C (abst) 517
Tozzo C: *See* Taccone-Gallucci M et al.
Traindl O (abst) 149, 150, 506
Trautmann M (abst) 418
Trevisan R (abst) 419
Trevisan R: *See* Vigano G et al.
Triolo G (abst) 465,491
Triolo G (letter) 238
Trivino R: *See* Morales-Barria J et al.
Trnačević S (abst) 443
Trolliet P: *See* Cahen R et al.
Trovati A (abst) 520
Trznadel K (abst) 451
Tschöpe W (letter) 399
Tsutomu Sanaka: *See* Mitsuyasu Toyoda et al.
Tucci A (abst) 431

Tuncker B: *See* Edmunds M E et al.
Tufveson G, Geelings W, Broyer M, Brunner F P, Brynger H, Dykes S R, Erich J H H, Fassbinder W, Rizzoni G, Selwood N H, Wing A J: EDTA Registry Centre Survey 1986 . . . 161
Tufveson G, Geerlings W, Brunner F P, Brynger H, Dykes S R, Ehrich J H H, Fassbinder W, Rizzoni G, Selwood N H, Wing A J: Combined Report on Regular Dialysis and Transplantation in Europe, XIX, 1988 . . S4:5
Tufveson G: *See* Brunner F P et al.; Ehrich J H H et al.; Hanas E et al.; Rizzoni G et al.
Tuk K (abst) . . . 752
Tulliez M (letter) . . . 675
Tulumović T (abst) . . . 443
Turello E (abst) . . . 491
Turgan Ç (abst) . . . 594, 601
Turner C: *See* Clarke A G B et al.
Turney J H: *See* Young G A et al.
Tvedegaard E (abst) . . . 480, 672
Uccello F (abst) . . . 516
Uccello F: *See* Sabbatini M et al.
Uhlschmid G (abst) . . . 509
Ulku U (letter) . . . 760
Ullrick W (abst) . . . 596
Ulrich W (abst) . . . 153, 519
Ureña P (abst) . . . 470
Ureña V (abst) . . . 428
Uri Kitano: *See* Kazuo Ota et al.
Urmson J (abst) . . . 428
Usadel K H: *See* Mann J F E et al.
Uygur C (abst) . . . 590
Vago L (abst) . . . 426
Valderrabano F (abst) . . . 484, 486
Valente U (abst) . . . 517
Valeri R (abst) . . . 507
Valetitsch H (abst) . . . 474
Van Acker K J (abst) . . . 753
van Bergeijk J D: *See* Wetzels J F M et al.
Van Cutsem J (abst) . . . 480
Van Damme-Lombaerts R (abst) . . . 479
Vandelli L (letter) . . . 1081
Vandenabeele P (abst) . . . 497
van den Berg B W: *See* Leunnissen K M L et al.
van den Heuvel L P W J, Savage C O S, Wong M, Price R G, Noel L, Grunfeld J P, Lockwood C M: The Glomerular Basement Membrane Defect in Alport-Type Hereditary Nephritis: Absence of Cationic Antigenic Components . . . 770
van der Hem G K (abst) . . . 455
van der Hulst R J (abst) . . . 752
van der Meer J (abst) . . . 459
Van der Merwe W M (abst) . . . 318
van der Meulen J (abst) . . . 752, 755
van der Veen E A (abst) . . . 459
Van Der Vorst P (abst) . . . 517
van der Woude F J (abst) . . . 509, 521
Van de Vyver F L, Visser W J, D'Haese P C, Silva F J E, Thomas H, De Broe M E: Risk of Aluminium Intoxication in Long-term Acetate Redy Dialysis . . . 555
Van Dijck M (abst) . . . 479
van Dorp W T (abst) . . . 509, 521
van Elven E H (abst) . . . 424
van Es L A (abst) . . . 505, 509, 521
Van Geet C (abst) . . . 479
van Gemert G W (abst) . . . 509
Vanherweghem J L (abst) . . . 421, 497
Vanholder R, Laekeman G, Herman A, Saragananda B, Waterloos M A, Kesteloot D, Lámeire N: The Inhibition of Thromboxane Synthesis Has No Influence on $HgCl_2$-Induced Acute Renal Failure in the Rat . . . 625
van Hooff J P (abst) . . . 515
van Hooff J P: *See* Cheriex E C et al.
van Hooff J P: *See* Knols G et al.
van Hooff J P: *See* Leunissen K M L et al.
Van Landuyt H W: *See* Boelaert J R et al.
van Rijn H J M: *See* Rabelink A J et al.
Van Saene H K F (abst) . . . 445
Van Waeleghem J P: *See* Heyrman R M et al.
van Ypersele de Strihou C (abst) . 434, 444, 481, 493, 506, 507
Vara F (abst) . . . 500
Varet B (abst) . . . 472
Varet B (letter) . . . 675
Varghese Z (abst) . . . 316, 837
Varghese Z: *See* Lui S F et al.
Varghese Z: *See* Sweny P et al.
Varini E: *See* Surian M et al.
Vaselov E (letter) . . . 602
Vasile G (abst) . . . 485
Vassault A (abst) . . . 470
Vaughan R W (abst) . . . 313
Vazelov E (letter) . . . 75
Vecsei P: *See* Mann J F E et al.
Vegeto A (abst) . . . 508
Velasco F (abst) . . . 491
Venherweghem J L: *See* Cappello M et al.
Veniero P (abst) . . . 516
Venkat Raman G: *See* Waters M R et al.
Vennegor M: *See* Williams B et al.
Venneker G T (abst) . . . 450
Venning M (abst) . . . 428
Venning M C (abst) . . . 832
Venning M C: *See* Atkin S L et al.
Verbeelen D (abst) . . . 488
Verbeelen D: *See* De Bock V et al.
Verberckmoes R: *See* Frenken L A M et al.
Verbrugh H A (abst) . . . 752, 755
Vercellone A (abst) . . . 442, 465, 466, 467, 486, 491
Vercellone A (letter) . . . 238
Vereerstraeten P (abst) . . . 517
Verhoef J (abst) . . . 752
Vermylen J (abst) . . . 479
Vernier I (abst) . . . 434
Vernon V: *See* Beardsworth S F et al.
Verrier Jones K (abst) . . . 419, 437
Vetter K (abst) . . . 453
Viberti G C (abst) . . . 419
Vidal M T (abst) . . . 493
Vienken J, Harding M: Dialysis Membranes and β_2-Microglobulin: Interactions, Limitations and Perspectives . . . S3:27
Vienken J: *See* Baurmeister U et al.
Vigano G, Gotti E, Comberti E, Giangrande A, Trevisan R, Remuzzi G: Hyperparathyroidism Does Not Influence the Abnormal Primary Haemostasis in Patients with Chronic Renal Failure . . . 971
Vijgh W v d (abst) . . . 754
Vilardell J (abst) . . . 492, 502, 517
Vilares S (abst) . . . 504
Vincent C (abst) . . . 492
Vincent D, Charmes J P, Benzakour M, Gualde N, Rigaud M, Leroux-Robert C: A Simple In Vitro Test to Evaluate Biocompatibility of Dialysis Membranes . . . 306

Visser W J: *See* Van de Vyver F L et al.
Visset J (abst) . . . 503
Vitale C (abst) . . . 437
Vlaanderen K (abst) . . . 755
Vögeler U (abst) . . . 502, 521
Vogiatzis K V (abst) . . . 462
Vogt P (abst) . . . 511
von Sperling V (abst) . . . 837
Vonesh E (abst) . . . 499
Vuillaume M: *See* Garnier J L et al.
Vulser C (abst) . . . 459
Vyzantiadis A T (abst) . . . 462
Wahl P: *See* Hasslacher Ch et al.
Walb D: *See* Röckel A et al.
Waldherr R (abst) . . . 429, 440, 506
Waldherr R: *See* Noronha I L et al.
Waldherr R, Rambausek M, Duncker W D, Ritz E: Frequency of Mesangial IgA Deposits in a Non-selected Autopsy Series . . . 943
Walker R G (abst) . . . 426
Walker R J: *See* Swainson C P, Walker R J
Walkowiak B (abst) . . . 451
Wallner M (abst) . . . 144
Walls J (abst) . . . 314, 515, 833, 834, 835
Walls J (letter) . . . 679, 918–19
Walls J: *See* Edmunds M E et al.
Walls J: *See* Jenkins D et al.
Walls J: *See* Williams B et al.
Walsley K M: *See* Woolf A S et al.
Walshe J: *See* O'Meara Y et al.
Wandel E (abst) . . . 424
Waniewski J: *See* Lindholm B et al.
Wanner C, Riegel W, Schaefer R M, Hörl W H: Carnitine and Carnitine Esters in Acute Renal Failure . . . 951
Ward G: *See* Clarke A G B et al.
Ward M (abst) . . . 470, 508
Ward M: *See* Edmunds M E et al.
Ward M K (abst) . . . 454, 495, 833
Ward M K: *See* Rodger R S C et al.
Ward M K: *See* Tomson C R V et al.
Ward R A, Schmidt B, Gurland H J: Biocompatibility of High-performance Membranes . . . S3:55
Ward R A: *See* Blumenstein M et al.
Warwick G (abst) . . . 831
Waterloos M A: *See* Vanholder R et al.
Waters M R, Albano J D M, Sharman V L, Venkat Raman G: Pharmacokinetics of Cyclosporin in Man Following a Single Oral Dose: Relationship to Body Fat Content . 71
Watschinger B (abst) . . . 146, 149, 150, 151, 506
Watson M J: *See* Rodger R S C et al.
Watson M L (abst) . . . 317, 436
Wattenberg M (abst) . . . 477
Watzinger U (abst) . . . 473
Watzke H (abst) . . . 155
Weber M (abst) . . . 424, 520
Weemaes C M R (abst) . . . 754
Weinreich T (abst) . . . 431, 471
Weissgarten J: *See* Modai D et al.
Welsh K (abst) . . . 319, 838
Welsh K I (abst) . . . 313
Wenning A: *See* Neumayer H-H et al.
Wens R: *See* Tielemans C L et al.
Wenz W (abst) . . . 469
Werner E (abst) . . . 469
Wertheim W J (abst) . . . 755
Werynski A: *See* Lindholm B et al.
Westeel P F (abst) . . . 418, 432, 467
Westeel P F: *See* Moriniere Ph et al.
Westlie L (abst) . . . 509
Westwick J (abst) . . . 835
Wetzels J F M, van Bergeijk J D, Hoitsma A J, Huysmans F Th M, Koene R A P: Triamterene Increases Lithium Excretion in Healthy Subjects: Evidence for Lithium Transport in the Cortical Collecting Tubule . . . 939
Wheeler D C (abst) . . . 837
Wheeler D C: *See* Sweny P et al.
White A G (abst) . . . 589, 599
Whitworth J (abst) . . . 831
Wibom R (abst) . . . 471
Widerøe T-E (abst) . . . 498
Widjaja A (abst) . . . 425
Widstam-Attorps U (abst) . . . 432
Wieçek A (abst) . . . 466, 475, 505
Wieçek A: *See* Kokot F et al.
Wiel T W M v d: *See* Knols G et al.
Wieslander J: *See* Bygren P et al.
Wight J P (abst) . . . 458
Wijk A v (abst) . . . 751, 754
Wijnveen A C (abst) . . . 521
Wilfling M (abst) . . . 436
Wilhelm E (abst) . . . 469
Wilkinson R (abst) . . . 437, 508, 834
Wilkinson R: *See* Rodger R S C et al.
Wilkinson R: *See* Thomas T H et al.
Wilks M F (abst) . . . 448
Will E J (abst) . . . 443, 503, 512
Will E J: *See* Davenport A et al.
Will E J: *See* Worth D P et al.
Willems D (abst) . . . 488
Williams A J (abst) . . . 314
Williams B (abst) . . . 833, 834
Williams B, Edmunds M E, Thompson J P, Burton P R, Feehally J, Walls J: Does Increasing Haemoglobin Concentration and Haematocrit Have a Pressor Effect in Dialysis Patients? . . . 787
Williams B, Vennegoor M, O'Nunan T, Walls J: The Use of Calcium Carbonate to Treat the Hyperphosphataemia of Chronic Renal Failure . . . 725
Williams D G (abst) . . . 313, 429, 837
Williams G: *See* Short C D et al.
Williams I (abst) . . . 444
Williams J D (abst) . . . 318, 319, 419, 427, 437, 476
Williams P S (abst) . . . 445
Williams P S (letter) . . . 917
Williams P S, Bone J M: Immunosuppression Can Arrest Progressive Renal Failure Due to Idiopathic Membranous Glomerulonephritis . . . 181
Williams S: *See* Short C D et al.
Wilson N: *See* Heney D et al.
Wilson R: *See* Rogerson M E et al.
Winberg J (abst) . . . 436
Winearls C G (abst) . . . 472, 494, 833
Winearls C G: Erythropoietin . . . 323
Winearls C G: *See* Edmunds M E et al.
Wing A J: *See* Brady A J B, Wing A J; Brunner F P et al.; Ehrich J. H. H. et al.; Rizzoni G et al.; Tufveson G et al.
Wingen A M (abst) . . . 432
Winkler H (abst) . . . 146
Winkler H M (abst) . . . 144, 474
Winney R J (letter) . . . 77
Winney R J: *See* Jenkins D A S et al.
Wizemann V (abst) . . . 479

Woitas R P (abst) 454
Wolfram J (abst) 596
Woloszczuk W (abst) 148, 520
Wong C (abst) 477
Wong K K: *See* Chan M K et al.
Wong M: *See* van den Heuvel L P W J et al.
Woodhead J S: *See* Bittar A E et al.
Woodrow D F (abst) 508
Woodrow D F: *See* Sethi D et al.
Woolf A S (abst) 317
Woolf A S: Atrial Natriuretic Peptide, and Renal Disease .1008
Woolf A S, Street P R, Walmsley K M, Cohen S L: Portal Vein Thrombosis in the Nephrotic Syndrome 581
Worth D P, Smye S W, Robinson P J, Davison A M, Will E J: Quantitative Bone Scanning in the Diagnosis of Aluminium Osteomalacia 721
Wöss E (abst) 145, 154
Wramner L (abst) 521
Wynckel A (abst) 438
Wyns W (abst) 481
Xatzikonstantinou J (abst) 470
Yamagami S (abst) 489
Yasavul Ü (abst) 594, 601
Yasuhisa Wakabayashi: *See* Yusuke Tsukamoto et al.
Yoneshima H (abst) 475
Yoshida O: *See* Hosokawa S, Yoshida O
Yoshida T: *See* Akizawa T et al.
Yoshihei Hirasawa: *See* Makiko Tsutsui et al.; Masashi Suzuki et al.
Yoshiyama N (abst) 467
Yoshiyuki Osamura: *See* Mitsuyasu Toyoda et al.
Youji Akagaki: *See* Susumu Yoshikawa et al.
Young G A, Dibble J B, Hobson S M, Tompkins L, Gibson J, Turney J H, Brownjohn A M: The Use of an Amino-acid-based CAPD Fluid over 12 weeks 285
Young G A, Dibble J B, Taylor A E, Kendall S, Brownjohn A M: A Longitudinal Study of the Effects of Amino Acid-Based CAPD Fluid on Amino Acid Retention and Protein Losses 900
Yusim A: *See* Cohen S L et al.
Yusuke Tsukamoto, Yasuhisa Wakabayashi, Michihito Okubo, Fumiaki Marumo: Abnormal Lipid Profiles at Various Stages of Uraemia S3:142
Yusuke Tsukamoto: *See* Fumiaki Marumo et al.
Zaché P (abst) 479
Zamboulis C X (abst) 462
Zanelli P (abst) 429
Zazgornik J (abst) 145, 148, 511
Zazgornik J: *See* Biesenbach G et al.
Zech P (abst) 456, 460
Zehnder C: *See* Morales-Barria J et al.
Zeier M (abst) 458, 471
Zemel D (abst) 501, 755
Ziachehabi F (abst) 144, 153, 154
Ziak E (abst) 144, 146, 474
Zidani R (abst) 591
Ziegler-Heitbrock H W L: *See* Blumenstein M et al.
Zimmerman R S (abst) 463
Zingraff J (abst) 470
Zins B (letter) 675
Zins B: *See* Najean Y et al.
Ziyaie M (abst) 500
Zlabinger C J (abst) 588
Zlabinger G (abst) 149
Zlabinger G J (abst) 506, 519, 589
Zlatarska S (letter) 75, 602
Zmerli S (abst) 593, 599
Zoccali C (abst) 439, 463, 468
Zoccali C (letter) 236
Zoccali C, Postorino M, Martorano C, Salnitro F, Maggiore Q: The 'Breakpoint' Test, A New Statistical Method for Studying Progression of Chronic Renal Failure 101
Zoellner K (abst) 476, 487
Zuber M, Steinmann E, Huser B, Ritz R, Thiel G, Brunner F: Incidence of Arrhythmias and Myocardial Ischaemia During Haemodialysis and Haemofiltration 632
Zuccalà A: *See* Zucchelli P et al.
Zucchelli P: *See* Passerini P et al.
Zucchelli P, Zuccalà A, Mancini E: Hypertension in Primary Glomerulonephritis Without Renal Insufficiency 605
Zukowskas-Szczechowska E (abst) 475

Subject Index to Volume 4

Ablation Nephropathy, renal transplantation in (abst). . . 457
ABO Antibodies, acquired haemolytic anaemia due to (abst) 671
Accessory Cells, in haemodialysis (abst) 490
Acetaminophen, photometric determination (abst) 456
Acetate
in haemodialysis 1061
in haemodialysis (abst) 481
Acetazolamide
effect on lithium clearance. 707
effect on lithium clearance (abst) 417
Acid-Base Status, effect of lactate-buffered solutions on . . 800
Acidosis
correction in uraemia 92
in chronic renal failure (abst) 833
Acinobactor, in CAPD peritonitis (letter) 759
Acute Renal Failure
anti-neutrophil cytoplasmic antibodies in (abst) 431
APACHE II score (abst) 317
atrial natriuretic factor in (abst) 464
C-reactive protein (CRP) in 864
captopril in. 311
carnitine in 951
carnitine esters in 951
cyclosporin in 311
dopamine- and frusemide-resistant (abst) 464
erythropoietin (abst) 671
felodipine in (abst). 447
$HgCl_2$-induced 625
$HgCl_2$-induced (abst) 448
hypertension in (abst) 443
in infants 535
in mercury vapour intoxication 133
in nephrotic syndrome. 914
in newlyborn infants. 870
in the tropics 535
indications for dialysis. 537
interleukin-2 in (abst) 445
mean blood pressure (MAP) in 691
muscle necrosis in (abst). 444
prognosis of (abst). 317
renovascular resistance and intrarenal blood flow (abst) 447
sepsis control in (abst). 445
thromboxane in 625
thyroid hormone profiles in (abst) 444
verapamil in (abst). 446
Acute Respiratory Failure, in mercury vapour intoxication 133
Acute Tubular Necrosis
in infants 535
in the tropics 535
Adaptive Glomerular Hypertrophy 845
Adhesion-promoting Glucoprotein
surface expression on granulocytes (abst) 490
Adrenal Dysfunction, in renal amyloid (abst). 834
Adriamycin
in chronic renal failure (abst) 457
in nephrosis 1037
Adriamycin (abst) 457
AIDS
EDTA Registry Centre Survey 161
HIV-related nephropathy in (abst) 434
in RRT S2:25
Albumin
in insulin-dependent diabetes mellitus (abst) 420
in nephrotic syndrome (abst) 466
in peritoneal solute transport (abst) 501
in pre-eclampsia (abst) 442
intraperitoneal human (abst) 755
Albuminuria, circadian rhythm of. 266
Aldosterone
in chronic renal failure (abst) 149
in uraemia (abst). 673
Allergy, dialysis materials 646
Allograft Monitoring, ultrasound (abst) 595
Allograft Rejection. *See* Rejection
$Al(OH)_3$
in renal osteodystrophy and soft-tissue calcification . . .1045
Alpha-mercaptopropionylglycine
in membranous glomerulonephritis (abst) 434
Alport-type Hereditary Nephritis 770
Alport-type Nephritis 262
Alport's Syndrome 144, 611
GBM changes in (abst) 145
glomerular basement membrane defect in 770
in renal transplantation (abst) 506
renal prognosis 1016
Alport's Syndrome (abst) 144
Aluminium
avoidance in haemodialysis 105
determination in biological materials S3:114
effect on erythropoiesis and ^{59}Fe absorption (abst). . . . 468
encephalopathy after treatment with desferrioxamine . . 110
encephalopathy exacerbation (letter) 676
gastrointestinal absorption in diabetic nephropathy (letter) 839
in bone disease 51, 555, 957, 1045, S3:100, S3:107

in CAPD patients (abst) . . . 671
in chronic renal failure . . . S3:97
in haemodialysis . . . 282
in haemodialysis (abst) . . . 488
in recombinant human erythropoietin therapy (abst) . . 474
in renal transplantation (abst) . . . 503
in uraemia (abst) . . . 484
in water pollution . . . S3:97
intestinal absorption of (abst) . . . 484
intoxication risk in long-term acetate Redy dialysis . . . 555
mass transfer and plasma kinetics (abst) . . . 467
plasma concentrations in CRF . . . 375
tissue mobilisation (abst) . . . 470
Aluminium Hydroxide
absorption risk factors (abst) . . . 468
in hyperphosphataemia 1005
phosphate binders . . . 51
plasma phosphate control . . . 51
Aluminium Intoxication . . . S3:97
Aluminium Osteomalacia, bone scanning in . . . 721
Amino Acids
dialysate containing (abst) . . . 500, 501
in CAPD . . . 285, 900
in chronic renal failure (abst) . . . 450
in peritoneal dialysis (abst) . . . 495
in uraemia (abst) . . . 448
parenteral nutrition (abst) . . . 673
peritoneal dialysate (abst) . . . 833
Aminonucleoside of Puromycin 1037
Ampicillin, in salmonella infection . . . 390
Amyloid Deposition, β_2-microglobulin-derived . . . S3:11
Amyloid Proteins, classification of . . . S3:19
Amyloidosis
AA . . . S3:19
AL . . . S3:19
β_2-microglobulin-related . . . S3:11
diagnostic imaging (abst) . . . 494
dialysis-associated . . . 1052, S3:83
dialysis-related (abst) . . . 493, 494
β_2-microglobulin in . . . S3:14
clinical and pathophysiological aspects . . . S3:7
pathogenetic aspects and open questions . . . S3:3
haemodialysis-associated (abst) . . . 492
in nephrotic syndrome (abst) . . . 438
role of AP in . . . S3:20
with protein permeable membranes . . . S3:78
Anaemia
acquired haemolytic (abst) . . . 671
atrial natriuretic peptide in (abst) . . . 478
erythropoietin in (abst) . . . 479
in CAPD (abst) . . . 753
in chronic renal failure (abst) . . . 597, 979
in chronic renal failure (abst) . . . 145
in dialysis . . . S4:23
of end-stage renal disease (abst) . . . 146
recombinant human erythropoietin in . . . 966
recombinant human erythropoietin in (abst) . . . 146, 147, 477, 597, 979
uraemic . . . S3:123
see also Erythropoietin
Analgesic Nephropathy
after renal transplantation (abst) . . . 150
malignancy in (abst) . . . 150
renal insufficiency in (abst) . . . 456
Angiodynography (abst) . . . 150
Angiomyolipomas, rupture of (abst) . . . 145
Angiotensin
generation in rat vasculature (abst) . . . 460
urinary excretion during sodium restriction and diuretics . . . 713
vascular response (abst) . . . 474
Angiotensin Converting Enzyme (ACE) Inhibitors . . 66, 696
in chronic renal failure (abst) . . . 444
in hypertension . . . 396
in insulin-dependent diabetes (abst) . . . 317
in renal failure . . . 311
Angiotensin II
plasma concentration of . . . 532
specific binding of . . . 530
vascular reactivity in pregnancy (abst) . . . 418
Antibody Responses
T-cell-independent and T-cell-dependent . . . 216
Anti-CD3, Antibodies, nephrotoxicity of (abst) . . . 517
Antidiuretic Hormone
syndrome of inappropriate secretion (abst) . . . 421
Anti-GBM Antibodies, in glomerulonephritis . . . 254
Antiglomerular Basement Membrane Antibodies
in autoimmune glomerulonephritis (abst) . . . 427
Anti-HB-C Antibodies, in haemodialysis (abst) . . . 487
Antilymphocyte Globulins (ALG)
in EBV lymphoma . . . 818
in RRT . . . S2:12, S4:15
Anti-Neutrophil Cytoplasmic Antibodies (ANCA)
in vasculitis (abst) . . . 832
Antineutrophil Cytoplasmic Antibody
immunoperoxydase technique (abst) . . . 438
in glomerulonephritis (abst) . . . 438
Anti-Pig Antibodies, identification and removal (abst) . . . 319
Antiplatelet Agents, oral administration of (abst) . . . 485
Anti-Proteases, in haemodialysis (abst) . . . 492
Antithymocyte Globulins
in antirejection therapy (abst) . . . 596
in release of cytokines (abst) . . . 517
in RRT . . . S2:12, S4:15
APACHE II Score, in acute renal failure (abst) . . . 317
Apolipoprotein Metabolism, in nephrotic syndrome (abst) 831
Apoprotein, in uraemia . . . S3:142
Arachidonic Acid Metabolites
biocompatibility with dialysis membranes . . . 306
Arginine-glycine-aspartic acid-serine (RGDS) . . . S3:65
Arterial Pressure, effect of endothelin (abst) . . . 835
Arterial Stenosis, in renal transplant in children . . . 575
Arteriovenous Fistulae
diagnosis and therapy (abst) . . . 153
duplex sonography of (abst) . . . 152
transcatheter embolisation of (abst) . . . 152
Ashing, of biological samples . . . S3:115
Aspirin-Dipyridamole, in diabetic nephropathy . . . 140
Atenolol, effect on atrial natriuretic factor (abst) . . . 464
ATG, in renal transplantation (abst) . . . 506
Atherosclerosis, in haemodialysis . . . S3:142
ATP, muscle mitochondrial formation (abst) . . . 471
Atrial Natriuretic Factor
ANF102–126 (WY 47987) . . . 776
effect of β-adrenergic receptor blockade (abst) . . . 464
in acute renal failure (abst) . . . 464
in CHF (abst) . . . 149
in chronic renal failure (abst) . . . 317
in heart failure (abst) . . . 465
plasma concentration of . . . 532
response of renal interstitial pressure to (abst) . . . 463
specific binding of . . . 530

Atrial Natriuretic Peptide 691
and renal disease 1008
effect on blood pressure and blood volume (abst) 464
immunoradiometric assay (abst) 466, 836
in anaemia (abst) 478
in CAPD (abst) 500
in chronic renal failure 1008
in haemodialysis 382
in haemodialysis (abst) 500
in haemodialysis (letter) 602
in haemofiltration (letter) 602
in healthy subjects 1008
in hypertensive rats (abst) 463
in nephrotic syndrome 1010
in nephrotic syndrome (abst) 466
in polycystic kidney disease (abst) 465
in progression of renal disease 1012
in recombinant human erythropoietin (abst) 478
in uraemia (abst) 464, 465
in venous renal blood (abst) 466
inactivation of (abst) 466
plasma concentrations of 222
polyclonal antibodies (abst) 466
release during nocturnal water immersion (abst) 420
Autoantibodies 1
Autoimmune Glomerulonephritis
antiglomerular basement membrane antibodies in (abst) 427
Azathioprine
in allograft rejection 387
in follow-up cases (abst) 594
in heart transplantation (abst) 505
in hypertension (abst) 512
in idiopathic membranous glomerulonephritis 181
in living related donor kidney recipients 293
in living related donor kidney transplantation (abst) . . 519
in rejection episodes (abst) 152
in renal graft recipients returning to haemodialysis (abst) 518
in renal transplantation 129
in renal transplantation (abst) 504, 508, 509, 510, 514, 517, 518
in RRT S2:12, S2:13, S4:17
in salmonella infection 390
in Wegener's granulomatosis (abst) 435
triple-therapy (abst) 594
Backfiltration, endotoxin transfer by S3:89
Balkan Nephropathy, β_2-microglobulin in (abst) 443
Balloon-dilatation 57
β-adrenergic Blockade, effect on atrial natriuretic factor (abst) 464
B-cell Markers in the Human Kidney 85
β_2-Microglobulin
amyloidosis imaging (abst) 494
collagen beads for removal of (abst) 494
dialysis-related amyloid deposits (abst) 493
elimination by polyacrylonitrile membrane dialyser . . . 356
in Balkan nephropathy (abst) 443
in dialysis arthropathy (abst) 318
in dialysis-associated amyloidosis 1054
in dialysis-associated amyloidosis (abst) 494
in dialysis-related amyloidosis S3:3, S3:7, S3:11, S3:14
in haemodialysis 282, 549, S3:43, S3:78
in haemodialysis (abst) 490, 492
in push/pull haemodiafiltration S3:83
influence of membrane characteristics on S3:27
mass transfer characteristics of high-performance modified cellulose membrane S3:55
removal of 653
sources of elevated (abst) 589
Beta-blockers, in hypertension (abst) 460
Bicarbonate
dialysate modelling (abst) 482
Dialysis Buffer S3:43
supplementation in uraemia 92
Biocompatibility
biological responses at non-physiological interfaces and molecular design of biocompatible surfaces . . S3:60
ex-vivo model S3:43
in dialysis S3:125
in haemodialysis S3:41
in haemodialysis (abst) 489
in hypoxaemia 489
of high-performance membranes S3:55
Biological Specimens, sampling of S3:115
Blindness, in acute glomerulonephritis (letter) 236
Blood, atrial natriuretic peptide estimation (abst) 466
Blood Concentration in post-transplant hypertension (abst) 601
Blood Flow Rate, effect on plasma C3a and C5a concentration S3:46
Blood–material Interfaces, thrombus formation S3:60
Blood Pressure, in uraemia (abst) 464
Blood Transfusion
cyclosporin in pre-transplant (abst) 838
donor-specific (abst) 588
in renal transplantation (abst) 588
in RRT S4:14
Blood Volume
correlation with VCD and collapse index 563
in uraemia (abst) 464
Body Fat Content, effect of cyclosporin 71
Body Temperature, in haemodialysis (abst) 483
Bone Biopsy, in oxalosis-induced bone disease (abst) . . . 469
Bone Density, in calcium stone formers (abst) 432
Bone Disease
aluminium in 51, 555, 957, 1045
aluminium-induced S3:98, S3:100, S3:107
non-aluminic adynamic (abst) 467
oxalosis-induced (abst) 469
Bone Marrow Cells
calcium uptake (abst) 475
response to erythropoietin (abst) 475
Bone Marrow Fibrosis, in haemodialysis (letter) 674
Bone Marrow, immunohistochemical examination . . . S3:23
Bone Scanning, in aluminium osteomalacia 721
Bopindolol, in renal impairment (abst) 835
Bourneville-Pringle disease (abst) 144
Breakpoint Test, in chronic renal failure 101
Cachetin, production and clearance of (abst) 491
Calcitonin-gene-related Peptide, in hypertension (abst) . . 463
Calcitriol
in chronic haemodialysis patients (abst) 318
in secondary hyperparathyroidism (abst) 318
in uraemia (abst) 451, 452
in uraemia with severe hyperparathyroidism and hypercalcaemia 545
Calcium
absorption in nephrotic syndrome (abst) 469
effect on parathyroid hormone secretion in uraemia . . . 339
in CAPD (abst) 496
in hypertension (abst) 461
in renal osteodystrophy and soft-tissue calcification . . .1045
in renal transplantation (abst) 514

ionised, effect on haemodialysis . . . 115
platelet-free mobilisation (abst) . . . 479
uptake by bone marrow target cells (abst) . . . 475
Calcium Antagonists
effect on T-cell proliferation (abst) . . . 520
in type II diabetes mellitus (abst) . . . 459
Calcium Carbonate
in children . . . 539
in children with chronic renal failure . . . 539
in haemodialysis . . . 105
in haemodialysis (abst) . . . 484
in hyperphosphataemia . . . 725, 1005
Calcium:Creatinine Ratio
in pre-eclampsia (abst) . . . 439
in pregnancy (abst) . . . 439
Calcium Deposition, β_2-microglobulin-derived . . . S3:11
Calcium Intake, in haemodialysis . . . S3:138
Calcium Stone Formers
bone density in (abst) . . . 432
hypocitraturia in (abst) . . . 437
Cancer. *See* Malignancy
CAPD . . . 41, 62
aldosterone concentration (abst) . . . 149
aluminium concentration in serum dialysate, urine and bone (abst) . . . 671
amino-acid-based fluid . . . 285, 900
amino acid dialysate (abst) . . . 833
anaemia in (abst) . . . 753
ANF plasma concentration (abst) . . . 149
antibody responses . . . 216
atrial natriuretic peptide in (abst) . . . 500
blood lead and plasma aluminium concentrations . . . 375
captopril in . . . 1084
catheter placement in urinary bladder (abst) . . . 751
coagulase-negative staphylococcal peritonitis (abst) . . . 495
comparison with continuous cyclic peritoneal dialysis (abst) . . . 752, 755
comparison with haemodialysis . . . 244
cyclic guanosine monophosphate in (abst) . . . 500
cytokine release (abst) . . . 496
dialysate IgG and peritonitis in (abst) . . . 501, 755
fluid reabsorption in . . . 805
haematocrit in . . . 787
haemoglobin in . . . 787
hypercholesterolaemia in (abst) . . . 753
idiopathic nephrogenic ascites in (letter) . . . 918
IgG_2 deficiency in children (abst) . . . 754
in developing countries (abst) . . . 499
in pregnancy . . . 583
insulin as additive to dialysate (abst) . . . 500
interleukin-6 in (abst) . . . 497
nephrogenic ascites in (letter) . . . 918
nitrogen losses in children (abst) . . . 497
ototoxicity monitoring (abst) . . . 752
peritoneal fibroblast proliferation (abst) . . . 496
peritoneal function in (abst) . . . 495
peritoneal IgG in (abst) . . . 496
peritoneal lymph flow in (abst) . . . 753
peritoneal macrophages in (abst) . . . 496
peritoneal solute transport in (abst) . . . 755
peritoneal transport kinetics (abst) . . . 498
peritoneal ultrafiltration in . . . 805
peritonitis (abst) . . . 752, 833
peritonitis (letter) . . . 759
pseudomonas peritonitis in . . . 814
recombinant erythropoietin in (abst) . . . 318
recombinant human erythropoietin in (abst) . . . 754, 833
recombinant human erythropoietin in (letter) . . . 676
renal function recovery (abst) . . . 499
residual renal function in (abst) . . . 499
rickets in infants on (abst) . . . 753
sclerosing peritonitis in (abst) . . . 498
serum vanadium concentrations . . . S3:98
survey in Belgium (abst) . . . 497
swan neck catheter in (abst) . . . 154
transport of macromolecules from peritoneal cavity (abst) . . . 498
ultrafiltration failure (abst) . . . 751
upper gastrointestinal tract pathology in (abst) . . . 496
vancomycin in (abst) . . . 751
Vitamin E (letter) . . . 75
Captopril
effect on glomerular hyperfiltration (abst) . . . 454
effect on thromboxane B_2 (abst) . . . 421
in acute renal failure . . . 311
in CAPD . . . 1084
in chronic renal failure . . . 696
in chronic renal failure (abst) . . . 457
in cryoglobulinaemic glomerulonephritis (letter) . . . 839
in diabetic nephropathy (abst) . . . 433
in hypertension (abst) . . . 461
in membranous glomerulonephritis . . . 172
in transplant renal artery stenosis . . . 66
Carbamylated Haemoglobin, in uraemia . . . 96
Carbidopa, in intravenous saline loading . . . 271
Carboplatin, in ovarian cancer (abst) . . . 754
Cardiac arrest, in RRT . . . S2:18
kidney donation in (abst) . . . 590
Cardiac Arrhythmias
in haemodialysis . . . 632
in haemofiltration . . . 632
Cardiac failure, in RRT . . . S2:18
Cardiac Function
by echocardiography . . . S3:146
in chronic renal failure (abst) . . . 461
in haemodialysis . . . 792
in uraemia (abst) . . . 465
Cardiac Performance
effect of erythropoietin (abst) . . . 477
in uraemia (abst) . . . 487
Cardiac Zygomycosis, desferrioxamine (DFO) in . . . 911
Cardiovascular Accident, in RRT . . . S4:19
Cardiovascular Dynamics, effect on recombinant human erythropoietin . . . S3:146
Carpal Tunnel Syndrome
granulocyte elastase-α_1-protease inhibitor in . . . S3:134
in dialysis . . . S3:134
in dialysis-related osteoarthropathy . . . S3:32
in haemodialysis . . . S3:14
Carnitine
in acute renal failure . . . 951
in haemodialysis . . . 366
Carnitine Esters, in acute renal failure . . . 951
Carpal Tunnel Syndrome (CTS), inflammation in (abst) . . . 492
Catabolic Patients, creatinine clearance in (abst) . . . 673
CCPD, in children . . . 893
CCPD (abst) . . . 752, 755
CD45 Monoclonal Antibodies (abst) . . . 838
Ceftazidime in pseudomonas peritonitis . . . 814
Cellular Adhesion, in thrombus formation . . . S3:65
Cellulose Acetate Membranes, biocompatibility tests on . . . 306
Cephradine, in peritonitis (abst) . . . 752

Cerebral Blood Flow
effect of erythropoietin therapy (abst) 474
Cerebrovascular accident, in RRT S2:17
Children
regular dialysis and transplantation of. S2:33
rehabilitation S2:37, S4:35
renal diseases in. S4:35
RRT in S2:33, S4:31
Chocolate, in transient hyperoxaluria (abst) 154
Chronic Ambulatory Peritoneal Dialysis. *See* CAPD
Chronic Renal Failure
acidosis in (abst). 833
aldosterone in (abst). 149
aluminium in S3:97
amino acids in (abst) 450
anaemia in 979
anaemia in (abst) 145, 597
ANF in (abst) 149
and age (abst) 468
angiotensin converting enzyme (ACE) inhibitors in (abst) 444
atrial natriuretic factor in (abst) 317
atrial natriuretic peptide in 1009
blood lead and plasma aluminium concentrations 375
breakpoint test in 101
captopril in 457, 696
cardiac function in (abst) 461
creatinine in (abst). 450
deferoxamine in. S3:97
dietary protein in 877
effects of ANF102–126 (WY 47987) 776
eicosapentanoic acid in (abst). 454
erythrocyte sodium and sodium flux in 21
erythropoietin in (abst) 145
factors affecting progression (abst) 457
fenoldopam infusion (abst) 418
GFR in (abst) 672
growth hormone in (abst) 451
hereditary renal disorders in (abst) 144
human neutrophil elastase (HNE) in (abst) 481
hyperparathyroidism in 971
hyperparathyroidism in children with 539
hyperphosphataemia in 725
hypertension in 21
hypertension in (abst) 461
hyperthyroidism in children with 539
in children (abst). 451
in Pringle-Bourneville disease (abst) 145
insulin resistance in (abst). 450
intrahepatic cholestasis in (abst) 590
keto acids in (abst). 453
lipid abnormality in. S3:142
lipoprotein in (abst) 448
luteinising hormone in (abst) 834
nephron adaptation in (abst) 458
nifedipine in (abst). 458
nitrogen in 877
pituitary-adrenal function in (abst). 146
platelet storage pool defect in (abst) 148
progression of 101
prostacyclin (PGI_2) in (abst) 148
protein-restricted diets in (abst). 457
recombinant human erythropoietin in 782
recombinant human erythropoietin in (abst). 474
renal function in (abst) 672
sicca-like syndrome in (abst) 439
T-cell-independent and T-cell-dependent antibody responses 216
tertatolol in (abst) 419
thromboxane B_2 in (abst) 148
trace elements in S3:97
vanadium in. S3:97
Cilastatin, in haemofiltration 640
Cimino-Brescia Fistula, duplex sonography (abst) 152
Ciprofloxacin. 390
in CAPD peritonitis (letter) 759
Circadian Rhythm, in glomerulopathies (abst) 420
Circadian Rhythm of Proteinuria 9, 266
cis-Dichlorodiamine Platinum
in glomerular haemodynamic evaluation (abst) 448
Cisplatin, in ovarian cancer (abst). 754
Clindamycin, in peritonitis (abst) 752
Clonidine, in restless leg syndrome (abst) 149
Coagulase-negative Staphylococci
(abst). 833
peritonitis due to. 62
Coagulation System, effects of blood-material interactions S3:60
Cocaine, in rhabdomyolysis (letter) 675
Colchicine, in Familial Mediterranean Fever 201
Collagen Beads for β_2-microglobulin removal (abst) 494
Colour-coded Doppler Sonography (abst) 150
Complement
activation in haemodialysis 646
C3 in Mesangial IgA Glomerulonephritis (abst) 440
C3d in renal failure (abst) 450
in active in-situ glomerulonephritis (abst) 315
terminal complex formation (abst) 489
Complement Activation
effects of blood–material interactions S3:60
in haemodialysis S3:41
Complement activation, in thrombogenesis S3:67
Complement Activation, membrane-induced S3:50
Complement Receptor (CR1)
effect on erythrocytes and in immune complexes. 932
Concanavallin A (Con A), in kidney graft (abst) 588
Congenital Heart Disease, in newlyborn infants 870
Continuous Ambulatory Peritoneal Dialysis. *See* CAPD
Continuous Arteriovenous Haemofiltration (CAVH). *See* Haemofiltration
Continuous Cycling Peritoneal Dialysis (CCPD). *See* CCPD
Coronary Artery Disease, in dialysis patients (abst) 479
Coronary Revascularisation, in haemodialysis (abst) . . . 481
Corticosteroids, in RRT S4:17
Co-trimoxazole, in salmonella infection 390
C-Reactive Protein (CRP), in acute renal failure 864
Creatinine
in chronic renal failure (abst) 450
reciprocal plasma (abst). 672
serial determinations in renal transplantation 1076
Creatinine Clearance
in catabolic patients (abst) 673
measurement of 266
Cryoglobulinaemia
captopril in (letter). 839
phagocyte cytoskeleton in (abst) 440
Cryoprecipitate, in uraemic thrombopathy (abst) 449
Cuprophane Membranes
biocompatibility tests on 306
effect on tumour necrosis factor (abst) 490

Cyclic Guanosine Monophosphate
in CAPD (abst) . . . 500
in haemodialysis (abst) . . . 500
Cyclophosphamide
in idiopathic membranous glomerulonephritis . . . 181
in systemic lupus erythematosus (abst) . . . 435
in Wegener's granulomatosis (abst) . . . 435
Cyclosporin
blood concentration in post-transplant hypertension (abst) . . . 601
chronic nephrotoxicity (abst) . . . 591
effect on body fat content . . . 71
effect on endothelium-dependent relaxation of human resistance vessels (abst) . . . 838
effect on glomerular dynamics (abst) . . . 516
effect on glomeruli and mesangial cells (abst) . . . 515–16
effect on peripheral resistance vessels (abst) . . . 516
effect on plasma lipids (letter) . . . 237
effect on superficial and juxtamedullary isolated human glomeruli (abst) . . . 513
effect on tubular function (abst) . . . 514
effect on vascular endothelium (abst) . . . 316
in acute renal failure . . . 311
in allograft rejection . . . 387
in EBV lymphoma . . . 818
in eicosanoid production (abst) . . . 513
in Familial Mediterranean Fever . . . 201
in glomerulonephritis . . . 923
in glomerulonephritis (abst) . . . 425
in glycosaminoglycans synthesis of human fibroblasts (abst) . . . 513
in heart transplantation (abst) . . . 459, 505
in hyperpigmentation . . . 309
in hypertension (abst) . . . 507, 512
in idiopathic membranous GN (IMGN) . . . 926
in IgA nephropathy . . . 926
in insulin-dependent diabetics (abst) . . . 514
in living related donor kidney transplantation . . . 293
in living related donor kidney transplantation (abst) . . . 519
in nephrotic syndrome (abst) . . . 432
in pre-transplant blood transfusions (abst) . . . 838
in pregnancy (abst) . . . 511
in pregnancy in renal transplant recipients . . . 667
in psoriasis (abst) . . . 511
in Raynaud's phenomenon (abst) . . . 512
in rejection (abst) . . . 519
in renal graft recipients returning to haemodialysis (abst) . . . 518
in renal transplant arterial stenosis . . . 575
in renal transplantation . . . 129
in renal transplantation (abst) 504, 505, 508, 509, 510, 511, 512, 514, 515, 517, 518, 521
in RRT . . . S2:12, S2:13, S2:36, S4:17
in systemic lupus erythematosus (SLE) . . . 923
in vitro alloreactivity inhibition (abst) . . . 589
influence of HLA phenotypes (abst) . . . 589
nephrotoxicity (abst) . . . 512, 514, 515, 516, 595, 835
nephrotoxicity reversibility by dopamine . . . 327
pharmacokinetics of . . . 71
triple-therapy (abst) . . . 594
Cysteinyl Leukotrienes
effect of sulindac sulphide on synthesis of (abst) . . . 418
Cytokines
in allograft rejection . . . 824
in dialysis-associated amyloidosis (abst) . . . 494
induction of prostaglandins by (abst) . . . 422
interleukin-1-like (abst) . . . 423
release of (abst) . . . 517
Cytomegalovirus Infection
after renal transplantation (letter) . . . 238
detection of cells infected with (abst) . . . 670
ganciclovir in . . . 906
in MHC Class I expression on endothelial cells (abst) . . . 521
in renal transplantation (abst) . . . 502, 504, 509, 520
Cytoplasmic Antigen, identification of . . . 3
Daltroban
effect on cyclosporin-induced nephrotoxicity (abst) . . . 512
Dazoxiben, in acute renal failure . . . 625
Death, from dialysis termination . . . 41
Deferoxamine
in aluminium-related bone disease . . . S3:98
in chronic renal failure . . . S3:97
Defibrotide, in haemodialysis (abst) . . . 487
Dehydration, renal vein thrombosis in . . . 992
Desferrioxamine
in aluminium encephalopathy . . . 110
in aluminium encephalopathy (letter) . . . 676
in aluminium-related bone disease . . . S3:107
in aluminium osteomalacia . . . 721
in aluminium toxicity . . . S3:101
in cardiac zygomycosis . . . 911
in haemodialysis . . . 883
in haemodialysis (abst) . . . 486
in haemofiltration (abst) . . . 467
in mucormycosis (abst) . . . 480
in parathyroidectomy (abst) . . . 470
Desmopressin, in uraemia (abst) . . . 452
Dextrans, glomerular transport of (abst) . . . 420
Diabetes Mellitus
angiotensin-converting enzyme inhibition in (abst) . . . 317
cyclosporin in (abst) . . . 514
fructosamines in . . . 748
glycosylated and carbamylated haemoglobin in . . . 96
haemodialysis in (abst) . . . 151
hyperglycaemia in (abst) . . . 436
hypertension in (abst) . . . 151
hypertensive type II (abst) . . . 459
in membranous glomerulonephritis . . . 172
in renal replacement (letter) . . . 399
in renal transplant recipients (abst) . . . 599
non-nephropathic Type I . . . 530
post-transplant (abst) . . . 509
risks of nephropathy in . . . 859
type I . . . 859
type I (letter) . . . 399
type II . . . 859
type II (letter) . . . 399
uraemic insulin-dependent (abst) . . . 507
vascular disease in (abst) . . . 151
Diabetic Nephropathy
aspirin-dipyridamole in . . . 140
captopril in (abst) . . . 433
glycosylated albumin (abst) . . . 420
in insulin-dependent diabetes mellitus (abst) . . . 151
secondary hyperparathyroidism in (letter) . . . 839
Dialox, in re-use of high-flux dialysers . . . 999
Dialysate
contamination by endotoxins . . . S3:89
fluoride contamination in . . . S3:99
vanadium contamination in . . . S3:98
Dialysate Calcium, stepwise reduction in . . . 105

Dialysers
characterisation and coding S4:21
regenerated cellulosic membrane S3:46
Dialysis
anaemia in S4:23
β_2-microglobulin-derived amyloid and calcium deposition in S3:11
biocompatibility in S3:125
carpal-tunnel syndrome in S3:134
failing arteriovenous fistulae 57
termination by viable patients 41
termination of (letter) 602
see also Amyloidosis, dialysis-related; Membranes; Osteoarthropathy, dialysis-related
Dialysis Arthropathy
diagnosis (abst) 494
haemodialysis in (abst) 492
high-flux haemodialysis (abst) 495
treatment of (abst) 318
Dialysis Dementia 110
Dialysis Dementia, aluminium-induced S3:97
Dialysis Encephalopathy, aluminium-induced S3:100
Diastolic Ventricular Performance, in haemodialysis (abst) 152
Diclofenac, in membranous nephritis 393
Diet Therapy, in uraemia S3:124
Dietary Protein, in chronic renal failure 877
Diffusion, hollow fibre membranes S3:73
Difluoromethylornithine, in duodenal mucosal atrophy (abst) 484
Digital Subtraction Angiography (DSA) (abst) 152, 153
Diltiazem
effect on thromboxane B_2 (abst) 421
in chronic renal failure (abst) 457
Diphosphoglycerate, in uraemia (abst) 452
Diphtheroids, in CAPD peritonitis (letter) 759
Dipyridamole, in diabetic nephropathy 140
Disequilibrium Syndrome, effect of membrane-induced complement activation S3:50
DNA, immunoglobulin switch region polymorphisms (abst) 313
DNA Synthesis, and renal growth factor 334
Donor Nephrectomy, glomerular hyperfiltration after (abst) 508
Dopamine
cyclosporin nephrotoxicity reversibility by 327
in renal transplantation (abst) 505
in sodium excretion 271
Double-lumen Quinton Catheter 586
D-penicillamine, in membranous glomerulonephritis . . . 172
Duodenal Mucosal Atrophy, difluoromethylornithine in (abst) 484
Duplex Sonography, of arteriovenous fistulae (abst) 152
ECG
hyperkalaemia simulating acute myocardial infarction 233
in end-stage renal disease (abst) 453
Echocardiography, cardiac function by S3:146
Echography, inferior vena cava 563
EDTA, Registry Centre Survey 161
Eicosanoid Production, cyclosporin in (abst) 513
Eicosapentanoic Acid, in chronic renal failure (abst) 454
Enalapril
in hypertension 396
in spontaneously hypertensive rat (abst) 836
Encephalopathy, aluminium (letter) 676
Endothelial Cells, effect of cytomegalovirus infection on (abst) 521
Endothelial-Monocyte System (abst) 315
Endothelin, effect on arterial pressure, renal blood flow and GFR (abst) 835
Endotoxin, blood concentration in haemodialysis (abst) 155
Endotoxin Antibodies, in haemodialysis (abst) 489
Endotoxin Transfer, by backfiltration S3:89
Energy Intake, in haemodialysis S3:138
Epstein-Barr Virus 818
Erythrocyte Sodium 21
Erythrocyte Sodium and Sodium Fluxes, in hypertension 21
Erythrocyte Sodium-Potassium Cotransport 24
Erythrocytes
and recombinant human erythropoietin (abst 476
complement receptor (CR1) and IgG or IgA on 932
fragmentation complications (abst) 484
glutathione peroxidase in haemodialysis (abst) 479
in haematuria (abst) 434
in haemodialysis 282
Erythrocytosis, post-transplant (abst) 600
Erythron Transferrin Uptake (ETU) 324
Erythropoiesis
effect of aluminium (abst) 468
in renal transplantation 1076
kinetics in haemodialysis 350
Erythropoietic Stimulating Factor (ESF), in renal transplantation 1076
Erythropoietin 782
bone marrow cell response (abst) 475
circulating concentrations of 323
cloning of gene coding for 323
daily self-administered subcutaneous (abst) 473
effect on cardiac performance (abst) 477
effect on exercise capacity (abst) 477
in acute renal failure (abst) 671
in anaemia (abst) 479
in chronic renal failure (abst) 145
in haemodialysis (abst) 471, 475, 487
in renal anaemia (abst) 146
in renal cancers associated with polycythaemia (abst) . . 472
in renal tubular cell production (abst) 420
influence on red blood cell glutathione perioxidase and selenium (abst) 479
intravenous versus subcutaneous application (abst) . . . 478
modulation by monocytes (abst) 472
optimal form of (abst) 473
serial determinations in renal transplantation 1076
synthesis of 323
target cells for 324
target point for (abst) 147
see also Recombinant human Erythropoietin
Escherichia coli
in CAPD peritonitis (letter) 759
in urinary tract infection (abst) 437
in wound infection (abst) 597
vertoxin-producing (abst) 314
Ethylene Oxide, allergic reactions 646
Exercise Capacity
effect of erythropoietin (abst) 477
in haemodialysis (abst) 319
Extracellular Fluid Volume, in haemodialysis 549
Extracorporeal Circulation, activation of body defence mechanisms during S3:60

Familial Haematuria, diagnosis of (abst) 145
Familial IgA Nephropathy, immunological and immunogenetic studies (abst) 441
Familial Mediterranean Fever
colchicine in 201
cyclosporin in 201
Familial Primary Glomerulonephritis, genetic mechanism of (abst) 440
Familial Renal Glycosuria, hypoglycaemia in (abst) 433
Felodipine, in acute renal failure (abst) 447
Fenoldopam, effect on natriuresis in chronic renal failure (abst) 418
Fenoprofen, in membranous glomerulonephritis 172
Fibrinopeptide, in haemodialysis (abst) 489
Fibronectin
effect on C3b and Fc receptor-mediated phagocytosis . . 15
in nephritis (abst) 429
Fine-needle Aspiration Biopsy (FNAB) (abst) 302, 595
Fish Oil
in psoriasis (abst) 511
in renal scarring (abst) 837
in renal transplantation 1070
Fistula Blood Flow, in haemodialysis (abst) 319
Fluid Reabsorption, in peritoneal dialysis 805
Fluoride, contamination in dialysate S3:99
Focal Sclerosing Glomerulonephritis
development and evolution of (abst) 457
Focal Segmental Glomerulosclerosis, in rats (abst) 457
Follicle-stimulating Hormone
in erythropoietin treatment (abst) 475
Formaldehyde, allergic reactions 646
Fructosamines
in diabetes mellitus 748
in renal transplantation 748
in uraemia 748
Frusemide
effect on lithium clearance 707
effect on lithium clearance (abst) 417
in membranous nephritis 393
Frusemide-sensitive Sodium-Potassium Cotransport . . . 22
Gallium, renal scintigraphy 76
Ganciclovir, in symptomatic cytomegalovirus infection . . 906
Gentamicin, ototoxicity monitoring (abst) 752
Glomerular Antigens, autoantibodies to 1
Glomerular Basement Membrane (GBM)
anionic site status in rats (abst) 836
antigenicity of 262
defect in Alport-type hereditary nephritis 770
electron microscopy (abst) 145
in nail-patella syndrome 262
reactivity of monoclonal antibody P1 with 611
see also Anti-GBM antibodies
Glomerular Cell Culture 1
Glomerular Cells, lymphocyte reactivity to (abst) 670
Glomerular Cellular Injury and Dysfunction 847
Glomerular Disease
and malignancy (abst) 435
Schistosoma haematobium in (abst) 431
Glomerular Dynamics, effect of CsA (abst) 516
Glomerular Filtration Rate (GFR) 27, 66
circadian rhythm 266
effect of captopril 696
effect of endothelin (abst) 835
effect of human recombinant erythropoietin 966
effect of lipids (abst) 421
effect of nifedipine (abst) 515
effect of nitrendipine 1030
in acute renal failure 625
in children with chronic renal failure 539
in chronic renal failure (abst) 672
in renal transplantation (abst) 504
in restitution of renal artery blood flow (abst) 462
in the elderly (abst) 417
measurement of 141
response to mixed protein meal 683
Glomerular Hyperfiltration
after donor nephrectomy (abst) 508
effect of nifedipine and captopril (abst) 454
Glomerular Neutrophil Counts
effect of lipopolysaccharide and tumour necrosis factor (abst) 315
Glomerular Transport, of dextrans (abst) 420
Glomerulonephritis
active in-situ (abst) 315
acute post-streptococcal (abst) 429
and cortical blindness (letter) 236
antineutrophil cytoplasmic antibodies in (abst) 438
autoantibodies in (abst) 314
circulating immune complexes in (abst) 153
complement depletion in (abst) 315
complement receptor (CR1) in 932
cryoglobulinaemic (letter) 839
cyclosporin in 923
cyclosporin in (abst) 425
familial occurrence of (abst) 441
Goodpasture and non-Goodpasture anti-GBM antibodies in 254
hypertension in 605
hypertension in (abst) 461
IgA in 932
IgG in 932
immune-mediated (abst) 423
immunosuppression in 196
immunosuppression in (letter) 917, 918
in renal transplantation 730
mesangial IgA 943
mesangial IgA (abst) 429
PGE_1 in (abst) 836
plasma exchange in 196
pregnancy in (abst) 831
recurrence in transplant recipients 927
renal effects of enalapril in hypertensive patients with . . 396
strain-dependent experimental autoimmune (abst) . . . 314
Glomerulopathies, circadian rhythm in (abst) 420
Glomerulosclerosis
animal model (abst) 837
focal segmental (abst) 314
hypertension in 846
initiation of 843, 846
interventions aimed at preventing initiation of 848
interventions aimed at preventing progression of 850
pathogenesis and treatment 843
progression of 847
therapeutic implications 848
Glomerulus
developmental biology (abst) 835
effect of CsA (abst) 515–16
effect of CsA on superficial and juxtamedullary isolated human (abst) 513
Glucocorticoids
effect on erythrocyte sodium transport (abst) 503
Glutathione Peroxidase, red blood cell (abst) 479

Glycocalcin, in haemodialysis (abst) 489
Glycosaminoglycan production
effect of cyclosporin (abst) 513
Glycosylated Haemoglobin, in uraemia 96
Goodpasture and Non-Goodpasture Anti-GBM
antibodies, in glomerulonephritis 254
Goodpasture Anti-genetic Determinant 262
Goodpasture's Syndrome 1, 611
Graft Monitoring, mitogen responsiveness in (abst) 588
Granulocyte Elastase, in uraemia S3:125
Granulocyte Elastase-α_1-protease Inhibitor, in
carpal-tunnel syndrome S3:134
Granulocyte LFA-1, in haemodialysis (abst) 489
Granulocyte-specific anti-nuclear antibody (GS-ANA)
(abst) 832
Granulocytes, expression of Mac-1 on (abst) 490
Grey Turner's Sign, in sclerosing peritonitis (abst) 754
Growth Hormone
in chronic renal failure (abst) 451
in compensatory renal growth (abst) 456
stimulation by amino-acid-containing dialysate (abst) . . 500
Haematocrit
in CAPD 787
in haemodialysis 787
Haematuria
in lung cancer 947
red blood cells in (abst) 434
Haemodiafiltration
adequacy of 32
β_2-microglobulin in 653
clinical tolerance to 32
paired filtration dialysis (abst) 485
push/pull S3:83
re-use of high-flux dialysers 999
Haemodialysis 15
accessory cells in (abst) 490
acetate in 1060
acetate in (abst) 481
allergic reactions 646
altitude exposure (abst) 154
aluminium avoidance 105
aluminium in (abst) 488
and renal cell carcinoma 763
anti-HB-C-antibodies in (abst) 487
anti-proteases in (abst) 492
antibody responses 216
atherosclerosis in S3:142
atrial natriuretic peptide in (abst) 500
atrial natriuretic peptide in (letter) 382, 602
backfiltration S3:41, S3:89
β_2-microglobulin in 549, 653, S3:14, S3:43, S3:78
β_2-microglobulin in (abst) 490, 492
bidirectional roller blood pump (abst) 483
biocompatibility in S3:41
biocompatibility in (abst) 489
biocompatibility in hypoxaemia (abst) 489
blood lead and plasma aluminium concentrations 375
body temperature in (abst) 483
calcium carbonate in (abst) 484
calcium intake in S3:138
cardiac arrhythmias in 632
cardiac function in 792
carnitine in 366, 951
carnitine esters in 951
central venous access 987
communication during 119
comparison with CAPD 244
complications related to S3:138
coronary revascularisation in (abst) 481
cyclic guanosine monophosphate in (abst) 500
defibrotide in (abst) 487
desferrioxamine in 883
desferrioxamine in (abst) 486
dialysis-associated amyloid 1054
diastolic ventricular performance in (abst) 152
'dry weight' estimation 563
EDTA Registry Centre Survey 161
effect of intravenous calcitriol in 545
effect of membrane-induced complement activation . S3:50
effect on intracellular cation content and transport (abst) 834
effects on plasma atrial natriuretic peptide 222
efficiency after treatment with recombinant human
erythropoietin 718
endotoxin antibodies in (abst) 489
endotoxin concentration (abst) 155
energy intake in S3:138
erythropoiesis kinetics 350
erythropoietin in (abst) 471, 475, 487
exercise performance (abst) 154
extracellular fluid volume in 549
fibrinolytic activity during (abst) 491
haematocrit in 787
haemoglobin in 787
high-flux (abst) 318, 484, 495
high-flux membranes S3:41
histamine in (abst) 480
HIV infection in (abst) 486
hollow-fibre 569
human neutrophil elastase (HNE) in (abst) 481
hyperoxalaemia in (abst) 454
hyperphosphataemia in S3:140
in diabetes mellitus (abst) 151
in hereditary kidney diseases (abst) 144
infection in 883
interleukin-1 in S3:42
interleukin-2 in (abst) 488
iron in 883
lipid metabolic abnormalities in S3:139
malnutrition in (abst) 485
membrane biocompatibility 306
metenkephalin retention in (abst) 468
mortality in (abst) 486
myocardial ischaemia in 632
non-heparin (abst) 485
non-steroidal anti-inflammatory drugs (NSAIDs) in
(abst) 482
non-transferrin-bound iron in (abst) 488
nutrition in S3:138
oxalate clearance in 792
oxalate plasma concentration in 792
parathyroid hormone in (abst) 672
parathyroid secretion in (abst) 468
phosphate control 105
picotamide in 1083
phosphorus intake in S3:138
plasma C3a and C5a concentration in S3:46
plasma protein absorption during (abst) 150
platelet activating factor (abst) 491
platelet lipid peroxidation in 975
pneumatosis intestinalis in 745
protein intake in S3:138
Pseudomonas aeruginosa in (abst) 155

Quinton double-lumen catheter . . . 586
re-use of high-flux dialysers . . . 999
re-use of polyacrylonitrile and polysulphone dialysers (abst) . . . 671
recombinant human erythropoietin in 1065
recombinant human erythropoietin in (abst) 319, 475
Redy dialysis system . . . 555
renal function recovery (abst) . . . 499
residual renal function in (abst) . . . 499
seizures in 1065
Staphylococcus aureus infections in . . . 278
superior vena caval obstruction . . . 586
ten-year follow up (abst) . . . 482
terminal complement complex formation by blood-membrane contact (abst) . . . 489
tumour necrosis factor (TNF) in . . . S3:42
ultrashort daily auto-dialysis (abst) . . . 483
ultrasonic neck examination . . . 45
vanadium in . . . 282
vancomycin in . . . 635
vitamin D in . . . S3:140
vitamin D in (abst) . . . 672
volume status in . . . 382
weakness in . . . 366
see also Membranes

Haemofiltration
atrial natriuretic peptide in (letter) . . . 602
β_2-microglobulin in . . . 653
cardiac arrhythmias in . . . 632
continuous arteriovenous . . . 640, 870
desferrioxamine in (abst) . . . 467
effects on plasma atrial natriuretic peptide . . . 222
myocardial ischaemia in . . . 632
polyacrylonitrile membrane dialyser . . . 356
pre-postdilution . . . 37
push/pull . . . S3:83
urea clearance in . . . 37
vancomycin in . . . 635

Haemoglobin
carbamylated . . . 96
glycosylated . . . 96
in CAPD . . . 787
in haemodialysis . . . 282, 787
serial determinations in renal transplantation 1076

Haemoglobin-S Monitoring
in renal transplantation (abst) . . . 600

Haemolytic Uraemic Syndrome
in childhood (abst) . . . 446
in infants . . . 535
in the tropics . . . 535
legionella-associated . . . 995
neutrophil count and prognosis in (abst) . . . 433
post-enteropathic (abst) . . . 313
renal biopsy in (abst) . . . 145
types of (abst) . . . 145

Hansen's Disease, renal involvement in . . . 81
Hantavirus Nephropathy, in Denmark (abst) . . . 672
HBS vaccination, influence of thymopentin (abst) . . . 154
Heart failure, atrial naturetic factor in (abst) . . . 465

Heart Transplantation
cyclosporin in (abst) . . . 459
hypertension in (abst) . . . 459
water immersion in (abst) . . . 505

Heart Valve Prostheses, renal siderosis in (abst) . . . 443
Henoch Schonlein Nephritis, mesangial cells in (abst) . . . 831
Hepatic Adenomectomy (abst) . . . 438

Hepatitis B
EDTA Registry Centre Survey . . . 161
in membranous glomerulonephritis . . . 172
in renal transplant recipients . . . 297
in RRT . . . S2:29
number of new cases in 1988 . . . S4:27
vaccination (abst) . . . 150
vaccination in children and adolescents . . . 372

Hepatorenal Failure, prostacyclin in (abst) . . . 443

Hereditary Nephritis
Alport-type . . . 770
types of (abst) . . . 144
without nerve deafness (abst) . . . 145

Hereditary Nephropathy . . . 611
5-HETE, biocompatibility with dialysis membranes . . . 306
12-HETE, biocompatibility with dialysis membranes . . . 306
15-HETE, biocompatibility with dialysis membranes . . . 306

$HgCl_2$
in acute renal failure (abst) . . . 448, 625
in renal MHC expression (abst) . . . 428

Hickman Catheters for haemodialysis . . . 987
Histamine, in haemodialysis (abst) . . . 480
Histology, chronic rejection established by (abst) . . . 151

HIV Infection
EDTA Registry Centre Survey . . . 161
in AIDS nephropathy (abst) . . . 434
in haemodialysis (abst) . . . 486
in nephrotic syndrome (abst) . . . 433
in RRT . . . S2:25, S4:26

HIV Nephropathy
absence of viral antigens in renal tissue in (abst) 426

HLA Class II Antigens . . . 618
in nephrotic syndrome (abst) . . . 313

HLA-DR Antigens
in allograft rejection . . . 824
in renal transplantation (abst) . . . 670
renal tubular display . . . 205

HLA Matching, clinical importance of . . . S4:14
HTK Solution, renal protection (abst) . . . 590
Human Atrial Natriuretic Peptide, measurement of (abst) . 148
Human Immunodeficiency Virus. *See* HIV

Human Neutrophil Elastase (HNE)
in chronic renal failure (abst) . . . 481
in haemodialysis (abst) . . . 481

Hydralazine, in glomerulosclerosis . . . 848
Hydrochlorothiazide, in glomerulosclerosis . . . 848

Hypercalcaemia
effect on prostanoid production (abst) . . . 417
in children with chronic renal failure . . . 539
in renal transplantation (abst) . . . 470
in uraemia . . . 545

Hypercalciuria, protein in (abst) . . . 468
Hypercholesterolaemia, simvastatin in (abst) . . . 753
Hyperfiltration, response to meat meal (abst) . . . 416, 455
Hyperglycaemia, in diabetes mellitus (abst) . . . 436
Hyperinsulinaemia, in pathogenesis of hypertension (abst) . . . 459

Hyperkalaemia
captopril-induced 1084
electrocardiographic manifestations in . . . 233
simulating acute myocardial infarction . . . 233
treatment in renal failure . . . 228

Hyperoxalaemia, in haemodialysis (abst) . . . 454

Hyperoxaluria
influence of chocolate (abst) . . . 154
Type I primary . . . 137

Hyperparathyroidism
and renal transplantation . . . 123
effect of 160K Dalton globulin (abst) . . . 467
end-dialysis values in evaluating suppressibility of . . . 115
in chronic renal failure . . . 971
in renal transplantation . . . 740
in uraemia . . . 545
recombinant human erythropoietin in (abst) . . . 472
secondary . . . 45, 105
secondary (abst) . . . 148, 318, 672
vitamin D in (abst) . . . 469, 480
Hyperphosphataemia
choice of therapy . . . 1005
in chronic renal failure . . . 725
in haemodialysis . . . S3:140
Hyperpigmentation, cyclosporin in . . . 309
Hyperplastic Parathyroid Autografts
ultrasonography of (abst) . . . 453
Hypertension
atrial natriuretic peptide in (abst) . . . 463
azathioprine in (abst) . . . 512
calcitonin-gene-related peptide in (abst) . . . 463
calcium concentration in (abst) . . . 461
captopril in (abst) . . . 461
cyclosporin in (abst) . . . 507, 512
enalapril in . . . 396
erythrocyte sodium and sodium fluxes in . . . 21
evolution of . . . 530
in acute renal failure (abst) . . . 443
in chronic renal failure . . . 21
in chronic renal failure (abst) . . . 461
in combined microalbuminuria and retinopathy (abst) . . . 151
in diabetes mellitus (abst) . . . 151
in glomerulonephritis (abst) . . . 461
in glomerulosclerosis . . . 846
in heart transplantation (abst) . . . 459
in primary glomerulonephritis without renal insufficiency . . . 605
in renal transplantation . . . 740
in renal transplantation (abst) . . . 507
in spontaneously hypertensive rats (abst) . . . 458
insulin in (abst) . . . 459
microalbuminuria in (abst) . . . 460
oxygen-derived free radicals in (abst) . . . 462
renal blood flow in (abst) . . . 462
renin activity-(PRA)-dependent renovascular (abst) . . . 462
renovascular (abst) . . . 599
sympathetic nervous system in (abst) . . . 462
^{99m}Tc DTPA clearance (abst) . . . 461
thromboxane B_2 in (abst) . . . 421
Hypocalcaemic Dialysate
in secondary hyperparathyroidism (abst) . . . 318
Hypocitraturia
in calcium stone formers (abst) . . . 437
of calcium nephrolithiasis (abst) . . . 437
Hypoglycaemia, in familial renal glycosuria (abst) . . . 433
Hypophosphataemia, in renal transplantation (abst) . . . 470
Hypoxaemia
and pulmonary hypertension (abst) . . . 480
haemodialysis-induced (abst) . . . 489
Idiopathic Membranous GN (IMGN), cyclosporin in . . . 926
IgA
circulating immune complexes in IgA nephropathy (abst) . . . 423
immune aggregates (abst) . . . 427
in chronic renal failure . . . 216
mesangial deposits . . . 943
nephropathy (abst) . . . 837
on erythrocytes and in immune complexes . . . 932
IgA Antibodies, in IgA glomerulonephritis (abst) . . . 426
IgA Nephropathy
(abst) . . . 424
chemotactic factor (abst) . . . 430
cyclosporin in . . . 926
DR-associated antigens (abst) . . . 430
enzymatic therapy in (abst) . . . 426
genetic susceptibility to autoimmunity in (abst) . . . 428
IgA in circulating immune complexes in (abst) . . . 429
in mice (abst) . . . 424
in recurrent glomerulonephritis . . . 730
mesangial cells in (abst) . . . 831
monoclonal antibodies in . . . 187
phagocyte cell function in . . . 618
renal function in (abst) . . . 432
urinary protein excretion (abst) . . . 432
IgE, allergic reactions . . . 646
IgG
and peritonitis (abst) . . . 755
and peritonitis in CAPD (abst) . . . 501
deficiency in children on CAPD (abst) . . . 754
immune aggregates (abst) . . . 427
in chronic renal failure . . . 216
in renal transplantation . . . 1078
incubation with (abst) . . . 424
on erythrocytes and in immune complexes . . . 932
IgM
anti-pig antibodies (abst) . . . 319
in chronic renal failure . . . 216
IgM Mesangial Nephropathy
nosological autonomy of (abst) . . . 442
Imidazole, in acute renal failure . . . 625
Imipenem, in haemofiltration . . . 640
Immune Complexes, complement receptor (CR1) and IgG or IgA in . . . 932
Immune Glomerular Injury
tumour necrosis factor and protases in (abst) . . . 428
Immunoperoxidase, in Wegener's granulomatosis (abst) . . . 438
Immunoradiometric Assay, atrial naturetic peptide (abst) . . . 466
Immunosuppression
EDTA Registry Centre Survey . . . 161
in advanced chronic rejection (abst) . . . 151
in antibody-mediated rejection (abst) . . . 589
in glomerulonephritis . . . 196
in glomerulonephritis (letter) . . . 917, 918
in membranous glomerulonephritis . . . 181
in patients with pre-transplant antibodies (abst) . . . 588
in renal failure . . . 181
in renal graft recipients returning to haemodialysis (abst) . . . 518
regimens used in RRT . . . S2:12, S4:15
rejection episodes by recurrent infection under (abst) . . . 152
Immunotactoid Glomerulopathy, clinical study (abst) . . . 430
Indomethacin
effect on renal lithium reabsorption . . . 27
in acute renal failure . . . 625
in protein feeding . . . 683
Infection
in haemodialysis . . . 883
in renal transplant recipients (abst) . . . 598, 599
Inferior Vena Cava, echography . . . 563
Information, renal transplantation . . . 119

Insulin
additive to dialysate (abst) . . . 500
in hyperkalaemia in renal failure . . . 228
in hypertension (abst) . . . 459
resistance in chronic renal failure (abst) . . . 450
secretion in uraemia (abst) . . . 451
transperitoneal passage of (abst) . . . 498
Insulin-like Growth Factor I (abst) . . . 316, 456
Interferon, in renal transplantation (abst) . . . 520
Interleukin-1
cytokine production (abst) . . . 423
gene expression (abst) . . . 315
in dialysis-related osteoarthropathy . . . S3:34
in haemodialysis . . . S3:42
in haemodialysis (abst) . . . 489
in long-term haemodialysis . . . 569
Interleukin-1β
effect on prostanoids (abst) . . . 422
in renal transplantation (abst) . . . 520
Interleukin-2
in acute renal failure (abst) . . . 445
in dialysis-related osteoarthropathy . . . S3:34
in haemodialysis (abst) . . . 488
in minimal-change nephropathy (abst) . . . 313
in rejection (abst) . . . 508
in renal carcinoma (abst) . . . 445
in renal transplantation (abst) . . . 506, 520
in T-cell proliferation (abst) . . . 424
Interleukin-2 receptor (IL-2R)
in minimal-change nephropathy (abst) . . . 313
Interleukin-6 in CAPD (abst) . . . 497
Interstitial Cell Infiltrates, in experimental nephrosis . . . 1037
Interstitial Nephritis
drug-induced (abst) . . . 428
in nephrotic syndrome . . . 393
in renal transplantation (abst) . . . 507
mechanism for (abst) . . . 427
Interstitial Pressure, atrial naturetic factor response (abst) . 463
Intrahepatic Cholestasis, in chronic renal failure (abst) . . 590
Intraperitoneal Chemotherapy
in ovarian cancer (abst) . . . 754
in treatment of cancer (abst) . . . 751
Inulin Diffusion, ECV measurement by . . . 550
Iron
effect of aluminium on absorption (abst) . . . 468
in haemodialysis . . . 883
in mucormycosis (abst) . . . 480
mass transfer and plasma kinetics (abst) . . . 467
non-transferrin-bound (abst) . . . 488
Isocyanates, allergic reactions . . . 646
Isoniazid, accidental poisoning (letter) . . . 156
Jejunal Dialysis, mannitol in . . . 658
Jeune Syndrome (abst) . . . 144
Keto Acids
in chronic renal failure (abst) . . . 453
in uraemia (abst) . . . 448
Kidney
abnormal, in renal transplant (abst) . . . 601
long-term functioning cadaver (abst) . . . 591
pelvic, for renal transplantation (abst) . . . 591
reactivity of monoclonal antibodies with . . . 85
small paediatric cadaveric (abst) . . . 592
spontaneous rupture of (abst) . . . 145
very long cold ischaemia time (abst) . . . 591
Kidney Diseases, hereditary (abst) . . . 144
Kidney Donation, in cardiac arrest (abst) . . . 590
Kidney/pancreatic Grafting. *See* Multiple Transplants
Klinefelter Syndrome with Nephrophthisis (abst) . . . 144
Lactate-Buffered Solutions, effect on acid-base status . . . 800
Laurence-Moon-Bardet-Biedl Syndrome (LMBB) (abst) . 144
Lead
biological monitoring of . . . S3:114
effects of leaded petrol on human health . . . S3:114
plasma concentrations in CRF . . . 375
Lecithin-Cholesterol-Acyltransferase (LCAT) Deficiency
Syndrome kidney disease in (abst) . . . 144
Lectins, in IgA nephropathy (abst) . . . 424
Legionella Infection, with haemolytic uraemic syndrome . 995
Leprosy, renal involvement in . . . 81
Leukocyte Aggregation and Activation, in haemodialysis S3:42
Leukotrien B_4, in peritoneal dialysis (abst) . . . 498
Lipid Abnormalities, in uraemia . . . S3:142
Lipid Metabolism
abnormalities in haemodialysis . . . S3:139
in uraemia . . . S3:123
Lipids
effect of combined diet and physical exercise on . . . 237
effect of CsA therapy (letter) . . . 237
effect on GFR (abst) . . . 421
effect on renal blood flow (abst) . . . 421
peroxidation in haemodialysis . . . 975
Lipopolysaccharide, effect on glomerular neutrophil
counts (abst) . . . 315
Lipoprotein
in chronic renal failure (abst) . . . 448
in nephrotic syndrome (abst) . . . 831
in uraemia . . . S3:142
in uraemia (abst) . . . 452
Lithium
in intravenous saline loading . . . 271
renal reabsorption . . . 27
Lithium Clearance
effect of acetazolamide and frusemide . . . 707
effect of acetazolamide and frusemide (abst) . . . 417
effect of triamterene on . . . 939
Lithium Transport, in cortical collecting tubule . . . 939
Loop Diuretic Medication, in renal transplantation . . . 740
LTB4, biocompatibility with dialysis membranes . . . 306
Lung Cancer
haematuria in . . . 947
proteinuria in . . . 947
Lung, proteases in . . . S3:130
Lupus Anticoagulant
recurrent thrombosis in patients with . . . 854
renal vascular disease in patients with . . . 854
Lupus Nephritis, genetics of (abst) . . . 424
Luteinising Hormone
in chronic renal failure (abst) . . . 834
in erythropoietin treatment (abst) . . . 475
Lymphocytes
in IgA nephropathy (abst) . . . 430
in minimal-change nephropathy (abst) . . . 313
reactivity to glomerular and tubular cells (abst) . . . 670
Lymphocytotoxicity, in renal transplantation (abst) . . . 588
Lymphokine Activated Killer (LAK) Cells . . . 824
Lymphoma, B cell . . . 818
Magnesium Hydroxide, in hyperphosphataemia . . . 1005
Malignancy
adenocarcinomas (abst) . . . 472
and glomerular disease (abst) . . . 435
B cell lymphoma . . . 818
death rates from . . . S2:20

in analgesic nephropathy after renal transplantation (abst) . . . 150
in nephrotic syndrome (abst) . . . 671
in renal transplant recipients (abst) . . . 511, 601
incidence in 1985/1986 . . . S2:22
intraperitoneal chemotherapy in ovarian cancer (abst) . 754
intraperitoneal chemotherapy in treatment of cancer (abst) . . . 751
Kaposi sarcoma . . . 601
metastatic renal carcinoma (abst) . . . 445
renal cancers associated with polycythaemia (abst) . . . 472
renal cell carcinoma and haemodialysis . . . 763
rhabdomyosarcoma in rats (abst) . . . 454
survival rates after diagnosis of . . . S2:23
Malnutrition . . . 15
in haemodialysis (abst) . . . 485
Malonyldialdehyde Concentrations, in dialysis-related osteoarthropathy . . . S3:35
Malonyldialdehyde (MDA), in haemodialysis . . . 975
Mannitol, in jejunal dialysis . . . 658
MCA-P1 Monoclonal Antibody . . . 262
Mean Blood Pressure (MAP), in acute renal failure . . . 691
Meat Meal, hyperfiltration response (abst) . . . 416, 455
Medullary Sponge Kidney, clinical studies (abst) . . . 435
Membranes
biocompatibility of . . . 306, S3:55
effect of granulocyte LFA-1 molecules, plasma interleukin-1, glycocalcin and fibrinopeptide A (abst) . . . 489
effect of membrane area on plasma C3a and C5a concentration . . . S3:46
effect on tumour necrosis factor (abst) . . . 493
high-flux . . . S3:89
high-flux synthetic versus cellulosic . . . 653
high-performance modified cellulose . . . S3:55
hollow fibre . . . S3:73
influence on β_2-microglobulin concentration . . . S3:27
protein permeable . . . S3:78
Membranoproliferative Glomerulonephritis
intrarenal microaneurysms in (abst) . . . 425
Membranous Glomerulonephritis
aetiology of . . . 172
alpha-mercaptopropionylglycine in (abst) . . . 434
immunosuppression in . . . 181
Membranous Nephritis, reversible . . . 393
Membranous Nephropathy
aetiology of (letter) . . . 757
in renal transplantation . . . 1080
long-term outcome . . . 525
steroids in . . . 1022
Mercaptoacetyltriglycine, imaging study (abst) . . . 436
Mercaptopropionylglycine, pharmacokinetics of (abst) . . 417
Mercury Vapour Intoxication . . . 133
Mesangial Cells
effect of CsA (abst) . . . 515–16
effect of interleukin-1β and tumour necrosis factor (abst) . . . 422
in Henoch Schonlein nephritis (abst) . . . 831
in IgA nephropathy (abst) . . . 831
incubated with IgA and IgG immune aggregates (abst) . 427
prostanoid generation by growth-arrested (abst) . . . 425
vitamin D_3 action on (abst) . . . 431
Mesangial IgA Glomerulonephritis . . . 943
complement component C3 in (abst) . . . 440
Metals, determination in biological materials . . . S3:114
Metastatic Calcification, in rhabdomyolysis (letter) . . . 675
Metenkephalin
plasma (letter) . . . 236
retention in haemodialysis (abst) . . . 468
Methylprednisolone
in allograft rejection . . . 387
in anti-rejection therapy (abst) . . . 590
in glomerulonephritis . . . 196
in idiopathic membranous glomerulonephritis . . . 181
in salmonella infection . . . 390
triple-therapy (abst) . . . 594
$Mg(OH)_2$
in renal osteodystrophy and soft-tissue calcification . . . 1045
MHC Expression, renal class I and II (abst) . . . 428
Microalbuminuria
hypertension in (abst) . . . 151
in hypertension (abst) . . . 460
Microscopic polyarteritis
antibodies to endothelial cells and neutrophil cytoplasm in (abst) . . . 426
Minimal-change Nephropathy, lymphocytes in (abst) . . . 313
Mitogen Responsiveness, in graft monitoring (abst) . . . 588
Molecular Proteins, removal rate by push/pull haemodiafiltration and haemofiltration . . . S3:83
Monoclonal Antibodies
allograft pre-treatment (abst) . . . 838
CMV (abst) . . . 670
Goodpasture anti-genetic determinant study . . . 262
in EBV lymphoma . . . 818
in IgA Nephropathy . . . 187
in renal transplantation (abst) . . . 504, 517
in RRT . . . S4:15
P1 . . . 611
reactivity on renal endothelium of (abst) . . . 315
reactivity with human kidney . . . 85
see also under specific monoclonal antibodies
Monocyte Activation, in long-term haemodialysis . . . 569
Monokines, generation of . . . 569
Mononuclear Cells, activation by aqueous extracts . . . 569
Mortality, in haemodialysis (abst) . . . 486
Mucormycosis, roles of desferrioxamine and iron in (abst) . . . 480
Multiple Transplants . . . S4:20, S2:24
Mupirocin, effect on *Staphylococcus aureus* infection . . . 278
Muscle Necrosis, in acute renal failure (abst) . . . 444
Myocardial Infarction
hyperkalaemia simulating . . . 233
in RRT . . . S2:18, S4:20
Myocardial Ischaemia
in haemodialysis . . . 632
in haemofiltration . . . 632
in RRT . . . S2:18, S4:20
Myoinositol
in proliferation of Schwann cells . . . 662
neurotoxicity of . . . 662
Nail-patella Syndrome, glomerular basement membrane in 262
Natriuresis, in intravenous saline loading . . . 271
Natural Killer Cells, in uraemia (abst) . . . 452
Neck, ultrasonic examination . . . 45
Neoplastic Diseases, in renal transplant recipients (abst) . . 601
Nephrectomy
in mice . . . 701
in spontaneously hypertensive rat (abst) . . . 836
Nephritis
Alport-type . . . 262
fibronectin in (abst) . . . 429
nephrotoxic PGE in (abst) . . . 836, 837

Nephrocalcinosis
in renal transplantation . . . 137
in-vitro model of (abst) . . . 316
Nephrogenic Ascites, in CAPD (letter) . . . 918
Nephron Adaptation, in chronic renal failure (abst) . . . 458
Nephroplathia Epidemica, in Denmark (abst) . . . 672
Nephrosis, interstitial mononuclear cell infiltrates in 1037
Nephrotic Syndrome
(abst) . . . 432
acute renal failure in . . . 914
albumin in (abst) . . . 466
amyloidosis in (abst) . . . 438
apolipoprotein metabolism in (abst) . . . 831
atrial natriuretic peptide in 1010
atrial natriuretic peptide in (abst) . . . 466
calcium absorption in (abst) . . . 469
cyclosporin in (abst) . . . 432
HIV infection in (abst) . . . 433
hypercoagulable state of (abst) . . . 438
in proteinuria (abst) . . . 455
induced by NSAIDs . . . 176
long-term outcome . . . 525
malignant disease in (abst) . . . 671
minimal change . . . 393
plasma fibrinolysis in (abst) . . . 439
portal vein thrombosis in . . . 581
protein diet in (abst) . . . 437
steroid-sensitive (abst) . . . 313
steroids in 1022
tubular dysfunction in . . . 914
vitamin D in (abst) . . . 469
with or without interstitial nephritis . . . 393
Nephrotoxicity
cyclosporin-induced (abst) . . . 512, 514, 515, 516
platelet activating factor in (abst) . . . 512
Newlyborn Infants
acute renal failure in . . . 870
congenital heart disease in . . . 870
Nicardipine, in renal impairment (abst) . . . 835
Nifedipine
effect on GFR (abst) . . . 515
effect on glomerular hyperfiltration (abst) . . . 454
in chronic renal failure (abst) . . . 458
in cyclosporin nephrotoxicity (abst) . . . 514, 515
in prevention of cyclosporin nephrotoxicity (abst) . . . 835
in transplant renal artery stenosis . . . 66
Nitrendipine
effect on blood pressure (abst) . . . 601
in radiocontrast-media-induced nephrotoxicity 1030
Nitrogen, in chronic renal failure . . . 877
Non-steroidal Anti-inflammatory Drugs (NSAIDs) . . . 27
in haemodialysis (abst) . . . 482
in membranous nephropathy . . . 393
in tubulointerstitial nephritis . . . 205
nephrotic syndrome induced by . . . 176
Nutrition, in haemodialysis . . . S3:138
Nutritional Assessment
in recombinant human erythropoietin therapy (abst) . . . 478
Nutritional Assessment (abst) . . . 478
Ofloxacin in pseudomonas peritonitis . . . 814
OKT3 . . . 818
(abst) . . . 149
in antirejection therapy (abst) . . . 596, 597
in release of cytokines (abst) . . . 517
in renal transplantation (abst) . . . 506, 517, 518, 519
Oral Contraceptives, and renal vein thrombosis . . . 992
Orthoclone OKT3. *See* OKT3
Osmotic Disequilibrium Syndrome . . . 549
Osteitis Fibrosa, prevention of 1045
Osteoarthropathy, dialysis-related . . . S3:32
Osteocalcin, in secondary hyperparathyroidism (abst) . . . 148
Osteomalacia
aluminium intoxication risk . . . 555
dialysis-related . . . 51
Osteonecrosis, in renal transplantation . . . 123
Ototoxicity, in CAPD (abst) . . . 752
Ouabain-sensitive Sodium Flux . . . 22
Ovarian Cancer, intraperitoneal chemotherapy (abst) . . . 754
Oxalate
clearance in haemodialysis . . . 792
metabolism in relation to urinary stone (book review) . . . 320
plasma concentration in haemodialysis . . . 792
Oxalic Acid, influence of chocolate on urinary excretion
(abst) . . . 154
Oxygen Radicals
in hypertension (abst) . . . 462
release by mesangial cells (abst) . . . 427
Oxygen Treatment, in pneumatosis intestinalis . . . 745
P1, monoclonal antibodies . . . 611
Paediatric Registry Data Base . . . S4:31, S2:33
PAF Antagonist, in experimental nephrosis 1037
Paired Filtration Dialysis, calcium in (abst) . . . 485
Pancreas Transplantation, segmental (abst) . . . 503
Pancreatic Grafts, in multiple grafting . . . S2:24
Pancreatic Hormones, in erythropoietin therapy (abst) . . . 475
Pancreaticorenal Transplantation
in uraemic insulin-dependent diabetes mellitus (abst) . . . 507
Parathyroid Gland, ultrasonography . . . 45
Parathyroid Hormone
C-terminal (abst) . . . 467
effect of calcium on secretion . . . 339
effect of vitamin D (abst) . . . 480
effect on haemodialysis . . . 115
in chronic renal failure . . . 971
in dialysis patients 1045
in haemodialysis (abst) . . . 672
in recombinant human erythropoietin therapy (abst) . . . 474
in renal transplantation . . . 740
in uraemia . . . 545
in use of calcium carbonate and reduced dialysate calcium concentration (letter) . . . 759
Parathyroid Secretion, in haemodialysis (abst) . . . 468
Parathyroidectomy
desferrioxamine in (abst) . . . 470
effect on plasma alkaline phosphatase activity and tissue aluminium mobilisation (abst) . . . 470
Parenteral Nutrition, amino acids (abst) . . . 673
Pepsinogens, tubular reabsorption (abst) . . . 422
Peptides, calcitonin-gene-related (abst) . . . 463
Percutaneous Transluminal Angioplasty . . . 57
(abst) . . . 153
in renovascular hypertension (abst) . . . 599
Pergolide, in sexual dysfunction in uraemia . . . 888
Peripheral Blood Monocytes . . . 15
Peripineral Blood Morphology, in graft rejection diagnosis 302
Peritoneal Dialysate, amino-acid (abst) . . . 495, 833
Peritoneal Dialysis
communication during . . . 119
continuous ambulatory. *See* CAPD
continuous cyclic. *See* CCPD
in infants . . . 535
in pregnancy . . . 583

in the tropics . . . 535
leukotrien B_4 in (abst) . . . 498
nocturnal (abst) . . . 751
systemic lupus erythematosus in (abst) . . . 500
tumour necrosis factor in (abst) . . . 498
Peritoneal Eosinophilic Reaction
after catheter implantation (abst) . . . 752
Peritoneal Function in CAPD (abst) . . . 495
Peritoneal Lymphatic Flow
and pleural effusion (abst) . . . 755
in CAPD (abst) . . . 753
Peritoneal Solute Transport
albumin in (abst) . . . 501
in CAPD (abst) . . . 755
Peritoneal Ultrafiltration, in peritoneal dialysis . . . 805
Peritonitis
and IgG (abst) . . . 755
due to coagulase-negative staphylococci . . . 62
eosinophilic (abst) . . . 752
in CAPD (abst) . . . 752, 833
in CAPD (letter) . . . 759
local defence status in (abst) . . . 755
sclerosing (abst) . . . 754
Staphylococcus epidermidis in (abst) . . . 752
Peroxyacetic Acid Solution, in re-use of high-flux dialysers 999
Phagocyte Cytoskeleton, in cryoglobulinaemia (abst) . . . 440
Phagocytic Cells, in IgA nephropathy . . . 618
Phagocytosis, C3b and Fc receptor-mediated . . . 15
Phosphatase, plasma alkaline (abst) . . . 470
Phosphate
cellular sequestration (abst) . . . 482
control in haemodialysis . . . 105
dialytic removal (abst) . . . 482
in haemodialysis . . . 282
plasma control . . . 51
Phosphate Binding
aluminium-containing . . . 105
aluminium-free . . . 829
Phosphorus
in renal transplantation (abst) . . . 470
in uraemia (abst) . . . 470
Phosphorus Intake, in haemodialysis . . . S3:138
Phthalates, allergic reactions . . . 646
Phytohaemagglutinin A (PHA), in kidney graft (abst) . . . 588
Picotamide, in haemodialysis . . . 1083
Pituitary-Adrenal Function, in chronic renal failure (abst) . 146
Plasma C3a and C5a Concentration, in haemodialysis . S3:46
Plasma Cell Dyscrasia, diagnosis of . . . 76
Plasma Exchange, in glomerulonephritis . . . 196
Plasma Proteins
absorption onto dialysis membranes (abst) . . . 150
Plasma Renin Activity
in glomerulonephritis . . . 605
in intravenous saline loading . . . 271
Plasmapheresis
in acute renal allograft rejection (abst) . . . 590
in antibody-mediated rejection (abst) . . . 589
in patients with pre-transplant antibodies (abst) . . . 588
in renal transplantation (abst) . . . 518
Plasminogen Activator Inhibitor
in nephrotic syndrome (abst) . . . 439
Platelet α-granules, in uraemia (abst) . . . 451
Platelet Activating Factor
cyclosporin nephrotoxicity in (abst) . . . 516
effect on cis-dichlorodiamine platinum (abst) . . . 448
in nephrotoxicity (abst) . . . 512
production during haemodialysis (abst) . . . 491
release by mesangial cells (abst) . . . 427
Platelet Aggregation, in haemodialysis . . . 975
Platelet Function
in recombinant human erythropoietin therapy (abst) . . 472
Platelet Storage Pool Defect, in chronic renal failure (abst) 148
Pleural Effusion, and peritoneal lymphatic flow (abst) . . . 755
Pneumatosis Intestinalis
in haemodialysis . . . 745
oxygen treatment in . . . 745
Polyacrylonitrile, re-use of (abst) . . . 671
Polyacrylonitrile Membrane Dialyser . . . 356
Polyacrylonitrile Membranes, biocompatibility tests on . . 306
Polyarteritis
autoantibodies to myeloperoxidase in microscopic (abst) 431
Polycystic Kidney Disease
atrial natriuretic peptide in (abst) . . . 465
prognosis of (abst) . . . 442
renal reserve capacity in (abst) . . . 458
tubular sodium handling in (abst) . . . 465
Polycythaemia
post-renal transplant (abst) . . . 599
renal cancers associated with (abst) . . . 472
Polymer Surfaces
biocompatibility . . . S3:60
effect of complement activation and thrombogenesis on . . . S3:67
Polymorphonuclear Leucocytes
activation by Tamm-Horsfall glycoprotein (abst) . . . 427
Polymyxin B, and monokine-inducing activity . . . 569
Polysulphone, re-use of (abst) . . . 671
Polyunsaturated Fatty Acids, in haemodialysis . . . 975
Polyuronic Acid Phosphate Binder . . . 829
Portal Hypertension, in rats (abst) . . . 458
Portal Vein Thrombosis, in nephrotic syndrome . . . 581
Potassium
direct potentiometric analysis (abst) . . . 673
in end-stage renal disease (abst) . . . 673
Predialysis Renal Failure
human recombinant erythropoietin in . . . 966
Prednisolone
in follow-up cases (abst) . . . 594
in idiopathic membranous glomerulonephritis . . . 181
in renal graft recipients returning to haemodialysis (abst) . . . 518
in renal transplantation . . . 129
in renal transplantation (abst) . . . 510, 517, 518
in Wegener's granulomatosis (abst) . . . 435
Prednisone
in membranous nephritis . . . 393
in renal transplantation (abst) . . . 509
Pre-eclampsia
albumin infusion in (abst) . . . 442
calcium: creatinine ratio in (abst) . . . 439
diagnosis of (abst) . . . 439
proteinuria in (abst) . . . 150
vasopressin release in (abst) . . . 442
Pregnancy
calcium:creatinine ratio in (abst) . . . 439
CAPD in . . . 583
cyclosporin in (abst) . . . 511
EPH gestosis (abst) . . . 150
in glomerulonephritis (abst) . . . 831
in mice . . . 701
in renal transplantation . . . 667
in RRT . . . S4:37, S2:39

peritoneal dialysis in . . . 583
renal disease in . . . 583
vascular reactivity in (abst) . . . 418
Pringle-Bourneville Disease, complications of (abst) . . . 145
Probenecid, in tubular urate wasting (letter) . . . 677
Progressive Dialysis Encephalopathy, aluminium in . . S3:100
Prolactin, in sexual dysfunction in uraemia . . . 888
Prostacyclin
endothelium-dependent relaxation mediated by (abst) . 516
in chronic renal failure (abst) . . . 148
in hepatorenal failure (abst) . . . 443
in legionella-associated haemolytic uraemic syndrome . 995
Prostaglandin E
in accelerated nephrotoxic nephritis (abst) . . . 836
in glomerulonephritis . . . 605
in protein feeding . . . 683
Prostaglandins
effect on indomethacin . . . 27
induction by cytokines (abst) . . . 422
Prostanoids, in glomerular haemodynamics (abst) . . . 425
Protease Inhibitors
beneficial effects in acutely uraemic rats . . . S3:131
see also Granulocyte Elastase-α_1-protease Inhibitor
Proteases
classification of . . . S3:127
in immune glomerular injury (abst) . . . 428
in lung . . . S3:130
in rat extraorbital gland . . . S3:131
in uraemia . . . S3:127
Protein, in hypercalciuria (abst) . . . 468
Protein C, in recombinant human erythropoietin therapy (abst) . . . 476
Protein:Creatinine Ratio . . . 9
Protein Diet, in nephrotic syndrome (abst) . . . 437
Protein Ingestion
renal, metabolic and hormonal responses (abst) . . . 419
Protein Intake
in chronic renal failure . . . 877
in haemodialysis . . . S3:138
Protein Load, renal responses to (abst) . . . 456
Protein Loss
in CAPD . . . 900
in peritoneal dialysis . . . 896
Protein Meal
renal haemodynamic and hormonal responses . . . 683
Protein-restricted Diet
in chronic renal failure (abst) . . . 457
in renal function (abst) . . . 455
Protein S, in recombinant human erythropoietin therapy (abst) . . . 476
Proteinase Inhibitors . . . S3:128
in uraemia . . . S3:130
Proteinases
effects of unrestricted release of . . . S3:128
in uraemia . . . S3:129
mechanisms of release . . . S3:128
Proteins, removal of small molecular . . . S3:83
Proteinuria
aspirin-dipyridamole in . . . 140
circadian rhythm of . . . 9, 266
complete remission of . . . 525
effects of evening meat meal . . . 266
in EPH gestosis (abst) . . . 150
in lung cancer . . . 947
in nephrotic syndrome (abst) . . . 455
nephrotic-range . . . 1080
Prune-Belly Syndrome, detection of (abst) . . . 144
Pseudomonas aeruginosa
in CAPD peritonitis (letter) . . . 759
in sclerosing peritonitis (abst) . . . 754
Pseudomonas Peritonitis, in CAPD . . . 814
Psoriasis
cyclosporin in (abst) . . . 511
fish oil in (abst) . . . 511
PTFE Fistulae, duplex sonography (abst) . . . 152
Pulmonary Hypertension and Hypoxaemia (abst) . . . 480
Pyridoxine, in nephrocalcinosis . . . 137
Quality Control, in determination of metals in biological materials . . . S3:116
Quinton Double-lumen Catheter . . . 586
Radiocontrast-media-induced Nephrotoxicity
nitrendipine in . . . 1030
Radioimmuno Detection, vitamin D (abst) . . . 470
Ramipril, in nephrotic syndrome (abst) . . . 455
Raynaud's Phenomenon, cyclosporin in (abst) . . . 512
RBC mass, determination of (abst) . . . 599
Recombinant Human Erythropoietin . . . 324, 325
(abst) . . . 146, 147, 478, 754
and bone marrow fibrosis (letter) . . . 674
and erythropoietic modulation by monocytes (abst) . . . 472
and red blood cells (abst) . . . 476
angiotensin infusion test (abst) . . . 474
atrial natriuretic peptide in (abst) . . . 478
effect on anaemia in dialysis . . . S4:23
effect on cardiovascular dynamics . . . S3:146
efficacy of (abst) . . . 471
hyperparathyroidism in . . . 740
hypertension in . . . 740
in anaemia (abst) . . . 477, 597, 966, 979
in CAPD (abst) . . . 833
in CAPD (letter) . . . 674
in chronic renal failure . . . 782
in chronic renal failure (abst) . . . 474
in haemodialysis . . . 718, 1065
in haemodialysis (abst) . . . 319, 475
in hyperparathyroidism (abst) . . . 472
in predialysis renal failure . . . 966
in uraemia . . . 350
in uraemia (abst) . . . 479
intravenous and intraperitoneal (abst) . . . 318
loop diuretic medication in . . . 740
parathyroid hormone in . . . 740
pharmacokinetics of (abst) . . . 477
plasmatic coagulation (abst) . . . 473
platelet function under (abst) . . . 472
role of aluminium and PTH (abst) . . . 474
single-dose pharmacokinetics . . . 345
subcutaneous versus intravenous administration (abst) . 473
thrombocyte function (abst) . . . 473
thrombotic complications (abst) . . . 476
see also Erythropoietin
Red Blood Cells. *See* Erythrocytes
Redy Dialysis, aluminium intoxication risk . . . 555
Reflux Nephropathy, in childhood (abst) . . . 436
Rehabilitation
combined report on children . . . S2:37
of children . . . S4:35
Rejection
antithymocyte globulin therapy (abst) . . . 596
cyclosporin in (abst) . . . 519
cytomegalovirus infection in (abst) . . . 520
diagnosis by biochemical assay (abst) . . . 595

diagnosis by peripheral blood morphology 302
diagnosis by ultrasound (abst) 508
endothelial-monocyte antigen system in (abst) 315
fish oil supplement in 1070
histologically established (abst) 151
in sickle-cell disease (abst) 600
interleukin-2 in (abst) 508
methylprednisolone therapy for 387
NK-like cells in 735
OKT_3 therapy (abst) 596, 597
plasmapheresis in (abst) 589, 590
recurrent infection in (abst) 152
steroid-resistant renal allograft (abst) 597
T-lymphocyte sub-subsets in 735
tubular epithelial cells in 824
Renal Amyloid, adrenal dysfunction in (abst) 834
Renal Artery Stenosis 66
in renal transplantation (abst) 506
Renal Blood Flow
autoregulation in ischaemic rat kidney (abst) 422
effect of endothelin (abst) 835
effect of human recombinant erythropoietin 966
effect of lipids (abst) 421
GFR after restitution (abst) 462
in acute renal failure 625
in hypertension (abst) 462
response to mixed protein meal 683
Renal Cancers Associated With Polycythaemia (abst) . . . 472
Renal Cell Carcinoma and Haemodialysis 763
Renal Cysts, acquired 763
Renal Damage, drug-induced (abst) 456
Renal Disease
end-stage 563
end-stage (abst) 144, 453, 473, 673
in children S4:35
in patients accepted for RRT S4:8
in pregnancy 583
recurrent and de novo (abst) 510
Renal Failure
angiotensin-converting enzyme (ACE) inhibitors in . . . 311
complement C3d in (abst) 450
end-stage (abst) 144, 475, 593, 800
hyperkalaemia in 228
immunosuppression in 181
recombinant human erythropoietin in 345
tumour markers in (abst) 449
see also Acute Renal Failure: Chronic Renal Failure
Renal Function
during treatment by angiotensin converting enzyme inhibitors 66
estimation by ^{99m}Tc-DMSA scintigraphy (abst) 673
prostanoid-dependent (abst) 417
protein-restricted diet in (abst) 455
reserve in the elderly (abst) 416
Renal Growth, compensatory (abst) 316, 456
Renal Growth Factor
and DNA synthesis 334
from uninephrectomised rats 334
Renal Haemodynamics
effect of captopril 696
in protein feeding 683
Renal Hypertrophy, in mice 701
Renal Insufficiency, in analgesic nephropathy (abst) 456
Renal Osteodystrophy
first indications of 470
vitamin D in S3:107
Renal Plasma Flow
effect of captopril 696
effect of human recombinant erythropoietin 966
Renal Protection, HTK solution (abst) 590
Renal Replacement, diabetes mellitus in (letter) 399
Renal Replacement Therapy (RRT)
age distribution and methods of treatment S2:7
AIDS in S2:25
ALG in S2:12, S4:15
annual death rates due to cardiovascular causes and malignant disease S2:16
ATG in S2:12, S4:15
azathioprine in S2:12, S2:13, S4:17
blood transfusions in S4:14
cardiac arrest in S2:18
cardiac failure in S2:18
cardiovascular accident in S4:19
cerebrovascular accident in S2:17
corticosteroids in S4:17
cyclosporin in S2:12, S2:13, S2:36, S4:17
death rates after S4:18
demography in Europe (1987) S2:5
demography in Europe (1988) S4:5
hepatitis B in S2:29
HIV infection in S2:25, S4:26
in pregnancy S4:37, S2:39
monoclonal antibodies in S4:15
myocardial infarction in S2:18, S4:20
myocardial ischaemia in S2:18, S4:20
of children S2:33, S4:31
quadruple therapy S2:13
survival after grafting S2:14
survival rates for 1982 to 1987 . . . . . S4:28
transplant co-ordination S4:20
transplant policies S2:9, S4:10
triple-drug therapy S2:12, S2:14, S4:17
waiting list for cadaveric transplantation S4:13
see also Multiple Transplants
Renal Responses to Protein Load (abst) 456
Renal Retransplantations, graft survival (abst) 670
Renal Scarring, fish oil in (abst) 837
Renal Siderosis, in heart valve prostheses (abst) 443
Renal Transplantation
abnormal kidney (abst) 601
ABO-incompatible (abst) 593
ABO-mismatched (abst) 671
allograft pre-treatment (abst) 838
Alport's Syndrome in (abst) 506
aluminium in (abst) 503
analgesic nephropathy after (abst) 150
and dialysis arthropathy (abst) 492
and hyperparathyroidism 123
anti-CD3 antibodies in (abst) 517
arterial stenosis incidence in children 575
aseptic necrosis of bone following 123
ATG in (abst) 506
azathioprine in 129
azathioprine in (abst) 504, 508, 509, 510, 514, 517, 518
blood supply determination (abst) 150
blood transfusion in (abst) 588
calcium in (abst) 514
CD8+ HNK1+ lymphocyte subset in (abst) 509
chronic graft-versus-host disease (abst) 424
circulating T-lymphocyte sub-subsets 735
class I and II histocompatibility antigen expression in (abst) 510

colour flow Doppler sonography (abst) 150
communication success 119
Concanavallin A in (abst) 588
cyclosporin in 129
cyclosporin in (abst)
504, 505, 508, 509, 510, 511, 512, 514, 515, 517, 518, 521
cytomegalovirus infection in (abst) 502, 504, 509, 520
cytomegalovirus infection in (letter) 238
cytotoxicity of acid eluates recovered from (abst) 521
doctor/patient communication in 119
donor quality of life (abst) 509
donor-specific presensitisation by flow cytometry (abst). 520
dopamine in (abst) 505
double-drug therapy (abst) 508
effect of combined diet and physical exercise on plasma lipids (letter) 237
erythrocytosis following (abst) 600
erythropoiesis in 1076
erythropoietic stimulating factor in 1076
fish oil in 1070
follow-up cases (abst) 593, 594
from elderly donors (abst) 594
fructosamines in 748
GFR in (abst) 504
glomerular hyperfiltration after donor nephrectomy (abst) 508
glomerulonephritis in 730
hepatitis B infection 297
histocompatibility (abst) 589
HLA-DR antigens in (abst) 670
hypercalcaemia in (abst) 470
hyperimmunised recipients (abst) 502
hypertension in (abst) 507
hypophosphataemia in (abst) 470
IgG in 1080
immunological impact on primary function (abst) 502
immunological risk factors (abst) 596
immunomodulators in serum of (abst) 520
immunosuppression (abst) 589
in ablation nephropathy (abst) 457
in children 575
in children (abst) 592
in end-stage renal failure (abst) 593
information 119
interleukin-2 in (abst) 506
interstitial nephritis in (abst) 507
living related donor (abst) 519
living unrelated donor (abst) 592
lymphocytotoxicity in (abst) 588
medical complication in (abst) 599
membranous nephropathy in 1080
monoclonal antibodies in (abst) 504, 517
multiple arteries (abst) 600
nephrocalcinosis in 137
NK-like cells 735
OKT3 in (abst) 506, 517, 518, 519
osteonecrosis in 123
pelvic kidney (abst) 591
phosphorus in (abst) 470
phytohaemagglutin in (abst) 588
plasma lipids in letter 237
plasmapheresis in (abst) 518
prednisolone in 129
prednisolone in (abst) 510, 517, 518
prednisone in (abst) 509
pregnancy in 667
psychological aspects (abst) 591
recurrence of glomerular disease in 927
rejection. *See* Rejection
renal artery stenosis in (abst) 506
renal reserve filtration capacity (abst) 504, 672
role of non-current cross-match (abst) 502
single, small paediatric cadaveric kidneys into adult recipients (abst) 592
skin lesions and peripheral lymphocyte subsets in (abst). 510
social aspects (abst) 591
steroid withdrawal from triple immunosuppression (abst) 518
steroids in (abst) 508, 518, 521
surgical complications (abst) 598, 599
Syrian patients (abst) 593
thrombosis in (letter) 759
triple-drug therapy (abst) 508, 594
tuberculosis in (abst) 594
tumour necrosis factor in (abst) 506
Tunisian experience (abst) 593, 599
vascular complications (abst) 599
vitamin D in (abst) 470
see also Transplantation
Renal Tubular Cells, erythropoietin in (abst) 420
Renal Tubular Epithelium, HLA-DR display by 205
Renal Vein Thrombosis, in dehydration 992
Reserpine, in glomerulosclerosis 848
Respiratory Failure, sepsis control in (abst) 445
Restless Leg Syndrome, clonidine in (abst) 149
Restriction Fragment Length Polymorphism (RFLP) Analysis (abst) 313
Retinol-binding Protein 266
Retinopathy, hypertension in (abst) 151
Rhabdomyolysis
cocaine in (letter) 675
metastatic calcifications in (letter) 675
Rhabdomyosarcomatous Cells, in rats (abst) 454
Rickets, in infants on CAPD (abst) 753
Rifampicin, accidental poisoning (letter) 156
Salbutamol, in hyperkalaemia in renal failure 228
Saline Loading, systemic and renal response to 271
Salmonella Infection, in renal transplant recipient 390
Salmonella Typhimurium hip joint infection, ciprofloxacin in 390
Salt and Water Homeostasis
in Tamm-Horsfall glycoprotein (abst) 419
Sampling, of biological specimens S3:115
Sarcoid Nephritis, and renal gallium scintigraphy (letter) . 76
Schistosoma Haematobium, in glomerular disease (abst) . . 431
Schwann Cells, proliferation of 662
Scintigraphy, renal gallium (letter) 76
Sclerosing Peritonitis
Grey Turner's sign in (abst) 754
in CAPD (abst) 498
SDS (Sodium-dodecyl-sulphate) Electrophoresis (abst) 150
clinical importance of (abst) 153
urinary proteins (abst) 153
Seizures, in haemodialysis 1065
Selenium, in haemodialysis (abst) 479
Sepsis Control
in acute renal failure (abst) 445
in respiratory failure (abst) 445
Septicaemia, epidemiology and prognosis (abst) 597
Sexual Dysfunction, in uraemia 888
Sicca-like Syndrome, in chronic renal failure (abst) 439

Sickle-cell Disease, graft rejection in (abst) 600
Silicon, in haemodialysis 282
Silymarin, in hepatic dysfunction 297
Simvasatin, in hypercholesterolaemia (abst) 753
Skeletal Muscle, protease content in uraemia S3:130
Skin Graft, donor-specific (abst) 593
Sodium
  direct potentiometric analysis (abst) 673
  in end-stage renal disease (abst) 673
  see also Erythrocyte sodium
Sodium Transport 21
  in arterial hypertension (abst) 512
Soft-tissue Calcification, in dialysis patients 1045
Sorbent Dialysis Syndrome 555
Sorbiphos, aluminium-free phosphate binder 829
Splanchnic Area
  in insulin resistance in chronic renal failure (abst) 450
Staphylococcus aureus
  in CAPD peritonitis (letter) 759
  in haemodialysis 278
  in wound infection (abst) 597
Staphylococcus epidermidis
  in CAPD peritonitis (letter) 759
  in wound infection (abst) 597
  peritonitis (abst) 752
  vancomycin in (abst) 751
Steroids
  in membranous nephropathy 1022
  in nephrotic syndrome 1022
  in renal transplantation (abst) 508, 518, 521
  in RRT S2:12, S2:13
Stone Formers, high-protein intake (abst) 468
Stone Recurrence, prevention of (abst) 437
Sudden Cardiac Death (letter) 75
Sulindac Sulphide
  effect on cysteinyl leukotriene synthesis (abst) 418
Superior Vena Caval Obstruction 586
Superoxide Dismutase, in ostoarthropathy S3:35
Surgical Complications, in renal transplantation (abst) 598, 599
Swan neck catheter in CAPD (abst) 154
Sympathetic Nervous System, in hypertension (abst) . . . 462
Syphilis, in membranous glomerulonephritis 172
Systemic Lupus Erythematosus (SLE)
  cyclophosphamide in (abst) 435
  cyclosporin in 923
  in membranous glomerulonephritis 172
  in peritoneal dialysis (abst) 500
Systolic Blood Pressure, in haemodialysis 282
Tamm-Horsfall Glycoprotein
  (abst) 427
  salt and water homeostasis in (abst) 419
T-cell Function, in minimal-change nephropathy (abst) . . 313
T-cell-independent and T-cell-dependent antibody
  responses 216
T-cell Proliferation
  effects of calcium antagonists (abst) 520
  interleukin-2-dependent (abst) 424
T-cell Receptor, in nephrotic syndrome (abst) 313
^{99m}Tc DIPA Clearance (abst) 461
^{99m}Tc DMSA renal scintigraphy (abst) 673
Tertatolol
  effect on atrial natriuretic factor (abst) 464
  in chronic renal failure (abst) 419
Tetanus Toxoid, in chronic renal failure 216
Thin-membrane Nephropathy 611
Thrombogenesis, complement activation in S3:67
Thrombogenicity, ex-vivo study S3:43
Thrombosis
  in renal transplantation (letter) 759
  recurrence in patients with lupus anticoagulant 854
Thromboxane
  effect of captopril and diltiazem (abst) 421
  in acute renal failure 625
  in chronic renal failure (abst) 148
  in cyclosporin nephrotoxicity (abst) 516
  in hypertension (abst) 421
  picotamide inhibition of 1083
Thrombus Formation, at blood–material interfaces . . . S3:60
Thymopentin, influence on HBS vaccination effect
  in haemodialysis (abst) 154
Thyroid Hormone, profiles in acute renal failure (abst) . . 444
Thyroiditis, in membranous glomerulonephritis 172
Total Lymphoid Irradiation, as pretransplant (abst) 518
Trace Elements, in chronic renal failure S3:97
Transplantation
  EDTA Registry Centre Survey 161
  effect of immunosuppressives (abst) 588
  effect of plasmapheresis (abst) 588
  renal artery stenosis 66
  see also Renal transplantation
Triamterene, effect on lithium excretion 939
Tuberculosis, in renal transplantation (abst) 594
Tubular Cells, lymphocyte reactivity to (abst) 670
Tubular Dysfunction, in nephrotic syndrome 914
Tubular Function
  during hyperfiltration response to meat meal (abst) . . . 416
  effect of cyclosporin on (abst) 514
  in medullary sponge kidney (abst) 435
Tubular Necrosis, prognosis in (abst) 444
Tubular Urate Wasting, probenecid in (letter) 677
Tubulointerstitial Nephritis, NSAID-induced 205
Tumour Markers, in renal failure (abst) 449
Tumour Necrosis Factor
  (abst) 315
  effect of cuprophane (abst) 490
  effect of membrane characteristics (abst) 493
  effect on prostanoids (abst) 422
  in immune glomerular injury (abst) 428
  in nephrotoxic nephritis (abst) 837
  in peritoneal dialysis (abst) 498
  in renal transplantation (abst) 506
  production and clearance of (abst) 491
Two-dimensional Electrophoresis (2-DE) S3:14
Ultrafiltration, failure in CAPD (abst) 751
Ultrasonography
  of hyperplastic parathyroid autografts (abst) 453
  parathyroid gland 45
Ultrasound
  allograft monitoring (abst) 595
  rejection diagnosis (abst) 508
  urinary tract obstruction (letter) 678
Uraemia 15
  aldosterone in (abst) 673
  aluminium in (abst) 484
  amino acids in (abst) 448
  apoprotein in S3:142
  arterial natriuretic peptide in (abst) 464, 465
  autonomic neuropathy (letter) 75
  calcitriol in (abst) 451, 452
  carcinogenesis in 765
  cardiac performance in (abst) 487
  comparison of haemodialysis with CAPD 244

correction of acidosis in . . . 92
desmopressin in (abst) . . . 452
diet therapy in . . . S3:124
2,3-diphosphoglycerate in (abst) . . . 452
endocrinological problems in . . . S3:123
fructosamines in . . . 748
granulocyte elastase in . . . S3:125
in children with chronic renal failure . . . 539
insulin secretion in (abst) . . . 451
keto acids in (abst) . . . 448
lipid abnormalities in . . . S3:142
lipid metabolism in . . . S3:123
lipoprotein in . . . S3:142
lipoprotein in (abst) . . . 452
metabolic problems in . . . S3:123
natural killer cells in (abst) . . . 452
parathyroid hormone secretion . . . 339
phosphorus in (abst) . . . 470
platelet α-granules in (abst) . . . 451
proteases in . . . S3:127
proteases in rat extraorbital gland in . . . S3:131
proteinase inhibitors in . . . S3:130
proteinases in . . . S3:129
recombinant human erythropoietin in . . . 350
recombinant human erythropoietin in (abst) . . . 147, 479
restless leg syndrome (abst) . . . 149
sexual dysfunction in . . . 888
sudden cardiac death (letter) . . . 75
vitamin D in (abst) . . . 451, 470
with and without hypertension . . . 21
with severe hyperparathyroidism and hypercalcaemia . . . 545
Uraemic Cardiomyopathy (abst) . . . 152
Uraemic Hyperphosphataemia, choice of therapy 1005
Uraemic Thrombopathy
cryoprecipitate in (abst) . . . 449
DDAVP in (abst) . . . 449
Urate Renal Handling (letter) . . . 677
Urbasone, in rejection episodes (abst) . . . 152
Urea, kinetic modelling (abst) . . . 482
Urea Clearance
calculation of . . . 39
in haemofiltration . . . 37
Urinary Proteins, SDS electrophoresis (abst) . . . 153
Urinary Tract, *Escherichia coli* infection (abst) . . . 437
Urinary Tract Obstruction
plain abdominal X-ray in (letter) . . . 678
Urine Sediment Cytology, diagnostic value of (abst) . . . 596
Urokinase
in relapsing peritonitis due to coagulase-negative staphylococci . . . 62
Vanadium
in chronic renal failure . . . S3:97
in haemodialysis . . . 282
Vancomycin
in CAPD (abst) . . . 751
in haemodialysis . . . 635
in haemofiltration . . . 635
in *Staphylococcus epidermidis* infection (abst) . . . 751
ototoxicity monitoring (abst) . . . 752
Vascular Disease
in IDDM and NIDDM (abst) . . . 151
recurrence in patients with lupus anticoagulant . . . 854
Vascular Endothelium, effect of cyclosporin (abst) . . . 316
Vascular Reactivity, in pregnancy (abst) . . . 418
Vasculitis . . . 1
anti-neutrophil cytoplasmic antibodies in (abst) . . . 832
Vasodilatory Prostanoids, relaxation mediated by (abst) . 838
Vasopressin
in uraemic thrombopathy (abst) . . . 449
release in pre-eclampsia (abst) . . . 442
Ventilation, during acetate haemodialysis 1060
Verapamil, in acute renal failure (abst) . . . 446
Verotoxin-producing *E. coli* (VTEC) (abst) . . . 314
Viscosity Measurement, in haemodialysis (abst) . . . 319
Vitamin B_{12}, and hollow-fibre membranes . . . S3:73
Vitamin D
action on mesangial cells (abst) . . . 431
effect on aluminium deposition in bone . . . 957
effect on cytokine production (abst) . . . 517
effect on vascular reactivity (abst) . . . 460
in CAPD (abst) . . . 496
in haemodialysis . . . S3:140
in haemodialysis (abst) . . . 672
in hyperparathyroidism (abst) . . . 469, 480
in nephrotic syndrome (abst) . . . 469
in renal osteodystrophy . . . S3:107
in renal osteodystrophy and soft-tissue calcification 1045
in renal transplantation (abst) . . . 470
in uraemia . . . 545
in uraemia (abst) . . . 451, 470
radioimmuno detection (abst) . . . 470
Vitamin E
in CAPD (letter) . . . 75
in haemodialysis . . . 975
Water Pollution, aluminium in . . . S3:97
Wegener's Antigen . . . 1
identification of . . . 5
Wegener's Granulomatosis
antibodies to endothelial cells and neutrophil cytoplasm in (abst) . . . 426
anti-neutrophil cytoplasmic antibodies in (abst) . . . 431
autoantibodies to glomerular antigens in . . . 1
clinical study (abst) . . . 435
immunoperoxidase in (abst) . . . 438
long-term follow-up (abst) . . . 832
Wound Infection, in renal transplant recipients (abst) . . . 597
X-ray techniques, urinary tract obstruction (letter) . . . 678
YTH24.5 Monoclonal Antibodies (abst) . . . 838
YTH54.12 Monoclonal Antibodies (abst) . . . 838
Zinc, in sexual dysfunction in uraemia . . . 888